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ABSTRACT	
Background: 
Abdominal Aortic Aneurysm (AAA) affects 4-5% of men over 65, and Aortic 
Dissection (AD) is a life-threatening aortic pathology where 75% of patients die within 
2-weeks post-onset. Relatively little is known about the underlying mechanisms, which 
warrants further investigation. Neutrophil Elastase (NE) is an enzyme with roles in 
priming of the immune system, clearance of large pathogens and remodelling of 
extracellular-matrix proteins, all influential in AAA and AD. The Angiotensin II (Ang 
II) and Calcium Chloride (CaCL2) procedures provide methods to model the AAA 
pathology within small rodents, which enables the study of the disease. Furthermore, 
the β-aminopropionitrile monofumarate (BAPN) model provides an animal model 
which mimics the AD pathology and allows in-depth study of both changes in mortality 
and pathological severity. 
Within AAA and AD, there is known to be a large immune system implication in the 
production and development of both pathologies, with enzymatic activity seemingly 
pivotal in the initiation of the AD and AAA phenotype. With the impact of enzymes 
such as immune cell-derived matrix metalloproteinases (MMPs)-2 and -9 studied in 
depth. Neutrophil Elastase (NE) is an, as yet, unstudied enzyme within these processes. 
Purpose: 
Current treatment regimen for AAA and AD both have significant flaws and is entirely 
surgical, with most at-risk groups being elderly and treatment consequentially of 
increased risk of complications. Surgical intervention has complex post-operative care 
considerations, with reintervention and morbidity being high within the following 
weeks after the procedures take place. Understanding of the underlying mechanisms 
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contributing to AAA and AD is poor and therefore designing a pharmacological agent 
to improve therapy is difficult. Understanding the role of NE and its implications within 
AAA will allow us to identify whether it has an impact within the pathology and, if so 
if it is an appropriate target for therapeutic intervention. 
Therefore, the primary aims of this project was to identify if Neutrophil Elastase is 
involved within the AAA and AD processes, to detect via what mechanism it may act 
and if NE is a potential novel drugs target for treatment of AAA and AD. 
Methods and Results: 
To study if NE gene expression is regulated by AAA pathologies, in Vitro experiments 
were conducted with multiple cell lines (human aortic SMCs, Raw264.7 macrophages 
and HuVECs). Data from RT-qPCR analysis was insignificant and failed to show a 
relation between NE, MMP2 and MMP9, when cells were treated with Angiotensin II 
(Ang II) and Calcium Chloride, respectively.  
Development of an MRI scanning technique to monitor the progression of AAA 
overtime was undertaken. A semi-automatic methodology was developed with 
representative and highly reproducible results achieved. This enabled the detailed study 
of animals whilst undergoing AAA-induction procedures, namely the CaCl2 and Ang 
II animal models. 
By utilising two in vivo models, so far we have observed a significant difference that 
the two Aneurysm models result in lower AAA incidence within NE deficient mice, 
with infrarenal aortic expansion significantly reduced. Investigations into flow and 
other dynamic aspects of the vessel differ between animal models and consequentially 
need to be furthered but at present no significant differences were observable. 
Underlying mechanisms for AAA and NEs contribution towards the pathology were 
assessed, with novel associations between NE and MMPs identified as well as the 
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involvement of proteins such as TBL1x, Caveolin-2 and COPS8 following proteomics 
analysis techniques. 
Similar results were seen within AD experimentation, with knockout of NE resulting 
in significantly lower mortality and vessel dissection rate. Similar histological staining 
patterns were observed within this model when compared to the two AAA animal 
models. This suggests a potential common pathway between the two that results in 
aortic medial degradation, and rupture of the vessel. 
Early Human translational experiments were carried out with a AAA patient audit, there 
were no significant findings that correlated any basic blood profile characteristic to size 
or progression of AAA. This work was continued, working with Barts BioBank 
Resource to obtain tissues from surgical repair patients. Diseased tissues displayed 
expression of NE with small areas of staining being seen alongside MMPs, such as 
within the remodelled medial portion of the vessel, similar to that of previous mouse 
works. Furthermore, blood serum samples from patients had no significant change in 
level of NE when compared to Healthy Controls. 
Conclusion: 
This study identifies NE as having potential therapeutic applications if similar results 
are seen within pharmacological inhibition of the enzyme as were produced as a result 
of genetic knockout in mouse studies, especially within AD models. Early Translational 
experimental results have not been as promising, but more work is needed to fully 
understand whether NE could play a similar role within the Human condition and 
therefore warrant further study as a potential drugs target, although current results need 
to be developed prior to this. 
Wider Implications: 
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Findings outlined within this thesis suggest NE has a potential role within both AD and 
AAA pathologies, with implications in the regulation of MMPs as well as potential 
direct enzymatic action within the modification of extracellular matrix proteins 
regulated within the AAA and AD conditions. Results so far show areas of promise, 
and with further investigation, NE inhibition could be established as a therapeutic 
option for AAA and/ or AD. In order to establish the link further, there is a need to 
determine if pharmacological knockdown of NE can produce the same results as those 
seen within in vivo experiments where genetic knockout was established. 
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1	INTRODUCTION	
An Abdominal Aortic Aneurysm (AAA) is the focal dilatation of the Aorta(1). 
Predominantly situated in the infra-renal segment(1), AAA is a localised weakening of 
the vessel wall which makes it prone to rupture (2). This pathology has a high mortality 
rate as a result and affects 4-6% of the male population and a smaller proportion of the 
female population also(3). The incidence of AAA is increased with Coronary Artery 
Disease (CAD) (4), family history and smoking(5), amongst others. However, the 
overall prevalence of AAA appears to be falling with a recent study indicating rates 
could be as low as 1.7% in a previously considered high-risk group(6). Contradicting 
this, rates of female AAA diagnosis has steadily increased to be not dissimilar to that 
of the male population, and screening programmes for middle-aged populations have 
been started in many countries, such as the UK. On top of this, rupture rates within the 
female population has been observed as much greater than that of the equivalent male 
counterpart(7). Consequentially, AAA is a significant health burden with relatively 
little known about the cause of the pathology. 
 
The exact aetiology of AAA is unknown and current treatment sub-optimal, both of 
which highlight the need for a disease model that can produce a greater understanding 
of the mechanisms involved in the process. This could potentially lead to new 
therapeutic advances as currently open surgical repair and stenting via endovascular 
repair surgery (EVAR) has huge drawbacks and large risks, especially when the 
demographic AAA affects is taken into consideration. The pathological characteristics 
of AAA include collagen and elastin dysregulation(8), chronic inflammation(9), 
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smooth muscle apoptosis(10) and breakdown of the extracellular matrix in the 
surrounding areas of vasculature(11).  
 
Chronic inflammation potentiated by the immune system is a process underlying the 
AAA phenotype(12). Immune driven production and activity of Matrix 
Metalloproteinases (MMPs) is highly up-regulated and appears decisive in the vessels 
expansion(9), potentiating the chronic inflammatory state, elevating numerous 
inflammatory markers(13). Inflammatory markers and chemokines are significantly up-
regulated within AAA. Golledge et al. (1) have reported the increase in adhesion 
molecules and homocysteine, both of which add to the inflammatory process and are 
associated with conditions such as atherosclerosis.  The function of Neutrophil Elastase 
(NE), a serine protease contained within azurophilic granules of neutrophils(14), has 
not currently been characterised within AAA. NE has been shown to play an important 
role in production of antimicrobial Neutrophil Extracellular Traps (NETs) and the 
developing stages of atherosclerosis(15), both of which have been suggested as 
predisposing or contributing factors to the AAA pathology. Resultantly, this enzyme 
could prove influential within the AAA pathology. Serine proteases have been observed 
to cleave Toll-Like Receptor-4 (TLR-4)(16), a receptor involved in inflammatory 
signalling, previously linked to AAA induction. Elastin degradation is a crucial step in 
the formation of AAA, a process performed by NE (17). Apart from its action on elastin, 
NE could act on other extracellular matrix (ECM) proteins, as well as non-ECM 
proteins, for instance, cytokines,  chemokines, and receptors(17). Chua and Laurent 
(18), have outlined the roles of NE within lung degeneration and damage. Furthermore, 
still, this study was backed up by a number of other studies linking tissue-derived NE 
to inflammation with damaging and increasingly severe pathological features within 
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respiratory conditions(19,20). These studies have been furthered, with NE being 
targeted in respiratory conditions such as chronic obstructive pulmonary disease 
(COPD) and emphysema, with beneficial effects. A number of drugs have also been 
seen to interact with the enzyme and inhibit its effects, some of which have known 
circulatory implications, such as Atorvastatin (21). 
NE is influential in the immune response to both gram-negative bacteria and fungi(16) 
and therefore strongly linked with potentiating inflammation. NE can exhibit effects 
both within cells and externally also, with associations with Associated Protein-3(AP3) 
determining its destination(16) (Figure I). 
	
 
Figure	1-	Action	of	Neutrophil	 Serine	Proteases-	The	 function	of	many	 serine	proteases,	
including	NE,	including	both	intra-	(a)	and	extra-cellular	(b-e)	effects.	Some	of	these	include	
interactions	with	immune	and	inflammation-associated	receptors	and	molecules	(15)	
Diagnosis of AAA is often incidental, with largely subclinical presentation. Screening 
programmes are in place for high-risk groups (males over 65 years old)(22). Treatment 
is limited, with various forms of surgery being the only course of action. This route is 
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not appropriate for all groups, with both EVAR and Open surgery having considerable 
associated risks. EVAR has a high re-intervention rate, 20% of patients within 5 
years(23), whilst open surgery has a high mortality rate specifically in the peri-
operative window(24). Development of alternate treatment regimens with less risk and 
lower invasiveness would improve patient outcome. To do this, a greater understanding 
of the pathology is needed. Human aneurysmal tissues give a good idea of the end-stage 
diseased state, but yield less of an insight into the disease aetiology. Therefore there is 
a need for the study of the early stages of AAA. This is near impossible in vivo within 
human studies or in vitro with human tissue samples, as early intervention is rare and 
consequentially minimal human tissue available from these time points. 
 
With this aspect, the Angiotensin II (Ang II) and Calcium Chloride (CaCL2) procedures 
provide a method to model the pathology within mice, enabling the study of the disease, 
especially at preliminary stages. CaCL2 application provides a trigger that causes the 
induction of aortic aneurysms that can be used across a number of genetic mouse 
backgrounds. Unlike AAA itself, there is no differential response between genders, nor 
with hypercholesterolemic status. Angiotensin II provides a good model for aneurysm 
rupture and is currently one of the two most utilised models within the AAA research 
field.  
 
In this PhD project, I will utilise both animal models of AAA (Ang II and CaCL2) to 
study the potential role of NE in the pathology of AAA.  A range of molecular and 
cellular biology techniques will also be applied, as well as In Vivo scanning techniques, 
to study the molecular mechanisms involved and the difference NE has to the condition. 
This project will allow for the study of the mechanisms underlying the AAA pathology 
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and possibly identify novel therapeutic targets. Small limitations of the models include 
discrepancies from the human phenotype such as the lack of; intra-mural thrombus, 
atherosclerotic background and AAA rupture, within the CaCL2 model for example. 
However, there are a number of strengths to this model, enabling research into 
inflammation and inflammatory cell infiltration, neovascularisation of the area, loss of 
elastin and vascular smooth muscle cell (VSMC) content, plus significant increases in 
the levels of oxidative stress. NE has potential roles within a multitude of these 
characteristics and resultantly could highly influence the progression or induction of 
AAA.  
1.1 AAA	
MODELS	OF	AAA	
AAAs are often categorised by the focal enlargement of the aorta to 1.5 times the size 
of the healthy or expected aortic diameter(25) usually within the infrarenal portion of 
the aorta. This increase in width is accompanied by the degradation of the medial 
segment wall, by invasion of inflammatory cells (26), as well as decreased structural 
organisation of both collagen and elastin. The initiator of these changes is as yet 
unknown, although the process has been associated with co-morbidities of heart disease 
as well as seen to be influenced by certain MMPs(27) and the low-density lipoprotein 
receptor-related protein 1 (LRP1) gene, amongst others variables.  Effecting 4-5% of 
males over the age of 65 and 1.3% of women within the same group(28), this is a large 
clinical burden, especially as rates amongst the female population is on the rise(29), 
rupture risk is high, and pathology associated with intervention (endovascular 
aneurysm repair) still 23% (30). 
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Aneurysm is pathology where animal models have enabled a greater 
understanding of what we now accept to be a polygenic and multifactorial disease 
process. However, current models largely reproduce the findings co-founded when 
aneurysms are encountered, such as extracellular matrix degradation, altered collagen 
and elastin configuration and MMP modulation. The reason for a need for animal 
models within aneurysms is the lack of access to human aneurysm tissue that is not at 
the end-stage, post rupture. It is possible to obtain tissues from open repair surgery, but 
this is rare, and therefore studies on the tissues are extremely infrequent. Resultantly, 
there is a need for a model that combines multiple assaults to the aorta, revealing how 
the pathology progressively develops leading to rupture, and, creating a more 
representative environment in which aneurysms are formed. Consequentially this 
should yield more representative information on aneurysms, from which, we would be 
able to direct research with the aim of producing drugs or treatments using the 
information we have obtained, possibly improving treatment or lowering occurrence 
and therefore the clinical burden of aneurysms.  
Currently, there are a number of animal models upon which aneurysms are 
studied. Each of these has aspects that they are representative of the pathology and 
others by which they are not. I will outline some of these benefits and flaws, including 
animal and process choice, with respect to the most commonly used and then conclude 
with what we can learn from these including what needs to be developed in order to 
gain a greater insight.  
Based on their relevance to the clinical setting, with this being defined as the 
possibility to obtain information that will lead to new treatments, either due to 
developing greater understanding which provides the opportunity for the development 
of pharmacological agents as a result(31), or technical advancements that lead to 
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improved recovery, as seen in Wang et al. (32), the animal models of AAA will be 
reviewed in the following sections. Furthermore, I will regard models as representative 
of the pathology if they produce two or more of the four stages of aneurysm such as 
inflammation and dilation of the aorta(33). 
1.1.1	Transgenic	models	
Transgenic animals allow the study of specific genes implication upon an organism as 
a whole as the genotype is altered across all tissues. From the removal of a single gene 
and its protein products, and by comparing the results to that of a control with the gene 
present we can conclude the effects that the missing gene has.  
1.1.2	LRP1	Knockout	
Low-Density Lipoprotein (LDL) LRP1 was the single gene to show up as relevant to 
incidence of aneurysm within a genome-wide association study (GWAS)(34), 
highlighting the relationship between this gene and the condition. Furthermore, studies 
upon LRP1 knockout mice have shown progressive development of aortic diameter 
increase(35). This model mimics the pathology seen within the human in some ways 
and therefore could be highly clinically relevant, due to its high age to aortic root 
diameter increase relation, similar to increased incidence of aneurysms within the 
ageing population(36). On top of this, there is the lack of need for invasive techniques, 
such as surgery or chemical exposure, which could potentially influence the 
inflammatory status of the animal and consequentially the aortic environment(37). On 
the other hand, LRP1 gene polymorphisms are not present within all aneurysm patients, 
with AAA being suggested to be a polygenic pathology(38). This limits the potential 
of this model as we know it to be inconsistent with observations of some patients. At 
the same time, this serves to highlight the problems with the use of animal models with 
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a view to carrying the information over to human disease. Differences in physiology 
between species can result in alternate causes for similar conditions.  
1.1.3 Marfan’s Model- FBN 1 Knockout 
 
Marfans Syndrome is an autosomal genetic disease that results in defects of the 
connective tissue. Genetic abnormalities centre around the truncation or deletion of the 
Fibrillin-1 gene (FBN1). This condition results in severe connective tissue disorders, 
with AAA and other vessel abnormalities being a common presentation. Due to the 
wide-ranging presence within multiple tissues, the presentation of symptoms are 
similarly widespread, affecting the cardiovascular, visual and musculoskeletal systems.  
Development of the knockout mouse model of Marfans syndrome resultantly acts also 
as a method of studying AAA, however, the limitation of this model is clear, with not 
all AAA patients suffering from conditions such as Marfan's, or associated conditions 
that affect the FBN1 gene. Mutations of the FBN1 gene show full penetrance within 
humans, however, within the mouse model most significant phenotypic presentations 
include but are not limited to microfibrillar deposition, aortic wall deterioration and 
kyphosis. Differences in stage of onset are seen with C57BL/6 animals less effected 
and display later onset of symptoms in comparison to 129/Sv strains. Strong negative 
correlation is seen between the level of mutated FBN1 and phenotypic presentations. 
In a study of effected mouse families, a group heterozygous for the mutant FBN1 
displayed rescuing effects of the healthy form of FBN1(39). Two forms of the mouse 
model are established with homozygous mgD and heterozygous mgDloxPneo, both of 
which have in-frame deletions of the exons 19-24 of the FBN1 gene. Aneurysmal 
features are produced within this model, with aortic degradation occurring over time. 
This degradation leads to dilation of the aorta and the aneurysmal phenotype by three 
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months of age, and associated levels of calcification observed(40). Whilst 
hemodynamic alterations associated with AAA have been observed within Marfan 
Syndrome sufferers, similar indications have not been observed within the mouse 
population as cardiovascular function was not found to be significantly different 
although there was an increased incidence of retrograde flow found within one study, 
however, this did not reach any level of significance(41). 
 
1.1.3	Chemically	induced	models:	
1.1.3.1	Angiotensin-II	Infusion	(AngII)	
This is one of the most studied and well-established models of AAA. This model works 
on ApoE and Low-Density Lipoprotein receptor knockout (LDLR) background mice, 
relying on systemic exposure to Angiotensin II, released from a sub-dermal osmotic 
pump. Daugherty et al. have discussed thoroughly how the renin-angiotensin system 
(RAS) has a direct role in the formation of aneurysms, when angiotensin II is 
consistently up-regulated, within mice, and how this could be translatable to the human 
condition(42). In addition, drugs that act upon the RAS system have been repeatedly 
shown to decrease the rates of aneurysm(43), reinforcing the link between the two.  The 
mechanism behind this model involves Angiotensin II, causing a decrease in 
Angiotensin type 1a receptor abundance and resultantly this is what causes the increase 
in aortic diameter(44)(45). However, this has not been shown to be the case within 
humans. In addition to this reported mechanism, Daugherty et al. report increase 
atherosclerotic plaques, haemodynamic changes and immune cell (macrophage) 
recruitment and stimulation(46), all of which often coexist with abdominal aneurysms, 
as well as hypertension. Many findings produced by studies using the ApoE ad LDL 
knockout background are not fully reproducible in non-transgenic animals, with 
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examples of contribution to the atherosclerotic burden, with the lipids becoming 
resident within aortic lesions(46). Multiple other similarities to other models, as well 
as the human pathology,  have been described with the implication of this model, such 
as; progressive aortic expansion, focal disorganisation of aortic wall proteins, 
neovascularisation of the aneurysm region and adventitial build up in surrounding 
regions of the aorta (47)(48). However, this model may be more a measure of aneurysm 
regression and post insult dissection rather than aneurysm itself. Longer-term studies 
are needed to highlight the consequences on stability of this technique, as although 
decreased stability and increased rupture risk are reported (46), a number of human 
aneurysms are subclinical and do not rupture for extended periods, even though rupture 
rates are increasing(49), and therefore this model may not be representative for the 
human condition, especially as this model produces suprarenal abdominal 
aneurysms(50), in contrast to the stereotypical infrarenal aneurysms seen in humans. 
Although, on the other hand, genetic polymorphisms of enzymes concerned with the 
RAS have in the past been suggested to relate to different types of aneurysm(51) and 
aortic expansion rates, although some investigations have since disproved the aortic 
relation(52). Resultantly, as there are many conflicting standpoints regarding this 
models relevance to aneurysms, I am unsure of the representation of this model with 
regards to aortic aneurysms and subsequently, its clinical relevance of certain aspects 
have been disproven. However, I would still suggest this model to have a very strong 
relevance in understanding what causes ruptures to occur, meaning that although it may 
have less relevance in understanding the overall pathology, it may still have clinical 
significance in understanding what causes the fatal infarct.  
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1.1.3.2	Intra-luminal	Elastase	or	collagenase	
This enzymatic model has more frequently been used to induce aneurysms within large 
laboratory animals such as swine, with elastase and collagenase being used at times 
singularly and in conjunction, producing highly differing appearances of aneurysm(53).  
Within the study by Czerski et al., elastase and mechanical stretching alone, were seen 
to be insufficient at producing an aneurysm within the swine model, in comparison to 
the addition of collagenase that produce a marked increase above 70%, suggesting 
collagenase to be the active and bioactive enzyme within the model. On the other hand, 
elastase has been shown to reproducibly form aneurysms within the mouse model(54), 
highlighting differential responses between species. This is an important point as many 
models may be effective within one species, but if it is not a system that reacts in the 
same way as the human, it renders the investigation and model itself insignificant to 
humans clinically.  
Importantly, this method has been compared to human tissues to see the relevance of 
the model, with respect to similar reactions occurring in human as in swine. Results 
suggested similar modulations of prominent biomarkers of aneurysm such as; increased 
MMP expression, increase cell size and spread as well as decreased proliferation(55), 
although this was shown in an in vitro representation of the in vivo model. However, 
this suggests that swine is very representative of human vascular conditions, with 
smooth muscle cells exhibiting the same behaviours in response to a stressor across the 
two species.  
The mechanism behind this model is highly representative of pathology seen within the 
human. For instance, the alteration of the extracellular matrix and immune cell 
infiltration of the affected vasculature by macrophage and neutrophil immune cells(56). 
Resultantly, the model, is one of the most complete and representative models of the 
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human condition and in terms of clinical relevance this is an extremely thorough model 
as it combines two insults due to the haemodynamic changes and consequential sheer 
stresses that are elicited in response to the enzymatic treatment, as reported by 
Miskolczi et al. (57). However, this is a very acutely formed aneurysm, and therefore 
contrary to human aneurysmal formation, is not a chronic activation of inflammation 
and with gradual degradation and expansion of the vasculature. This I feel is under 
looked in many models as, although cheaper to simulate, if it is misrepresentative, 
clinical significance and the usefulness of the information yielded on aneurysm is 
diminished as the changes seen in acute phases will be very different to that in the 
chronic phase. Overall, I would say this was a good model of aneurysm initiation rather 
than the complete pathology aiming to be studied, furthermore still, due to the use of 
exogenous elastases and collagenases that mimic the functionality of NE, this model is 
inappropriate for use within this study.  
 
1.1.3.3	Calcium	Chloride	(CaCl2)	
The Calcium chloride model has been extensively used within rodents(58)(27)(59)(60), 
however many small differences between techniques mean it is hard to draw overall 
conclusions as it is impossible to distinguish between what differences are due to 
technique discrepancies and what is due to true biological effects. Observational 
discrepancies, for instance, different average levels of calcification within the aorta can 
be dependent upon application technique of the CaCl2(61). Alternately discordant 
average aorta diameter increases between strains(62), species(63), and even 
investigations result in the information gained from the separate investigations not 
being able to be extrapolated to the human clinical setting very easily. 
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Furthermore, the model has been developed to include secondary assaults upon the 
aorta. However this has led to a more representative model being produced(64), 
comparative histology and protein analysis is similar within updated models to what 
has been observed within human aneurysm tissue samples(65)(66). This updated 
calcium chloride model, acting alongside elastase or collagenase models, brings about 
increased elastin degradation, apoptosis, inflammation and MMP production, to a 
greater extent than solely calcium chloride(67)(64). Further aortic modifications have 
been seen, within more recently advanced methods, with a combination of calcium 
chloride and Phosphate Buffer Solution (PBS), which produces Calcium Phosphate 
(CaPO4). Levels of apoptosis were seen to be 3.7 times within calcium phosphate 
treatment in comparison to that of calcium chloride by Yamanouchi et al. (68), along 
with other modulations of cell phenotype such as inflammation markers and 
calcification. This suggests the calcium phosphate model could be superior to calcium 
chloride. One huge weakness, however, is that this modified technique comparison 
mentioned was performed in cultures (in vitro techniques), namely cell culture of 
vascular smooth muscle cells, and not in vivo as numerous other calcium chloride 
studies(67)(64). This is influential in our ability to interpret the relation between 
comparable data sets, such as calcification and inflammation levels, as apparent 
differences may be due to cell culture and in vivo discrepancy rather than actual 
difference in induction of aneurysms or organism’s response to treatment. Hence, the 
study by Yamanouchi et al. is a promising development, yet until verified in vivo, lacks 
the evidence needed for it to be considered as the current gold standard of chemically-
induced aneurysm models. 
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 Arteriosclerosis 
and/or immune 
invasion 
Aortic 
dilatation 
Aortic wall proteins 
degradation 
Haemodynamic 
alterations  
Overall 
relevance 
LRP1 
knockout 
Increased  Gradual 
increase  
By PDGFRb  
dysregulation  
Not reported 3/4 
AngII- 
infusion 
Increased plaques and 
macrophage 
activation (46) 
 
Receptor 
level 
modulation 
causing 
increase (44) 
Focal  dysregulation 
(47) 
Some reported 
change (46) 
4/4 
Intra-
luminal 
elastase/ 
collagenase 
Reported in rabbits 
(69) 
Receptor 
modulation 
Elastin degradation 
and MMP production 
Not reported 3/4 
Calcium 
chloride 
Inflammation, 
apoptosis and 
calcification  
Varied levels 
of dilatation 
(62)(63) 
Elastin degradation 
and MMP production 
Not reported 3/4 
Fibrillin-1 
Knockout 
Decreased stability of 
atherosclerotic 
plaques when on 
ApoE background, 
however, no innate 
Significant 
and 
widespread 
Widespread 
connective tissue 
abnormalities. With 
decreased presence 
Increased aortic 
stiffness but no flow 
alteration 
3/4 
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Table	1	-	Summary	of	mouse	aneurysm	models-	includes	features	and	basic	mechanism	by	
which	they	each	model	acts	and	their	relevance	to	the	study	of	AAA	
 
1.1.3.4	Surgical	models	
Many surgical techniques have been trialled to induce aneurysms, however, none as yet 
have been able to accurately replicate the pathology of an aneurysm. However, some 
have led to new methods of treatment being created due to the ability of people to 
practice repairs and novel repair techniques on large laboratory animal models such as 
swine and canine(32)(71). This, therefore, has produced potentially clinically important 
signs of progress in surgical techniques rather than the understanding of the pathology 
and pathophysiology, with haemodynamic changes, shear stress and overall larger 
animals being more comparable than mice to human physiology. 
 
Overall, there are currently a number of different models by which aneurysms and 
specifically AAA are studied, the vast majority of these are performed upon small 
animals such as mice. This is economically the most viable due to the lower cost in 
comparison to larger animals such as pigs, however, there are many important 
drawbacks such as differences in immune system(72), which is especially relevant with 
suggested relations to genes such as Early Growth Response gene-1 (Egr-1)(73,74) and 
their subsequent relation to leukocytes(75), and this resultantly may influence 
pathology.  
increase of 
atherosclerosis or 
immune invasion(70) 
 
of elastic 
lamellae(41) 
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Conclusion		
To conclude, there are currently many models of aneurysm within different size and 
species of animals, some of which are more representative of the human vascular 
system than others and therefore I would suggest that these are where the most clinically 
relevant information will come from. However, due to economic constraints, these 
models will be less widespread, as the swine model appears to mimic human 
vasculature and the response it elicits the most accurately. Swine are more expensive 
to keep and use but the potential benefit of using these animals is high.  
The models studied above are some of a number of models that exist. However, these 
processes I believe to be the most often used and are the processes from which the large 
proportion of information regarding aneurysm originates. As explained, this does not 
mean they are faultless nor complete representations. Current models tend to focus on 
one specific insult producing the aneurysmal pathology, although some induce 
secondary changes, such as the hemodynamic stressors mentioned above(76). This I 
feel is where development needs to occur and has started to occur, with some 
intervention studies using a combination of models to see which produces the greatest 
change, close to the pathology of the human condition(53). The complete conditions of 
human pathology need to be looked into and recreated within a model that combines 
multiple stressors of different forms, as this is what has been suggested to create the 
disease within the clinical setting. We know this as many different alterations of 
numerous systems lead to modulation in aneurysm prevalence in the clinical setting. 
This occurs at times via interactions with other associated factors such as enzymes and 
inflammatory cells driving the chronic inflammatory process(77)(78)(79). Therefore 
multiple assault models could possibly yield us the greatest insight into how to treat, 
regress or inhibit the aneurysms we see widespread within the western population.  At 
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present, I regard the Angiotensin II model of aneurysm as the best model of aortic 
rupture, and the Calcium chloride model as the best overall technique to induce the 
chronic inflammatory phenotype seen in the expanding and stable aortic aneurysms. 
Resultantly, these are the preferred models within my study. 
Limitations 
Current limitations to all of the above studies include the vast array of co-existing 
conditions that often preclude and compound AAA. Atherosclerosis and AAA are 
vastly intertwined with the majority of AAA patients exhibiting widespread 
atherosclerosis. None of the current models mimic this unless perform under high fat 
diet or western diet conditions on an ApoE knockout background. This in itself has 
some flaws, however is currently the best alternative found within the field as it allows 
production of the AAA phenotype on top of the underlying conditions such as 
atherosclerosis and associated CVD. Beyond atherosclerosis, neovascularisation and 
calcification, both often observed comorbidities are rarely replicated within animal 
models of the disease. Calcification is seen within calcium chloride, and has even been 
observed within elastin perfusion techniques within larger animals  , however this is a 
rarely observed aspect of animal models that is overlooked, as high levels and incidence 
exist within the true AAA population (81). Although, atherosclerosis and calcification 
are limited, neovascularisation is limited to human aneurysm studies (82),  although 
VEGF inhibition within AngII experiments did have efficacy at reducing rates of 
aneurysm. Angiogenesis is observed widely within human AAA samples, and is 
understood to occur in the regions of inflammation and hypoxia, to the extent where it 
becomes erroneous. Often associated with areas of thick ILT, angiogenesis can be 
driven in these areas by production of factors such as hypoxia inducible factor-1alpha 
produced by the VSMCs. This influential mechanism potentiates the expansion of the 
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vessel as further factors such as nitrous oxide are released by hypoxic areas in an 
attempt to counter the level of low perfusion. Consequently, as this mechanism is not 
widely seen within animal models it is a glaring limitation and shortfall within the 
animal model representation of the disease.  
In conclusion, whilst animal models are a very good method by which AAA may be 
studied, there are significant limitations to the translatability to the human phenotype, 
with key characteristics and processes lacking within many of the models. 
Consequently, multiple studies are needed with more than one model being employed 
prior to any conclusions being able to be drawn or applications made to the human 
pathology.  
 
1.1.4 Review of Calcium Chloride Induction 
The CaCl2 Abdominal Aortic Aneurysm induction method provides a controlled and 
reproducible protocol, with greater localisation of the active agent in comparison to 
other models. Inflammation is limited to the area of interest and therefore minimal 
change to the animals overall inflammatory status occurs. In contrast to other AAA 
models, such as Angiotensin II infusion, the CaCl2 model produces an aneurysm in the 
same anatomical location as within the human pathology. This makes it more relatable 
to the clinical setting. These characteristics allow for the study of AAA development, 
as well as monitoring the progression of the pathology. One limitation is the low rate 
of rupture in comparison to other techniques. By utilising this technique, we will be 
able to study the early changes in the vessel that cause the formation of the AAA 
phenotype. From this, we are able to identify proteins and cells involved in the 
formation as well as detect potential novel targets for treatment.  
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Controlling administration of Calcium Chloride is one of the largest areas of variability 
within this procedure, and along with it comes a number of risks. Localisation of the 
Calcium needs to be controlled as if the solution comes in contact with other organs in 
the area widespread calcification and consequential complications can occur. These can 
lead to delayed recovery and the death of the animal in some cases. To minimise this 
possibility calcium chloride-soaked filter paper was used, as this contains the solution 
and only allows the application to occur at the surface it is placed upon. Positioning and 
removal of the filter paper can occur easily with tweezers, this further reduces the risk 
of erroneous application.  
 
Following on from this, handling of organs, specifically the intestines, can produce a 
number of problems. Handling of the delicate mesentery can be an area by which 
mortality is increased. If the mesentery is disrupted or damaged, blood supply to the 
intestinal tract is impeded. This can lead to hypoxia of the affected area. If blood supply 
is not restored, which is often the case, the affected area will undergo necrosis. This in 
many cases leads to death of the animal. To avoid this, incisions should be made away 
from the midline and saline-soaked gauze used to gently handle the movement of the 
entire intestine as one. This minimises disruption to the area and its bloody supply, 
whilst still being able to cleanly access and dissect the aorta.  
 
Aortic measurement is one of the most important steps within the entire process, as 
without accurate measurement of the vessel all data is invalid and inaccurate. A number 
of options are available including video micrometry, ultrasound and MRI. All of these 
have different strengths. MRI is the highest resolution of the three techniques, however, 
length of time and level of invasiveness are much greater with this technique also. 
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Video micrometry enables measurement of the vessel during surgery, however, this 
means that to gather expansion data you must first re-dissect the aorta. Resultantly, to 
measure different time-points AAA progression you have to use multiple animals. 
Ultrasound is by far the quickest procedure and non-invasive, allowing relatively fast 
data collection and minimising the number of animals needed. Whilst ultrasound data 
is of a lower resolution compared to other techniques, it gives a good representation of 
lumen size.   
This protocol allows for a reproducible, sterile and largely representative model of 
AAA within the mouse.  This will allow for the study of AAA and allow for the 
potential identification of new therapeutic targets, stemming from a more thorough 
understanding of the mechanism behind the AAA pathology. Variability in the 
application process that existed in the previous model has now been minimised within 
this updated protocol. 
   
Calcium chloride directly activates matrix metalloproteinase (MMP-2 and -9) activity 
within the area of application via interaction between the divalent cations within the 
molecule and the tissues itself. This, in turn, causes the calcification of elastin and 
general vasculature(83), as well as the breakdown of the extracellular matrix (ECM) 
components. These events kick-start a cycle of apoptosis within vSMCs and structural 
breakdown that induces inflammatory cells to activate and invade both medial and 
adventitial layers of the aorta (84). These processes are largely caused by action and 
internalisation of calcium crystals respectively(84). By doing so this heightens the level 
of dysregulation within the ECM, and in turn, perpetuates the activation of MMPs. 
Further inflammatory processes cause oxidative stress levels to increase, causing the 
induction of proteins such as elastase, further adding to the cycle of deterioration within 
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the vessel wall. Neutrophil elastase, as yet to be studied with relation to this field is 
another potential regulator of many steps within this process.  
 
Figure	2-	Flow	diagram	outlining	the	role	of	CaCl2	application	within	the	In	Vivo	model	of	
AAA,	including	proteins	and	cells	involved,	as	well	as	processes	that	occur	due	to	application	
of	CaCl2.	(84)	
This	 procedure	 will	 allow	 for	 the	 study	 of	 the	 AAA	 phenotype,	 enabling	
progression	in	the	understanding	of	the	pathology.	This	protocol	produces	many	
of	 the	 same	 features	 seen	within	human	AAA	 tissues,	 such	as	 localised	chronic	
inflammation,	 neovascularisation	 of	 the	 area	 and	 a	 decreased	 elastin	 content	
within	layers	of	the	vasculature.	The	precise	location	can	differ	minimally,	as	well	
as	the	model	lacking	some	characteristic	features	of	human	AAA.	These	include;	
intra-mural	 thrombus,	 atherosclerosis	 and	 eventual	 rupture	 of	 the	 aneurysm	
itself.	 Some	 of	 these	 discrepancies	 can	 be	 rectified,	 such	 as	 by	 using	 Apo-E	
knockout	mice,	so	that	atherosclerosis	is	present	within	the	model.		
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1.1.5	Comparison	of	Human	and	Mouse	AAA	
As	highlighted	above,	there	is	significant	benefit	from	studying	animal	models	in	order	to	
achieve	a	greater	understanding	of	the	AAA	pathophysiology.	However,	at	the	same	time,	
whilst	there	are	great	benefits	and	similarities,	disparities	between	animal	models	and	
the	 human	 condition	 exist.	 For	 instance,	 SMC	 and	 medial	 depletion	 and	 destruction	
respectively,	are	evidenced	within	both	human	and	the	majority	of	animal	models(1,53).	
Further,	remodelling	of	the	elastic	lamellae	is	a	key	pathological	feature	in	both	also.	The	
production	of	an	 inflammatory	environment	 is	an	essential	element	of	AAA	formation,	
and	is	observed	within	aortas	isolated	from	both	animal	and	human	studies.	Building	on	
this	however,	 is	the	significant	presence	of	atherosclerosis	within	human	patients(85),	
however	this	has	not	been	fully	replicated	within	in	vivo	studies,	although	ApoE	knockout	
and	high	fat	diet	mouse	protocols	attempt	to	address	this	shortcoming	in	the	field(46).	
Where	instances	of	atherosclerosis	are	recreated	within	animal	models,	a	greater	level	of	
representation	of	the	human	phenotype	is	produced.	In	these	instances,	a	higher	presence	
of	the	Intra-Luminal	Thrombus	(ILT)	is	observed	which	has	a	significant	impact	within	
the	human	condition	and	less	seen	within	animal	models.	The	ILT	is	a	site	of	protease	
production,	 such	 as	 the	 production	 of	 MMPs(8).	 These	 are	 largely	 due	 to	 the	 high	
concentration	of	WBCs	that	are	contained	within	the	ILT	and	lead	to	further	deterioration	
of	 the	adjacent	vessel	wall(8).	WBCs	such	as	neutrophils,	macrophages	and	mast	 cells	
have	all	been	observed	to	influence	the	phenotype	within	both	human	and	animal	studies,	
with	 knockout	 of	 these	 cell	 types	 leading	 to	 significantly	 smaller	 or	 less	 incidence	 of	
AAA(15,86,87).	Such	WBCs	lead	to	action	upon	cells	and	proteins	of	the	vessel,	leading	to	
deterioration	of	the	aortic	wall	structure	and	structural	proteins,	as	well	as	depletion	of	
VSMC	numbers,	again	a	feature	of	AAA	present	in	both	human	and	some	animal	models	
of	AAA.	The	source	of	these	WBC	has	been	a	source	of	investigation,	with	the	discovery	of	
Adventitial	 Tertiary	 Lymphoid	 Organs	 (ATLOs)	 and	 the	 understanding	 of	 its	 role	
developed	over	more	recent	years.	ATLOs	develop	at	 the	site	of	chronic	 inflammation,	
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produced	 through	 lymphoid	 neogenesis(88),	 and	 are	 responsible	 for	 adventitial	
inflammation	 and	 subsequent	 destruction	 of	 the	medial	 portion	 of	 the	 aorta(89).	 The	
formation	of	these	vessels	is	a	consequence	of	VSMC	stimulation,	producing	CXCL13	and	
CCL21	chemokines	and	stimulation	of	ATLOs.	Production	of	ATLOs	allows	for	passage	of	
WBCs	through	the	media	and	into	the	adventitial	portions	of	the	vessel(90).	Multiple	cell	
types	 home	 to	 these	 ATLOs	 structure	 within	 the	 atherosclerotic	 and	 AAA	 diseased	
portions	of	 the	vessel	wall,	namely	WBCs	such	as	Neutrophils,	B-	and	T-cells,	with	the	
consequent	destruction	of	the	surrounding	vessel	due	to	release	of	cellular	contents,	such	
as	proteases	and	 the	 induction	of	 an	 inflammatory	environment.	These	 structures	are	
only	 significantly	 present	 in	 the	 human	 phenotype,	 although	 they	 have	 been	 outlined	
within	the	animal	but	at	present	only	recognised	within	ApoE-/-	severely	atherosclerotic	
mice(88),	which	can	be	utilised	alongside	some	models	of	AAA	such	as	the	AngII	model.		
The	AngII	model	of	AAA	has	many	similarities	to	the	human	phenotype,	however	whilst	
it	 possess	 significant	 aortic	 expansion,	 inflammatory	 infiltration,	 structural	 protein	
destruction,	 VSMC	 depletion	 and	 ILT	 production	 amongst	 others,	 one	 of	 the	 most	
important	aspects	of	the	pathology	is	the	chronic	expansion	seen	in	the	human	condition	
which	 fails	 to	 resolve	and	 is	 stable	 for,	 at	 times,	many	years.	Within	 this	model,	 large	
expansions	are	seen	often	within	the	suprarenal	portion	of	the	aorta	and	have	a	high	risk	
of	rupture	around	week	three	of	the	protocol.	Comparatively,	within	human	conditions,	
the	expansions	are	more	often	seen	in	the	infrarenal	segment	and	can	are	typically	far	
more	stable,	moving	through	expansive	and	stable	periods,	often	asymptomatic	for	many	
years.	Similarly,	within	the	AngII	model	expansions	are	accompanied	with	elastic	lamellae	
breakdown	and	dissection	of	the	intimal	and	medial	layers	of	the	aorta.	Comparatively	in	
the	 human	 condition,	 expansion	 of	 the	 aorta	 does	 not	 have	 to	 be	 accompanied	 by	
dissection,	a	characteristic	which	is	often	absent	within	stable	AAA	presentations.	
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One	further	aspect	of	Human	AAA	is	that	of	VSMC	apoptosis,	the	process	by	which	cells	
undergo	self-programmed	death	in	order	to	remodel	and	regulate	mass	or	architecture	of	
tissues(91).	This	phenomena	has	been	evidenced	within	the	aorta,	and	more	specifically	
gives	 rise	 to	 the	 medial	 depletion	 of	 VSMCs	 within	 a	 diseased	 aorta	 such	 as	 within	
AAA(91).	VSMCs	are	a	source	of	elastin,	a	key	component	of	a	healthy	vessel(92).	Studies	
by	Cao	et	al.	studying	tissues	of	human	AAA	origin	display	that	regulation	of	apoptosis	
pathways,	such	as	the	p53	pathway	by	miRNAs	(such	as	miRNA	504,	 in	this	 instance),	
occurs	within	AAA	and	manipulation	of	this	system	is	intrinsic	to	the	production	of	the	
pathological	 phenotype(92).	 Beyond	 the	 production	 of	 elastin,	 VSMCs	 produce	 ECM,	
another	important	component	to	a	healthy	vessel(93),	loss	of	both	ECM	and	elastin	are	
key	 in	 the	 depletion	 and	degradation	 of	 the	 vessel	 architecture	 that	 leads	 to	 the	AAA	
phenotype.	The	regulation	of	VSMC	apoptosis	within	human	tissues	and	AAA	was	backed	
up	by	subsequent	studies	within	the	AngII	mouse	model,	within	increased	TUNEL	staining	
evidencing	the	significant	medial	VSMC	apoptosis	within	tissue	samples(94)(95).	Control	
and	restriction	of	VSMC	apoptosis	has	been	observed	to	reduce	incidence	and	severity	of	
AAA,	 which	 in	 turn	 highlights	 the	 importance	 of	 the	 mechanism	 within	 the	 AAA	
condition(94,95).		
In	 summation,	 there	 are	 many	 differences	 between	 the	 human	 and	 animal	 model	
phenotypes	produced,	and	whilst	there	are	many	similarities	continued	development	of	
animal	models	 and	methods	 by	which	 AAA	 is	 studied	 is	 required	 in	 order	 to	 further	
understand	the	pathology.		
1.2	AORTIC	DISSECTION	
Aortic Dissection (AD) is another potentially lethal aortic pathology with acute onset 
and minimal prior symptoms. Effecting between 5 and 30 people per million, dependant 
on background, this pathology has a significant prevalence and as yet only a vague 
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understanding of the underlying pathology. AD has at times been included within the 
category of Acute Aortic Syndrome (AAS), which include Thoracic Aortic Dissection 
(TAD), Intramural Hematoma and Penetrating Aortic Ulcer. AD is part of a spectrum 
of thoracic aortic pathologies that are monitored for clinical outcomes and management, 
this monitoring helps to form the most up to date research from which predictors of 
survival, demographics and management originate. Whilst AAA is one of the most 
researched topics covered within the AAS bracket, AD has significantly higher rates 
than ruptured AAA, with an estimated 3.5 dissections yearly within each 100000 of the 
population. However similarly to AAA rates among the male demographic are also 
significantly higher when compared to the same disease rates within the female 
population.  
AD has been categorized in a number of ways dependant upon the region affected and 
severity, however, the differing categorizations have distinct peaks in age of incidence. 
The most common classification system utilized is the Stanford Classification system, 
whereby Type A, Type B and Type C, are used to describe aortas where the dissection 
affects the ascending and descending, ascending only and thoracic aorta 
respectively(96). This enables for distinction and differentiation to occur between 
patients’ pathologies, as this is often indicative of both the eventual treatment required 
as well as the likely clinical outcome. Alternative classification systems, such as the De 
Bakey classification system, with Type 1, Type 2 and Type 3 referring to AD involving 
the entire aorta, solely the ascending portion or the dissections that spare the ascending 
portion or the arch (most commonly descending or thoracic aneurysms).  
Demographic of AD patients differ between groups, with recent studies observing that 
Type A patients are typically younger than those affected by Type B, with a new 10-
year disparity in the average ages of onset(97). One common underlying co-morbidity, 
46	
	
	
the presence of hypertension, is recorded in both Type A and B patients, with over 75% 
of the studied cohort presenting with the condition.  Furthermore, other similarities 
include the sudden onset of symptoms with sudden chest pain being felt and described 
in at least 85% of patients. The precise location of the pain patients present with is often 
an indicator of which Type of AD they are suffering from. Type A patients most 
characteristically present with sudden central chest pain solely, with back and/ or 
abdominal pain more consistent with Type B and C categorizations. The initial pain 
patients present with can change over time, as the dynamic nature of the pathology can 
lead to worsening or spreading pain as the vessel dissects over time(98). Monitoring of 
the pathology can be adjudged in more ways than solely referring to patient pain levels 
or location, as blood tests for such markers as d-dimer, soluble elastin fragments and 
smooth muscle myosin heavy chain proteins have been linked with both identification 
of AD and used as an indicator of a worsening pathological phenotype(99).  
With the change in classification come differences in survival rates, prognosis and 
treatment. The different regions of the aorta involved are the main determinant of the 
type of treatment required(96). Dissections in the initial portion of the aorta, namely 
the ascending and aortic arch will most likely require surgery and are the most lethal. 
Surgical interventions, much similar to AAA, consist of either open repair or 
endovascular reparative surgical interventions. Dissections involving the more distal 
portions of the vessel may be monitored and treated more conservatively with blood 
pressure modifying drugs and beta-blockers or such drugs that limit the increase in heart 
rate. More distal portions, namely the descending and thoracic aorta can also be 
operated on, however, this is usually reserved for cases where complications arise or 
are expected, such as in instances where other vascular pathologies may interfere with 
the process and exacerbate one another, for instance with AAAs. Type A AD sufferers 
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have a much higher likelihood of also being effected by AAA, with 12.4% of Type A 
patients suffering from both within one study, compared to just 2.3% in Type B 
patients(100). In patients not undergoing treatment, type of AD has a large impact upon 
clinical outcome. Half of Type A patients die in the first three days post dissection, in 
comparison to Type B patients who fare much better, with Type B patients have around 
a 90% survival rate at 1-month post-onset of dissection(101).  
1.2.1 Hemodynamic changes 
Aortic dissection exhibits large differences in aortic flow in comparison to the healthy 
vessel. Due to the highly pulsatile flow, pressure and sheering forces that are present 
within the aorta, the vessel wall is placed under large amounts of stress. This increase 
in stress is highest within the ascending portion of the aorta and proximal descending 
portion of the aortic arch, and furthermore still greater within the external surface of 
the arch. This was superbly modelled by Qiao et al. (102) who demonstrated that these 
areas of higher pressure and stress coincided with the portions of the vessel that also 
suffer most greatly from conditions such as atherosclerosis and most importantly AD. 
At the same time, they were able to demonstrate that there was an increase in both 
transit and contact time of blood cells, within the same area. Disturbances of the intima 
led to turbulent and vortexed flow, coinciding with the previously mentioned regions 
of high risk of atherosclerosis and atheroma. 
 
1.2.2 Pathology 
A healthy artery is comprised of three basic layers all serving different purposes that 
collectively work to aid the function of the vessel. The innermost layer of the aorta and 
all arteries is the intimal layer which lines the vessel forming the point of contact 
between the blood and the vessel itself. This lining is predominantly endothelial cells 
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and basement membrane that anchors the cells into place. The intima is the portion of 
the vessel that is stripped from the remaining layers of the aorta, this can occur at 
various landmarks along the vessels' course however areas of high shear stress and 
turbulence are at increased risk due to these factors having a large influence on the 
pathology’s initiation. As a result, the locations surrounding the heart and aortic arch 
are the most at-risk portions of the vessel, however, dissection is not limited to these 
areas. Within histological sections a break in this layer can be seen, leading to the 
production of an entry point by which the blood enters the vessel wall. From this point, 
the blood enters and serves to strip the proximal portion of the vessel wall of intimal 
coverage. This can extend both distally and proximally to the intimal tear. The stripping 
of the intimal layer can lead to the production of both a true and false lumen, seen when 
the vessel is visualized by either histological sectioning or scanning methods. Within 
the false lumen, blood can pool with highly pulsatile turbulent flow entering from the 
dissection site. This turbulence and pooling only serves to exacerbate the degradation 
and damage done to the vessel, leading to expansion and progression of the tear. The 
production of the true and false lumen phenotype, also known as double barrelling less 
often leads to complete rupture as opposed to dissection that causes pressure to be 
placed onto the external adventitial side of the aorta. The productions of these tears are 
due to unknown causes, however, large extracellular matrix modifications are believed 
to precede the intimal tearing(103). ECM proteins namely, elastin and collagen are 
highly deregulated by processes not yet fully elicited within the cystic medial necrosis 
process. This is common to a number of ECM conditions often of genetic origin, such 
as Marfan's syndrome (Fibrillin-1 deficiency) and Ehlers-Danlos syndrome (structural 
collagen insufficiency of various genetic origin), both of which will be discussed 
further later(104).  
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The secondary layer is the medial portion; this layer undergoes huge amounts of 
degradation and modification during the AD process. In a healthy state, the vessel 
should contain the main cell types that give the vessel its tensile strength and elasticity, 
namely smooth muscle cells and the multiple layers of the elastic lamina held together 
by connective tissues. This layers degradation as the smooth muscle cell component of 
the vessel become increasingly depleted due to apoptosis is considered the primary 
causal factor of AD and the eventual rupture of the vessel(99). These processes are 
largely driven by inflammatory processes that trigger apoptosis and the destruction of 
medial components. Inflammatory cells that are heavily involved with the occurrence 
of AD are macrophages and lymphocytes, which have both been identified in a number 
of studies within the medial space although these often are most concentrated within 
the adventitial segments of the vessel(105). As the pathology progresses the effects of 
inflammation and inflammatory cells have on the structure of the vessel increases, with 
the destruction of elastic tissues and compaction of elastic plates increasing. This 
change is irreversible and leads to the release of some markers of AD, as mentioned 
above. Markers such as D-dimer and pro-B type natriuretic peptide rise following 
initiation of dissection and do not fall after the chronic phase of pathology(106). This 
is in contrast to most vascular pathologies such as AAA which has similar rises in D-
dimer, however, in chronic aneurysm patients, this marker is only transient with levels 
resolving and falling back to expected levels(106). This is used in the diagnosis of the 
pathology assisting with diagnostic scanning such as Ultrasound, MRI and CT.   
Finally the adventitial layer, the least altered in structure during the AD process, 
however, this portion of the vessel has been seen to contain the predominant 
inflammatory cells(107). Whilst the medial dysregulation occurs it appears that 
inflammatory cells migrate into the adventitial portion of the vessel whereby they exert 
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their pro-inflammatory effects. Key inflammatory mediators such as MCP-1 and IL-6 
predominantly occur in this portion of the vessel as outlined by Tieu et al. (107), who 
goes on to suggest that the production of such molecules leads to the recruitment of 
macrophages causing the interaction between these inflammatory cells and adventitial 
fibroblasts. These interactions serve to stimulate the migrating monocytes of the area, 
driving macrophage differentiation by paracrine signalling, with factors derived from 
the adventitial fibroblasts. In turn, these processes also serve to produce MMPs, a key 
player in the breakdown of the vessel walls integrity with substrates including both 
collagen and elastin, both of which are diminished within the deteriorating wall. 
Resultantly, whilst the adventitial structure remains largely intact during AD the same 
portion is being more and more accepted as the hub for pro-inflammatory molecule 
production and resultantly is highly influential in the production and development of a 
number of vascular diseases, not limited to but including AD. 
 
Medial degradation coupled with SMC apoptosis is the primary cause of TAD and 
causal in the eventual rupture of the aorta. A large inflammatory component exists, with 
inflammatory cells and mediators key in the regulation of these processes. Macrophages 
and lymphocytes, largely localized within the adventitial portion of the vessel, cause 
the release of many enzymes and proteins, such as c-type natriuretic peptide, b-type 
natriuretic peptide and d-dimer. These proteins have particular expression patterns 
across acute and chronic dissection patients, elevating during acute phases of rupture. 
These patterns of increased expression do not resolve after repair. Such Inflammatory 
activity is much higher in aortic walls of clinically symptomatic patients. This increase 
leads to weakening of the aortic media. This weakening includes the loss of smooth 
muscle cell density as well as ECM disorganization and disruption, such as the 
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fragmentation of elastin layers. These main change pre dissection are confounded by 
mucopolysaccharides causing loss of elastic tissues and compaction of elastic plates. 
These symptoms were observed in patients with bicuspid valve problems which is an 
associated comorbidity to the TAD pathology. 
 
 
1.2.3 Genetics 
Aortic dissection has a large genetic influence with a number of inherited syndrome 
and familial traits making up a significant proportion of the treated patient 
demographic. Within the general population that suffer from AD almost a quarter of 
these have a family history of AD within 3 generations(108). The specific genes that 
cause the dissection are yet to be fully understood however it is believed to be an 
autosomal dominant mode of inheritance with incomplete penetrance. Many studies 
have had to objective of deciphering the precise genes responsible for familial AD, 
currently, the most significant studies have highlighted a number of genes, most 
interestingly MMP-3 and -9, TIMP-2 as well as gene loci 5q13-14 to name a 
few(109)(108)(110). The same studies have also highlighted loci implicated within the 
syndromes associated with AD, far more is known about these syndromes and the 
genetic foundation of them, this will be discussed further below. The onset of AD 
within the Familial demographics of those affected by AD is over ten years younger 
than that of the sporadically occurring AD sufferers. With the average age of onset 
standing at 55.4 years of age in comparison to 65.7 within the familial and sporadic 
groups respectively(111). Furthermore to the age of onset the region of the aorta that is 
most commonly and severely affected by AD is also dramatically altered. Within 
Familial AD half of the incidence occurs within the descending aorta, in comparison, 
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47.5% of cases affected the same area in sporadic groups. In contrast, the ascending 
aorta is only implicated in 20% of familial AD dissections compared to 82.1% showing 
aneurysm-like expansion within the sporadic group, but only 17.9% displayed clear 
dissection(111). The change in occurrence between the familial and sporadic groups 
compared to the syndrome groups differentiates and determines the optimal clinical 
management of each patient. Beyond differences in management survival rates differ 
within each group. Preliminary research being undertaken at the University of 
Kentucky have shown that both the different regions and layers of the aorta affected is 
likely due to differential responses of the cells to alternate stimuli is highly influenced 
by their embryological origin(112)(113)(114). The aortic arch smooth muscle cells are 
derived from three separate embryological origins: Second Heart Field (SHF), Cardiac 
Neural Crest (CNC) and somites (113). The SHF makes up the aortic root and the most 
proximal portion of the aortic arch. This then has a crossover zone with the CNC, 
overlapping each other initially before solely the CNC continues to solely form the 
ascending aorta and the majority of the arch itself. In the crossover zone, the SHF makes 
up the majority of the external media, with CNC derived cells populating the luminal 
inner portion of the media. The descending aorta then is made up predominantly of 
somite cells. As you can see within the demographic data, distinctive areas of the aorta 
are affected differently. The study by Sawada et al. displayed that the cells derived from 
the SHF coincide with the outer medial deformation, seen within mouse studies, 
however not confirmed to be similar within the human aneurysm and AD pathology 
(112). This could shed light on why the different genetic differences lead to the 
pathology presenting within the different portions of the aorta. Syndrome related 
expansion and AD is predominantly located within these areas. Marfan Syndrome and 
Ehlers-Danlos Syndrome aortic remodelling largely occurs within the aortic root, 
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whereas Turners and Loeys-Dietz syndrome happen slightly more distally in the 
ascending portion(Table 2) (104,109). However both of these areas are still composed 
of SHF derived cells, this suggests that the origin of the cell could have a distinct impact 
of pathological outcome. This work is in its infancy and mechanisms of action need to 
be elicited and verified however this is an area of research that is becoming increasingly 
of interest due to its potential in targeted treatments.  
Table	2-	Summary	of	genetic	conditions	that	lead	to	a	significant	increase	in	AAA	incidence	
Genetic 
Disorder 
Gene 
Affected 
Protein Expression Mechanism of 
Action 
Clinical 
Presentation 
Marfan 
Syndrome 
FBN1 Expression of mutant 
fibrillin-1 
Mutation of 
cbEGF 
domains lead 
to defective 
protein folding 
and defective 
secretion, 
leading to 
defective 
myofibril 
formation and  
TGF-b 
signalling 
Widespread 
vascular 
alterations 
with 
frequent 
dilation and 
dissection of 
the 
aorta(115) 
Ehlers-
Danlos 
Syndrome 
COL5A1
, 
COL5A2 
538 genes expression 
modulated, 368 
overexpressed and 180 
Decreased 
stability of 
mRNA and 
Descending 
and 
abdominal 
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AND 
COL3A1 
under expressed, 
including; non-
functional COL5A1 allel
e and COLLV 
haploinsufficiency, 
whilst COL5A2 mutation
s affecting collagens 
structural integrity 
 
premature 
dissembly of 
collagen, 
leading to 
hypermobility 
and poor 
wound healing  
aorta 
rupture(104) 
Loeys-
Dietz 
Syndrome 
TGFBR1 
and 
TGFBR2 
Production of 
TGFBR1, TGFBR2, SM
AD3, TGFB2, 
or TGFB3 gene occurs at 
comparable levels but 
lacking function 
 
Unregulated 
TGF 
signalling, 
causing greater 
intensity of 
TGF 
signalling, 
disrupting 
ECM 
formation 
Rapidly 
expanding 
aneurysm 
with high 
incidence of 
dissection(1
16) 
Familial 
Aortic 
Aneurys
m and 
Dissectio
TGFR2, 
MYH11 
and 
ACTA2 
ACTA2 point mutation 
leads mutant protein 
expression in Smooth 
muscle α-2 actin protein 
 
 
ACTA2- 
defective 
sarcomere 
function 
Ascending 
aortic 
aneurysm 
and 
dissection(1
10) 
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n 
Syndrome 
Turners 
Syndrome 
45X Partial or complete 
absence of an X 
chromosome 
Cystic medial 
necrosis 
Increased 
AAA 
incidence(11
7) 
 
Syndrome related AD has a very different penetrance and impact upon life span in 
comparison to Familial and Sporadic AD. For instance, one of the most well-known 
syndromes where AD impacts patients is Marfans Syndrome. A defect in Fibrillin-1, 
leading to a severe connective tissue disorder that results in very tall, pigeon-chested 
and hypermobile joints amongst others(115). The most significant and life-threatening 
change is the cardiovascular changes that result from the defect in Fibrillin 1 
production. The genetic defect causes alterations in TGF-b signalling, this impacts 
vascular production with enlarged vessels, namely the aorta being a result. This 
expansion results in aneurysm and aortic dissection in most instances with this often 
being the cause of death for Marfans patients. Aneurysm and AD is most commonly 
seen within the aortic root and descending portion of the aorta, with 100% of 
descending expansions studied showing signs of AD within a recent study, compared 
to just 12.8% within the aortic root or ascending expanded areas(118). Furthermore, the 
expansion of the aortic root was alarmingly quick, increasing on average 0.26cm a 
year(119). This incredibly high level of dissection carries a huge mortality risk. Other 
syndromes such as Turners Syndrome and Ehlers-Danlos Syndrome have similar risks. 
Turners Syndrome is caused by the complete or partial loss of a chromosome, resulting 
in a 45X genotype(117). This can occur across the whole body, as well as in a mosaic 
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form. The mechanism by which AD affects Turners Patients is not yet clear, however, 
significant cystic medial necrosis has been documented within these patients and, as 
discussed earlier, is a known precursor to AD(105). Furthermore, Ehlers-Danlos 
syndrome is caused by a mutation to one of a number of genes, with each effected gene 
causing slightly altered phenotypes and inheritance of symptoms as a result(104). 
Collectively, the patients with this syndrome have a number of connective tissue related 
symptoms, with chronic pain, premature osteoarthritis, multiple dislocations of joints 
and scoliosis being some of the more common symptoms. Like with inheritance, life 
expectancy is variable depending on the specific gene or genes mutated, with some 
variants having normal life expectancy. However, mutations with associated vascular 
pathologies life expectancy is significantly shortened(120), largely as a result of the 
vascular deformation or associated conditions that are produced as a result.  
 
1.3	PROTEASES	IN	AAA		
AAA is a pathology in which a number of degradative processes occur. Chronic 
inflammation leads to dysregulation, depletion and disruption of structural proteins, cell 
content and extracellular matrices respectively. A large proportion of said processes are 
enzyme driven. This chapter will summarise the many roles of proteases within the 
development of AAA, outlining what is currently established within the literature and 
highlighting potential aspects in which proteases could have a further potential role. 
A AAA is the focal dilatation and weakening of the aorta, making it prone to rupture, 
significantly increasing mortality. There is known to be a large immune system 
implication in the production and development of the pathology, with enzymatic 
activity evidently pivotal in AAA initiation. NE is an, as yet, under-studied enzyme 
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within this process. Preliminary investigations suggest the current In Vivo AAA models 
to modulate levels of key proteins such as MMP-2 and -9 as well as NE. All of these 
proteases degrade the ECM, immune receptors and structural proteins that give rise to 
the vasculatures scaffold.  
1.3.1	MMPs	
MMPs are a class of endopeptidase proteins (121), all with different proteolytic abilities 
and functions within physiological processes, such as angiogenesis (122), but also 
pathologies, such as cancers (122) and cardiovascular disease (123).  
They consist of 24 different endopeptidases and are all enzymatically active giving 
them the ability to process the entirety of the ECM. MMPs are able to control the 
microenvironment surrounding cells, which in turn alters their viability within it (124). 
They also alter the internal environment of cells by modulating signalling in and around 
the cell membrane (124). Having such an important role in physiology, deregulated 
MMPs can strongly contribute towards disease pathology and its progression, such as 
in AAA.  
Originally grouped by the substrate that they degrade, namely collagenases, 
stromolysins and gelatinases, following the discovery of more members, a numbering 
system was adopted with groupings only made with relation to structure. Each MMP 
contains a conserved signal peptide along with a pro-domain and catalytic domain, 
within each different sub-group, such as in gelatinases for instance. Added regions are 
present and required for the breakdown of each respective substrate. Other features 
include hinge regions and Furin-recognition motifs in different subsets. 
 
As noted, the MMP family is a diverse group of proteins, both structurally and 
functionally. They serve to regulate and breakdown the ECM, with substrates and 
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localisation of activity greatly differing between the MMPs. Some are secreted, whilst 
others membrane-bound. The MMPs that have been shown to be most relevant to 
aneurysm are MMP-2, -9 and -12 (27)(58). These, respectively, are structurally, 
gelatinase and archetypal type MMP proteins that are secreted and cleaved at both ends 
into an active component. This cleavage can be triggered by alternate MMPs or other 
factors found in the ECM, such as the MMP-9 activation by MMP-2, activated protein 
C (125) or the presence of Zinc (121). MMP-2 and -9 degrade collagen (largely 
collagen IV and V) and gelatin, and MMP-12 degrades elastin.     
MMP-2 and -9 are seen as important contributors to AAA. Longo et al. (27) 
demonstrated the combinational effect of localised activation of MMP-2 and 9, before 
going on to look into the relation between MMP-12 and AAA (58). Whilst MMP-2 and 
-9 were showcased to be crucial for the creation of the aneurysm phenotype, MMP-12 
knockout studies were seen to minimise aortic expansion seen within the surgically-
induced aneurysm models. These two MMPs are of great significance and are required 
for the production of the AAA phenotype, it has been observed that both mesenchymal 
cells and macrophages produce these enzymes, with both needed in order to produce 
the AAA phenotype seen in studies of the condition(27). These studies examined the 
phenotypic differences made histologically by the presence of MMPs. MMP-12 loss 
had a dramatic difference, most notably on elastin structures within the vasculature 
(58). Similar structural defects were also evident in MMP-2 and MMP-9 knockouts. 
However, the significant differences exhibited between the three separate knockouts 
were that in MMP-12 models, recruitment of macrophages into the aortic wall was 
notably disrupted. In MMP-2 and -9 knockout mice, macrophages were recruited to 
levels similar to the ones seen in wild-type littermate controls, but instead, the 
degradation of elastin was defective(27). These findings demonstrated that important 
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AAA milestones, such as macrophage activation and recruitment, as well as elastin 
dysregulation are regulated by separate MMPs. Furthermore, these datasets highlighted 
the key immunological component of aneurysms and that level of macrophage 
recruitment and activation can be relatable to aortic diameter. This has been reproduced 
and further looked into, with suggestions of multiple immune cells such as neutrophils, 
amongst other cell types, possessing varying degrees of influence over the initiation 
and development of the pathology (126). 
A number of pathways that are also involved in AAA are responsible for up-regulation 
of MMPs  (127). Aortic histological samples have shown that such MMP up-regulation 
accompanies the dysregulation of collagen fibres (128). Other activating influences 
include MMPs being up-regulated by the Egr-1, ERK and NF-kB transcription factors 
(73), these are induced at times of inflammatory stress. 
Specific MMPs have also been shown to sustain fibroblasts that perpetuate 
inflammation in conditions such as Rheumatoid Arthritis (129). Fibroblasts produce 
MMPs in different conditions; primary cardiac fibroblasts respond to 
lipopolysaccharide stimuli and produce, via activation of ERK pathway, a number of 
growth factors, as well as the discussed MMPs, MMP-2 and 9  (130). Ehrlichman et al. 
and Zhang et al. have demonstrated the involvement of the ERK pathway within AAA 
(131) (132). ERK also perpetuates the induction of Egr-1, mediating the increase by 
promoting Egr-1 up-regulation(133). Egr-1, specifically within myeloid-derived cells, 
is crucial in the formation of aneurysms in Calcium-Chloride derived models(134). 
MMP-2 and -9 have been shown to be down-regulated in elastase-infused female mice 
at 14 days when compared to males at the same time point. This finding correlated with 
the decreased aortic diameters taken from random females at the same stage. 
Additionally, this data was inversely and proportionally correlated to the presence of 
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oestrogen receptor-a (ER-a), where oestrogen had been used as a protective agent 
against aneurysm formation. Alternate studies have also supported this idea, linking 
low oestrogen levels to increased rates of aneurysm (135). Furthermore, population 
statistics have shown that women overall, have a much lower occurrence of aneurysms 
than men (28), although this point of view has started to change with population data 
arising from Scandinavia contrasting these results(6). Supporting this alternative school 
of thought, the majority of mice studied within laboratories of some of the most highly 
regarded researchers into aneurysm use female mice preferentially within studies. 
Contribution of MMPs towards the AAA pathology may not stop at ECM breakdown, 
elastin and collagen dysregulation, immune recruitment and priming.  Dysregulation of 
MMP levels have been shown to also cause cerebral aneurysms (136). It has been noted 
that increases in MMP expression are not matched by rises in the levels of Tissue 
Inhibitor of Metalloproteinases (TIMPs). The presence of MMP-to-TIMP mismatch 
implies an increase in MMP activity, which is a widely reported finding, from multiple 
AAA studies (137). The increased activity comes from MMP protein up-regulation, as 
a result of altered MMP gene regulation. As mentioned earlier, MMP expression is 
modulated in part by the Egr-1 transcription factor. Evidence for this finding comes 
from fibroblasts within early stages of inflammation (138), macrophages and smooth 
muscle cells, amongst others (139). Interestingly, in chronic inflammatory conditions, 
of which AAA is considered one, Egr-1-induced MMPs are continually activated, 
which could potentiate the pathology (139).  
1.3.2	The Role of Neutrophil Serine Proteinases in AD and AAA  
 
NE is a serine protease harnessed within azurophilic granules, produced by neutrophils 
and macrophages alike(140). The deposition of such granules elicits an array of 
reactions, such as elastin breakdown, initiation and modulation of inflammatory 
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signalling and production of NETs. A number of said proteins and processes are 
relevant to AAA and the chronic inflammatory environment involved within the 
pathology. Whilst the link between NE and AAA has not yet been well established, this 
protease has many characteristics that make it a strong candidate for further study. With 
so many links to pathways and molecules associated with the AAA pathology, I will 
aim to shed light on the role NE plays within the pathology. 
 Inflammatory signalling and immune cell invasion is intrinsic to the AAA 
phenotype. A number of papers have shed light upon many different aspects of these 
processes; NEs influence on cleavage of TLR4 for instance. TLR4 cleavage leads to 
potent inflammatory cascade activation, which is, in part, responsible for the expansion 
of the aorta. Furthermore, the anti-microbial functionality of the serine protease serves 
to eradicate microbes and triggers mechanisms for clearing. NE enables the release of 
chromatin from neutrophils to engulf and nullify the microbes that are otherwise unable 
to be dealt with. NETs have been seen within histological samples of AAA, and 
blockage of the process has led to eradication of expansion within in-vivo models of 
aneurysms(141)(142). 
NE, as well as having direct effects upon structural proteins and receptors has indirect 
functionality, acting to potentiate and exacerbate the roles of other proteases and 
proteins shown to be intrinsic to the development of AAA. Dysregulation and 
breakdown of elastin, collagen and other ECM proteins are some of the most well-
studied and documented functions of NE(140,143), whilst all present and imperative 
for the development of AAA. Taking all of this into consideration, this area is an area 
of interest relevant to AAA and is currently understudied, I will aim to address some of 
the gaps in knowledge within this area as part of this series of works.  
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As mentioned above, NE is part of a family of enzymes with close relation to Cathepsin 
G (CG) and Proteinase 3 (P3), known as the Neutrophil Serine Proteinases (NSPs). PR3 
is expressed within a number of cells, largely of the granulocyte lineage(144), and can 
exist as both a membrane-bound enzyme(145) or in a secreted form(146). PR3, whilst 
expressed on some subsets of neutrophils, is able to be secreted from granules into the 
ECM, known as inducible PR3(146). Whilst PR3 has many similarities to NE, such as 
an enlarged binding region, there are also some distinct differences. These include large 
differences in the subsites of the binding site, such as the inclusion of three charged 
residues (Lys99, Asp61 and Arg143) within the binding site itself. PR3 has capabilities 
differing from other NSPs, due to its ability to reach deeper portions of the vessel in 
comparison to alternate NSPs and exert its catalytic effects (144). Furthermore, PR3 
has many roles within inflammation and the apoptosis of the immune cells themselves, 
regulating immune processes and prolonging neutrophil lifespan by inhibition of the 
caspase-3 dependent apoptosis pathway(147)(148). Within AAA, NSPs such as PR3 
have been suggested to play a role within the development of the pathology, with 
decreased levels of their inhibitor leading to worsening of the phenotype produced(16). 
Within the same study, CG was noted for its direct contribution to the AAA pathology, 
notably its direct actions upon elastin within the breakdown of the substance within the 
vessel wall of the aneurysmal aorta.  
Similarly to PR3, CG can be produced in a number of different cell types, including 
both Neutrophils and Mast Cells(86). CG has a multitude of direct actions upon the 
AAA process, with the ability to modulate MMP-1, directly degrade the ECM, induce 
SMC apoptosis and contribute to angiogenesis, all key features of AAA(86,149). CG 
was initially identified within the immunological response as part of large pathogenic 
clearance, within the NETosis process (150). NETosis has been identified as a 
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contributory mechanism by which AAA occurs, highlighting the relevance of CG and 
the NSPs within the AAA process(151).  
NSPs are not the sole influential group of enzymes within the AAA and AD processes, 
with a multitude of proteases associated with the pathologies, a selection of which will 
be raised and discussed within the following section. 
1.3.3	Sources	of	AAA-related	proteases	
 
The proteases involved within the AAA pathology come from a number of differing 
sources. SMCs, WBCs and even perivascular adipose tissue (PVAT), are all known to 
contribute significantly to the degradative environment. Each tissue contributes specific 
proteases that selectively break down the ECM of the aorta and help form the 
pathological phenotype.  
 
SMCs have been well studied within basic physiology and have now begun to be 
studied in association to the AAA pathology. SMCs aid the healthy aorta by producing 
the essential structural proteins, namely elastin and collagen, which provide support for 
the cellular content of the vessel. As well as these structural proteins that are produced, 
proteins with enzymatic function are also produced. In the case of SMCs, these are 
predominantly MMPs, which serve to degrade the same structural proteins the SMCs 
produce in order to support a healthy microenvironment. Within the AAA pathology, 
the balance of these two functions is both delicate and pivotal.  Dysregulation of this 
equilibrium causes the disruption of the ECM, evident within samples of AAA tissue. 
This appears to be influential, if not essential, in the progression of the AAA pathology. 
Many aspects of the immune system have been evidenced to influence AAA, both from 
in vivo and in vitro tissues.  Golledge, amongst others, has extensively shown the 
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impact of immune cells, namely macrophages and neutrophils, and the role that they 
play in the causation of the AAA phenotype. Production of molecules, such as 
Neutrophil-Gelatinase Associated Lipocalin (NGAL), by neutrophils, act to potentiate 
the abilities of vessel damaging proteases, such as MMPs. MMPs also have inhibitors, 
most influential in AAA are TIMP-1 and TIMP-2, which inhibit MMP-9 and MMP-2 
respectively(143). Macrophages are another leukocyte that has the potential to produce 
and influence the AAA phenotype, with similar work by Daugherty and Golledge 
amongst others shedding light on the potent proteins that they express and roles that 
they play within the breakdown of the vasculature(1,48,152). Not only does the 
macrophage lead to vasculature damage, but it also has key roles within initiating 
chronic inflammation, ECM breakdown and further problems such as SMC death(153). 
All of these are known markers for AAA and are seen within the early stages of the 
pathology. Macrophages and later foam cells that build up in various regions of the 
vessel wall activate macrophages. These cells have been stained within the adventitia, 
whilst the cells were also discovered within the media. These cells, recruited by 
inflammatory signals such as MCP-1 and IL-6, then serve to potentiate the immune 
recruitment and activation of the innate immune system via CD14 activation of TLR4 
and TLR2 (152). Following this activation we see a further up-regulation of monocyte 
recruitment and infiltration, leading to a self-perpetuating cycle of increased 
inflammation and immune cell invasion. Large quantities of proteolytic enzymes are 
produced as a result of this consistent invasion and production of an inflammatory 
environment, furthermore still, some proteases have been reported to elicit similar 
effects to that of bacteria and immune cells. For example, NE has been shown to 
activate TLR4 leading to increased function, triggering downstream effects with 
decreased need for a ligand such as LPS or CD14(154), as cleaved fragments become 
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active peptides. This complex immune component has begun to be studied within a 
number of differing contexts related to AAA, from vessel wall tissue to the relatively 
new area of perivascular fat. Mast cells and T-cells, along with the previously discussed 
macrophages and neutrophils, have been found within these areas and are now thought 
to contribute to the production of the AAA pathology(155). 
Perivascular fat, or PVAT, as it is referred in most literature, has roles related to cell 
trafficking and blood flow in and around the neovascularised areas of the aorta(155). 
AAA is an exception to the normality of WBCs invading tissues within small capillary 
networks and post-capillary venules, with the vessel lacking these features. 
Angiogenesis is a feature of AAA, and neovascularisation of the area leads to intricate 
networks of vessels around the aneurysmal area(156). These small vessels adventitia 
are encompassed by PVAT, in different quantities depending on health state. This fat 
is highly vascularized and appears to influence flow and function within the vessels 
passing through and surrounding it via a vasocrine system(157). This modulation, 
dependant on the health of the vessel can lead to endothelial dysfunction and immune 
cell invasion to the areas surrounding the vessel(158). This has been hypothesized as a 
contributor to the AAA pathology. Proteases originating from the macrophage and 
neutrophils, which are now free to move into the areas surrounding the adventitia, are 
then able to start breaking down the ECM, triggering apoptosis of the SMCs and 
contributing to the inflammatory background of the area, which in turn recruits further 
immune cells. This process kick-starts the weakening of the vessel wall and the eventual 
formation of the ballooned vessel wall.  
 
In summary, proteases have been shown to be involved in many different aspects of the 
AAA phenotype. Many proteases have known functions within the process such as the 
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well-studied MMP family, however others, such as NE, are still to be fully explored 
within the AAA setting. Protease complexes modulate the activity of these enzymes 
and the abundance of complexes is based in part upon the expression of regulators, 
which in healthy physiology is tightly regulated, but appears erroneous in instances of 
AAA. Proteases are expressed in large parts by the WBCs, and these enter the tissues 
via small vessels under the control, in part, of PVAT, cytokine signalling and 
inflammatory signals. This leads to the production of an inflammatory environment, 
within which the degradation of the aortic wall occurs. More detailed study is needed, 
especially in the case of less well-known proteases, such as NE, and their role within 
the pathology. Following this, we may be able to understand the mechanism by which 
AAA occurs to a greater extent.  
1.3.4 PDGFRB- a key receptor in protease expression 
 
PDGFRB, is a receptor that is intrinsic to vascular health. This includes binding to a 
number of growth factors, namely PDGF-B and –D amongst others. Resultant 
conformational changes that ensue trigger the receptors kinase domain which has 
widespread implications on intracellular enzymatic activities and can initiate the 
potentiation of AAA-associated proteases, transcription factors and proteins as a result 
(159). Ephrin-B2 is one key regulator of platelet-derived growth factor receptor b 
(PDGFRb) distribution in the VSMC plasma membrane, endocytosis, and signalling in 
a fashion that is highly distinct from its role in the endothelium. Absence of ephrin-B2 
in cultured VSMCs led to the redistribution of PDGFRb from caveolin-positive to 
clathrin-associated membrane fractions, enhanced PDGF-B-induced PDGFRb 
internalization, and augmented downstream mitogen-activated protein (MAP) kinase 
and c-Jun N-terminal kinase (JNK) activation but impaired Tiam1–Rac1 signalling and 
proliferation. Accordingly, mutant mice lacking ephrin-B2 expression in vascular 
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smooth muscle developed vessel wall defects and aortic aneurysms, which were 
associated with impaired Tiam1 expression and excessive activation of MAP kinase 
and JNK which in term regulate key protease activity e..g. MMPs (160). Published data 
suggests that ephrin-B2 is an important regulator of PDGFRb endocytosis and thereby 
acts as a molecular switch controlling the downstream signalling activity of this 
receptor in mural cells. (160) 
Platelet-derived growth factor receptor-B (PDGFRb) has intrinsic roles within the 
maturation and development of the cardiovascular system within embryogenesis and 
knockout of the protein leads to reduction of VSMCs and pericytes. Interruption of 
pericyte growth and viability impacts the production of capillary cell walls and leads to 
the production of microaneurysms within the capillary network (161). Loss of the 
PDGFRβ protein consequentially decreases the functionality of multiple organs 
including the brain and the heart. Containing intracellular kinase activity, once 
internalised within the VSMC PDGFRb induction can increase the activity of MAP-
kinase and JNK, both highly influential in AAA. Consequentially due to lack of 
PDGFRb presence and subsequent kinase activity, AAA and other vessel wall defects 
can ensue as a result. Furthermore, PDGFRβ has known interactions with LRP1, and 
again this influences kinase activity downstream with regards to MAPK. However, the 
level of influence and direction of mediation is highly debated with some studies 
observing the suppression of MAPK and other stimulation when the two interact. 
Alternately, LRP6 has a negative effect on PDGFRβ levels which in turn diminishes 
levels of VSMC proliferation(160). 	
1.4	ROLES	OF	NE	IN	IMMUNITY	AND	DISEASE	
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Whilst there have been many known proteases associated with the AAA phenotype, 
novel proteins and new associations with already identified enzymes are being made 
all of the time. As we begin to unravel the contributing mechanisms to AAA we 
understand the processes and roles certain proteins have within the phenotype. For 
instance, the previously mentioned MMP9 that has a huge impact on the production of 
the AAA phenotype is now known to be regulated in part by an array of miRNA 
proteins, namely miR-133b, miR-133a, miR-331-3p, miR-30c-2 and miR-204 which 
were all downregulated within human AAA aortic samples (162). Furthermore, some 
proteins and even cell types with known function in other areas are now beginning to 
be evidenced as to playing an influential role within the AAA condition(163). For that 
reasoning, it is valid to look into other areas of research with associations to the 
pathological processes occurring within AAA for a deeper insight into the currently 
poorly mapped out mechanisms controlling aneurysm development. For instance, NE 
is a molecule with known roles in pathology, immune implications and regulation of 
key molecules such as some of the aforementioned proteases(17,143,164). Resultantly 
being an enzyme of interest and a candidate for further study.  
NE is an enzyme contained predominantly within azurophilic granules of the 
Neutrophil prior to degranulation into the cellular surroundings; however latest 
research is suggesting its ability to be produced by other cell types most abundantly 
within other white blood cell subtypes(17). Azurophilic granules harness a number of 
proteases, two of which highly structurally related to NE. Cathepsin G and Proteinase 
3 are both serine proteases that work in conjunction with NE within microorganism 
clearance within the phagolysosome(154). NE was firstly known to degrade elastin, 
however further studies have gone on to identify the enzymes ability to cleave many 
other extracellular matrix proteins, enzymes, cytokines and adhesion molecules, a 
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number of which with relevance to AAA. MMP2 and MMP9 are both able to be cleaved 
by NE(165)(143), along with TLR4 and VCAM-1 amongst many others(166), all of 
which have known roles within the production of AAA. NE cleaves peptide bonds by 
arrangement of a catalytic trio of protein residues, a property conserved within the 
chymotrypsin family of serine proteases that it belongs.  
Inactive NE is synthesized in the endoplasmic reticulum prior to activation and 
packaging into azurophilic granules. The activation and packaging step is dependant 
upon processing of the peptide. Firstly dipeptidyl peptidase I cleaves the signal 
sequence to activate NE, following on from this NE can be further modified with 
alterations made to the carboxy-terminal. The secondary modification of NE, whilst not 
necessary for activity, aids trafficking of the enzyme to azurophilic granules with non-
cleaved versions directing the molecule to the plasma membrane. This direction alters 
NE ability to function within a number of immune and disease-related 
mechanisms(167). For instance, NE has a significant role within the deployment of 
NETs as well as the previously mentioned role within clearance of pathogens within 
phagolysosomes. NETs are web-like structures composed largely of chromatin that 
bind to pathogens in order to aid the clearance of larger pathogens. NE and other 
mediators such as myeloperoxidase (MPO) and protein-arginine deiminase type-4 
which are responsible to trigger the release and decondensation of the later released 
chromatin(14). Whilst the process is predominantly beneficial, links to disease have 
started to emerge. Roles within cancer metastasis and thrombosis have been 
documented, whilst links to AAA have also emerged.  
NETosis is the tertiary mechanism of defence of neutrophils, with the release of 
chromatin, containing antimicrobial properties and proteins, in an effort to trap and 
nullify pathogens(168). However, problems arise from the failure to clear such 
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chromatin, as this leads to the triggering of the host immune system against the proteins 
and cellular components expelled during the release of NETs(168), in turn this can lead 
to disease and has associations with AAA(142). Within this process, beyond the 
decondensation mechanism, ROS are produced in order to target and eradicate the 
pathogen. NADPH oxidase complexes drive this, through activation upon initiation of 
NETosis, this converts to Hydrogen peroxide. This is subsequently broken down by 
MPO and in turn stimulates the release of NE containing granules, which proceed to 
stimulate the degradation of histones and allow for the release of chromatin(95). NE 
and MPO are then able to attach to NETs when the nuclear membrane of the effected 
cell disintegrates. This both stabilises and increases the antibacterial properties of the 
released NET. This process, due to the membrane rupture mechanism, leads to the death 
of the neutrophil(169).    
The role of NE within pathology is far better documented and well understood in other 
areas, most prominently COPD(164,170). Within COPD NE is understood to drive 
many of the processes where the lung and its microstructure deteriorate, leading to the 
fall in indicators such as FEV1 with the rise in NE levels. This was first determined as 
a result of poor pulmonary health within patients suffering from a-1 anti-trypsin 
deficiency, a known inhibitor of NE. These patients presented with early-onset 
symptoms and far more severe phenotypes within patients suffering from both the 
deficiency and COPD. With the loss of a-1 anti-trypsin, even healthy individuals suffer 
signs of COPD and associated diseases due to the proteolytic breakdown that results 
from unregulated NE expression(171).  
Resultantly, with NEs known roles within COPD as well as a number of associated 
contributing elements of AAA, namely; immunity, inflammation and ECM 
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degradation, further investigation into the role of NE within AAA appears necessary to 
elicit its full role within the disease.  
1.4.1 The role of Neutrophils in AAA 
 
Of the multiple WBCs that are known to have a role within the AAA pathology, most 
prominently studied being the macrophages, neutrophils are a less studied subgroup of 
WBCs, previously regarded as having limited role largely contained to phagocytic 
actions. However, identification of neutrophils and their roles within inflammation 
have been brought to light, with roles relating to release of reactive oxygen species and 
neutrophil proteases into the medial vessel wall and throughout the intraluminal 
thrombus specifically(87).  
 
Neutrophils are recruited into tissues at times of acute inflammation, performing 
phagocytosis and pro-inflammatory functions with an aim to recruit further more 
specialised cells and promote clearance or resolution of infection or injury, 
respectively. Initial extravasation is a more complex process than previously thought, 
with cells forming a ‘tether and slingshot’ mechanism to be released from the 
bloodstream. Neutrophils follow multiple gradients of chemokines, initially following 
intermediate signals before progressing to further localised pathogen chemoattractant 
mechanisms (172). This chemotaxis is controlled by MAP-kinases amongst other 
mechanisms. This function highlights MAP-kinases importance and level of control 
over cellular activities. Beyond homing of the neutrophils and their basic functions as 
an immune cell, neutrophils produce numerous proteins and proteases that serve to 
prime the differing arms of the immune system by methods of activation and release of 
such mediators.  
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Neutrophil associated proteins such as D-Dimer and MPO, have been discussed as 
potential markers of AAA as a result of their correlation with the AAA pathology. 
Further, DPPI, dipeptidyl peptidase 1, a neutrophil-associated enzyme, was key in the 
production of experimental AAA, with knockout studies of the gene responsible for its 
expression abolishing the pathology (142). This strengthens the growing argument from 
within the literature that there is a key influence from neutrophils within the AAA 
pathology and its evolution. Supporting this, observations of neutrophil recruitment to 
the aneurysmal site, along with their activation resulting in NETosis, a characteristic 
discovered in both animal model and human AAA tissues. With relation to this study, 
it has been outlined that DPPI is responsible for release of key NSPs, such as NE and 
Cathepsin G in mature neutrophils.  
 
Expression of NE within neutrophils- 
Following bacterial infection, NE is known to be released into the extra-cellular space 
in order to aid in the battle against such pathogens. Release of NE produces increases 
in proinflammatory cytokines, namely TNF-alpha, MIP-2 and IL-6 via the NK kB 
pathway, this has been shown to improve immune function and consequently improve 
mortality rates (173). This is likely due to the evidenced recruitment properties of the 
aforementioned molecules which increase neutrophil translocation to the infected site. 
Stored within neutrophil granules at high concentration NE is released and exerts anti-
microbial properties, often in conjunction with NETs. However, NEs increased 
production of pro-inflammatory molecules mRNA can be limited by the presence of 
silvestat, which stunts the enzymes catalytic activity. This catalytic activity enables the 
induction of protein expression, including IL-8 expression mediated by TLR4(174). 
Multiple studies have outlined the role of NE and its relevance in the production of pro-
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inflammatory molecules such as IL-8, IL-6, MIP-2 and TNF-alpha in various cell types, 
most importantly macrophages. As such, NE appears to have TLR4 cleavage properties, 
which in turn produces active fragments with biological mRNA expression modulation 
potential, investigations into whether other serine proteases possess similar ability to 
achieve these results are being looked in to (174).  
As well as having a direct role in AAA formation, by influencing structural proteins via 
processes such as proteolytic action and NETs, neutrophils can govern the production 
and release of key cellular mediators such as chemokines and cytokines. This can take 
the form of Interferons and Interleukins, with increased expression of type-1 IFN 
mRNA found in both tissues and serum of afflicted patients.  The discovery that NETs 
and interferon alpha not only play a critical role in promoting experimental AAA but 
are also increased in human AAA suggests a high level of influence, and targeting of 
neutrophils and the cell type associated proteins may slow the expansion of AAA (142). 
Beyond cellular mechanisms of AAA, matrix proteins are importantly regulated within 
the AAA process, with modifications to the arrangement of collagen and elastin being 
two of the key steps to AAA production. These changes can, in part, be brought about 
by neutrophil action, with proteolytic degradation of elastin a known function of NE , 
a neutrophil derived protease. Furthermore, neutrophils have been suggested to support 
further production of proteases within the ILT, with large-scale production of MMPs 
and cytotoxic molecules that in turn degrade the vessel wall and deplete the vascular 
integrity by inducing VSMC damage (175) 
As identified above, neutrophils have key roles within the formation of AAA and its 
pathological phenotype. Neutrophils are located largely within the ILT and adventitial 
portions of the pathological vessels. Studies into neutrophil expression patterns within 
AAA made the observation of key regulators of AAA such as NGAL, MMPs and MPO, 
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amongst others, were largely expressed within the ILT, and most specifically the 
luminal portions of the thrombus. NE, an enzyme with involvement within a number 
of the processes associated with AAA, such as NETosis and chronic inflammation, is 
the focus of this work. NE and its role within AAA is less well defined and has the 
potential to have significant impact on the AAA pathology due to its multiple relations 
to initiating molecules and mechanisms of AAA such as direct elastin degradation. 
Whilst neutrophils are traditionally seen as responders to acute inflammation, evidence 
suggests them to have a role within chronic inflammatory processes and  the 
potentiation of a worsening phenotype long term within aspects of the pathology such 
as the high concentration of neutrophils identified within the ILT. Current research into 
neutrophils and their role within AAA demonstrates impaired neutrophil recruitment 
can lead to improved AAA outcomes, at least within animal models (176). 
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2 HYPOTHESIS & AIMS 
HYPOTHESIS 
The foundation for this is the known contribution elastin breakdown and immune cell 
recruitment has to both the AAA and AD pathologies, taking into account the impact 
NE is proven to elicit on elastin, and involvement NE has been shown to have on 
relevant immune-related receptors, such as TLR4 amongst others. More directly, NE 
has a key role in NETosis(142), a phenomenon recently put forward as a further 
contributing aspect to the AAA pathology. Medial dysregulation and apoptosis are 
largely responsible for changes that lead to AD, with NE having known influence 
within these processes. Furthermore, NE can modulate MMPs which are known 
triggers of AD(177). 
The hypothesis of this PhD study is that NE is involved in a mechanism contributing to 
AAA production and stability and that by knocking out this enzyme rates of AAA will 
be decreased. Similarly, we predict AD to be influenced by NE in a similar fashion to 
AAA. Consequentially, we hypothesize that NE will become a novel drugs target for 
the treatment of AAA and AD.  
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AIMS 
Þ To	produce	a	protocol	to	monitor	and	measure	AAA	expansion	and	characteristic	
features,	 such	 as	 blood	 flow	 alterations,	 vascular	 remodelling	 and	 vessel	
pulsatility	changes.	
Þ To	understand	the	effect	changes	in	expression	levels	of	NE	has	on	AAA	and	AD-
associated	proteins,	such	as	MMPs,	on	a	cellular	and	tissue	level	
Þ Study	the	effect	that	the	loss	of	NE	gene	has	within	Angiotensin-II	and	Calcium	
Chloride	models	of	aneurysm	
Þ Study	the	effect	that	the	loss	of	NE	gene	has	upon	TAD	within	animal	models	
Þ If	a	difference	is	discovered,	identify	the	mechanism	by	which	NE	contributes	to	
the	production	of	the	AAA	and	AD	pathologies.	
Þ Verify	 if	 knowledge	 gained	 from	 this	 study	may	 be	 translatable	 to	 the	Human	
conditions	
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3 GENERAL MATERIALS AND METHODS 
3.1	CELL	CULTURE	
Culturing of a number of cell lines occurred, predominantly; Human Umbilical Vein 
Endothelial Cells (HuVECs), Human Smooth Muscle Cells (hSMCs) and mouse 
macrophage cell line (RAW 264.7). These cell lines were chosen due to their relevance 
to the AAA pathology. By studying HuVECs we were able to elicit an understanding 
of how the vascular endothelium reacts to inflammatory insults utilised within the 
different models of AAA. hSMCs, from the aortic vascular bed, were cultured to give 
us information on the changes of expression that occur within the smooth muscle 
component of the vasculature. Finally, RAW 264.7, a monocyte-macrophage cell line, 
will give us a general comprehension of how an integral part of the inflammatory cell 
component is implicated within the models.  
HuVEC cells were cultured in T75 flasks on a surface of 0.04% gelatin in Medium 199, 
10% FBS and Antibiotics, until 60% confluent prior to use for experiments. hSMC and 
Raw264.7 cells were also cultured within T75 flasks within DMEM media, 10% FBS 
and Antibiotics, reaching 75% and 60% confluence respectively before experimental 
usage.  
3.1.1 In Vitro Calcium Chloride and Angiotensin-II Experiments 
All experiments reported below used the same protocol of AngII exposure. Cells were 
grown in 12-well plates overnight, with 500µl of media (Dulbecco’s Modified Eagle 
Medium (DMEM)(Sigma Aldrich UK) or Medium 199, 10% fetal bovine serum 
(FBS)(Sigma Aldrich UK), 1% L-glutamine (2.5mM), Penicillin (100U/ml), 
Streptomycin (0.1mg/ml)(Sigma-Aldrich UK)) containing AngII diluted within the 
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relevant growth media to specific concentrations. Cells were left for 48, 24, 4, 2 and 1 
hours under treatment conditions before immediately being harvested.  
Within reported data, CaCl2 exposure was for a period of 5,15 or 30 minutes, with 
media refreshed and cells recovered for 8hours following this before harvest. Multiple 
concentrations of CaCl2 were trialled.  
 In Vivo models of AAA are used in order to gain a greater understanding, as 
currently there is limited knowledge with relation to the initiation and progression of 
the pathology. The degradation of elastin, collagen and other structural proteins, is a 
widely accepted early-stage event in the formation of the aneurysmal phenotype. NE is 
an enzyme able to degrade some of these proteins and is therefore, the initial protein 
being explored with relation to AAA.  
Translating the In-Vivo models of aneurysm into an In-Vitro method by which we can 
look at the impact each method has within each cell-type is first needed. By establishing 
an In-Vitro model, we will be able to measure a number of AAA associated proteins, 
such as MMP2 and MMP9, as well as the level of expression NE.  
In-Vitro exposure to Calcium Chloride was varied as to best assess which duration 
caused expression most akin to that of the aneurysmal phenotype seen within animal 
models. In-Vivo, exposure has been reported to range from 6 to 15 minutes. Resultantly, 
similar time-points were trialled, as well as longer durations of exposure in order to 
mimic the chronic pathology AAA is regarded as. 
In-Vitro exposure to Angiotensin II (AngII), is a much more well-established protocol 
and therefore less variation in conditions were needed to be trialled. Current literature 
was followed as a guideline of appropriate concentrations for use within 
experimentation. 
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A time course of the varying effects differing concentrations has on expression of the 
relevant genes was carried out in both models. Utilising RT-qPCR, modulations in the 
gene expression were determined and compared.  
 
 
Figure	3-	Schematic	diagram	of	the	seeding	and	treatment	of	cells	using	Ang	II	and	CaCl2.	
Cell	seeding	describes	cells	seeded	within	each	well	on	a	12-well	plate.	Each	individual	well	
contained	 one	 cell	 type,	 treated	 with	 one	 stimulant	 for	 one	 time	 duration.	 Each	 set	 of	
conditions	was	performed	in	triplicate	for	each	set	of	parameters.		
 
3.2 ANIMAL HUSBANDRY 
All mice were housed in accordance with the regulations specified within the Animals 
Scientific Procedures Act 1986, with all experiments being approved by the Home 
Office prior to commencement of all procedures. This included the housing of animals 
in ventilated cages with controlled lighting, light and dark cycles of 12 hours each, with 
temperature regulated between 20 and 23 degrees. Food and water were available ad 
libitum, with standard chow diet available at all times. With the commencement of any 
highly invasive procedure, such as the Calcium Chloride model of aneurysms, mice 
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were individually housed in order to minimize the risk of breakage or biting of sutures 
causing infection or disembowelment. Upon the completion of all experiments, mice 
were humanely culled by Schedule 1 procedures most commonly CO2 chamber 
followed by cervical dislocation. 
 
3.3 MOUSE STRAINS 
3.3.1 C57/BL6-ApoE Knockout mice:  
ApoE deficient mice on a C57BL/6 background were originally purchased from 
Charles River Laboratories (Margate, UK) before inbred breeding in house to expand 
the colony took place. All Control mice were of this background due to the pro-
atherosclerotic phenotype that is a consequence of the genetic deficiency. This is 
representative of the demographics of AAA sufferers.  
 
3.3.2 NE Knockout mice: 
These mice are deficient in the ELANE gene responsible for the production of NE. 
Elane−/− mice from The Jackson Laboratory, 006112 mice were bred with C57/BL6-
ApoE Knockout mice to produce a double knockout for both ApoE and NE genes as 
described in our previous study(167). Genotype was confirmed following birth of 
litters, with mice separated into cages based upon gender and genotype. All mice were 
caged with littermates of similar gender and genotype. These mice were confirmed to 
be deficient for both NE gene and protein.  
Within all AAA protocols, mice of both genders were aged until 8-weeks old prior to 
the commencement of CaCl2 or AngII protocols, outlined below. Alternately, for BAPN 
induced AD studies, mice were placed upon protocols at 3 weeks of age and limited to 
the male population of pups.  
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3.4 GENOTYPING 
All mice underwent genotyping in the period prior to weaning from mothers at the 3-
week postpartum period. DNA of each mouse was isolated from tail tips of the mice, 
with samples digested overnight at 55 degrees in 250µl of lysis buffer containing 
100mM Tris-HCL (pH 8.5), 5mM EDTA, 200mM NaCl, 0.2% SDS and 100µg/ml 
Proteinase K. Following lysis, contaminant debris was pelleted by centrifugation at 
17000 RCF for 10 minutes. Supernatant was transferred into new sterile labelled tubes 
and the pellet discarded. Isopropanol was added to each tube (250µl per tube) with 
gentle vortexing carried out in order to precipitate DNA. This DNA was further 
centrifuged, again at 17000 RCF for 10 minutes, with supernatant discarded, washing 
in an ethanol gradient and air-drying. Following this wash and drying, the pellet 
containing DNA was suspended within sterile DNAse free H20.  
PCR reactions were performed to identify the genotype of each mouse, with primers 
selective for the NE Knockout and Control mice utilized within each reaction. PCR 
cycle details, as well as further information regarding the primers used within each 
reaction, are detailed below in Table 3. 
Table	3-	PCR	details	utilized	within	the	PCR	and	qPCR	experimentation,	including	primer	
information,	cycle	details	and	size	of	gene	targeted.	
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PCR amplification enabled the expansion of genetic materials, following this the 
amplified mixture was mixed with loading buffer prior to vortexing to ensure sufficient 
mixing occurs. This was then placed within wells of 10% self-poured polyacrylamide 
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gels, with the gel ran within an electrophoresis unit it 1x Running buffer at 100 volts 
for 45 minutes before being stained and visualized for identification of genotype.  
 
3.5 ANGIOTENSIN-II MODEL OF ANEURYSM 
The procedures for AngII-induced AAA were similar to previous studies with 
modifications(178)(46). Specifically, animals were selected for this procedure based 
upon genotype, age and gender. All mice were kept with littermates, in cages of no 
more than 6 mice, until insertion of an osmotic pump (Alzet, model 1004, 0.11µl/hr). 
All mice studied were scanned using an MRI (1Tesla), prior to pump insertion, and 
injected with 90µl Galbumin (BioPal) solution, diluted 1:10 Galbumin stock: saline) 
immediately preceding imaging. Isoflurane anaesthesia (Piramal Critical Care Ltd) is 
used to sedate animals during the scan, with heart rate and breathing rate monitored 
throughout the scan. This scan gives us a composite image that is then reconstructed in 
order to give us volumetric data of the infrarenal portion of the aorta, as well as diameter 
measurements of specific places along the course of the aorta, for comparative reasons 
when compared against scans on the same animal at later time points.  
Pumps were inserted sub-dermally, being placed into the excess skin fold of the 
abdominal wall, entering via a small incision at the back of the neck. Connective tissue 
is loosened using blunt dissection sub-dermally within the skin folds.  The pump is 
inserted lid first and lubricated using saline, to minimize chances of contents leaking or 
dislodgement of the central pin before sutures close the wound.  Following the 
procedure, animals were individually housed and recovered, whilst being checked daily 
for health and condition. There is a high risk of complications, especially in the first 5 
days of Angiotensin-II administration, therefore close attention to the condition of the 
animal is essential so that it does not undergo any unnecessary pain or prolonged 
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complications. A hypertensive phenotype is produced within this period and 
remodelling of the vasculature ensues over the next few days and weeks. Dilation of 
the vessels, tissue remodelling and endothelial dysfunction or loss occurs. Following 
this aneurysm formation can occur, generally within the last week of incubation with 
the hypertensive agent. 
Mice are left for 28 days post-implantation of the pump, before removal and a second 
MRI taking place. Pumps must be removed prior to MRI taking place for the safety of 
the mouse, as the steel pin within the pump is magnetic and therefore the magnetic 
forces within the MRI would attract this, causing potentially fatal problems. Monitoring 
of the animals' aorta can occur during the 28 day time period but must be in the form 
of ultrasound scanning. This occurred in a cohort of the mice within this study.  During 
ultrasound scanning, ensure that the probe is never focused over the pump, as this can 
affect flow rates and has the potential to cause deviation in the level of angiotensin 
within each mouse. This is monitored and controlled in each mouse relative to body 
weight at a dose of 1.44 mg/kg/day AngII (Sigma Aldrich) diluted in saline (Sigma 
Aldrich). The weights of the mice are measured and recorded prior to pump filling, at 
the halfway stage and prior to the final MRI scan. This allows for the pumps to be filled 
with a specific concentration of Ang-II solution so that the correct dosage is 
administered to each mouse. 
The second MRI scan is performed post-pump-removal, this enables comparison with 
the original ‘Week 0’ scan and for quantification of changes in infer renal aortic 
diameter and volume. From the reconstruction and individual sections produced by the 
MRI scan, we are able to determine the precise expansion of the vessel both in terms 
of diameter of the vessel and volumetrically. The use of Galbumin enables us to make 
luminal measurements that are as distinct as possible, as it highlights the areas in which 
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blood has pooled/ is present. One drawback to this technique is that, although we are 
able to distinguish between luminal and vessel walls, we may not be able to 
differentiate, with complete accuracy, between lumen, intra-mural thrombus and vessel 
wall. With this in mind, the use of ultrasound and MRI in conjunction with each other 
allows the verification of results at each time-point.  
3.8 MRI SCANNING OPTIMISATION 
Imaging of the abdominal aorta is complex due to it being a deep-lying structure, 
covered by a number of vital organs. This can distort the image in many methods of 
imaging, such as ultrasound. However, due to the MRI taking a series of sectional 
images, this minimizes such problems, with the magnetic forces being able to penetrate 
all tissue types, again unlike ultrasound, where sternum shadow can be a big issue with 
cardiac imaging especially. The clarity of the image needed to be optimized further, 
however, as with all MRI scans, the selection of the type of image and further 
optimization steps such as pixel size and field size adjustments. Furthermore, the type 
of scan needed to be decided too, with options of both T1 and T2 weighting. The T1 
and T2 imaging selection decides whether tissues with high water content will appear 
bright or dark, and tissues with low water content dark or bright respectively. The ratio 
between echo time (Te) and repetition time (Tr) determines these differences in 
appearance. Sort Te and Tr gives you T1 weighted images and Long Te and Tr produces 
T2 weighted images. In order to make aortic images as clear as possible, to enable the 
most precise and accurate measurements of the infrarenal aorta, T1 weighted imaging 
was chosen after a trial of the two imaging techniques. T1 allowed the blood to be 
visualized as a bright field, enabling us to determine the borders of the vessel, and 
therefore the volumetric content. One issue that arose in the post imaging analysis was 
the blur created by distortion of the image, as the signal strength was not different 
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enough between the lumens border and the blood-filled lumen itself. This created the 
problem of potential inaccuracies in infrarenal quantification. To minimize this, a 
contrast agent was looked into, as this would increase the difference in signal between 
the vessel wall and the lumen of the vessel. Being able to distinguish between the two 
would allow us to see the changes in luminal size, the area of most interest. We would 
still be able to visualize the wall, with more detailed information regarding the vessel 
wall coming from alternate imaging, i.e. ultrasound. The options for contrast agents 
included gold nanoparticles and Gadolinium labelled albumin (Galbumin) amongst 
others. Due to its high molecular weight and therefore slow clearance, as well as cost 
restrictions, Galbumin was chosen as the preferred contrast agent. Galbumin was seen 
to be the most value for money and of sufficient quality to produce the difference in 
signal needed for the accuracy of quantification. Following the addition of Galbumin 
via tail vein injection, signal intensity within the aorta increased significantly and 
allowed for accurate measurement of the infrarenal portion of the aorta, as illustrated 
within Figure 3. Volume and dilution of this was altered and optimized to ensure the 
minimal amount was used, whilst maintaining optimal effect. This reduction ensured 
that the animal was administered the minimum quantity of the Galbumin and carrier 
substances, in case of adverse reactions.   
	
3.8.1 Ultrasound Scanning 
During this sequence of experiments, 2 different ultrasounds have been utilized, with 
the Vevo 770 and Vevo 3100. Initial scanning procedures were started on the Vevo 
770, then after completion of pilot experiments involving the calcium chloride 
procedure all techniques transferred and updated utilizing the Vevo 3100 for increased 
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resolution and quality of the image. Ultrasounds intended use was to obtain information 
on the vessel wall, and later on information regarding flow.  
Functionalities available on the Vevo 3100 included colour and pulse wave Doppler, as 
well as B-/M- modes. This allowed for a variety of additional assessments to be carried 
out. The intended use of the probe available is cardiac imaging, this means that frame 
rate is much higher to increase the pictures taken so that you can see the heart at all 
points of the heart cycle, however, this reduces resolution. This was able to be altered 
slightly, via modifications to the software controls such as gain, frame rate, pixel 
resolution, dynamic range and ultrasound focus depth. These adjustments allowed for 
clear images to be obtained at a greater depth within the animal, in comparison to 
cardiac imaging. From this, we were able to build protocols and troubleshoot the 
orientations of the ultrasound that was both reproducible and produced clear images. 
The clarity of M-mode imaging especially altered greatly with a change in orientation 
of the probe (See Below). Initial measurements were taken with the probe in a 
longitudinal orientation, whereas whilst in cross-section images produced far less noise 
and much more precise imaging. This meant the measurements of the vessel could more 
precise, increasing the accuracy of the study. From this increase in clarity, we can now 
precisely measure the artery at the point of max systole and diastole, giving us a 
measurement of the pulsatility of the vessel and how this changes over time in response 
to treatment. At the same time, we are consequentially able to measure vessel wall 
thickness as a result of the increases seen in the clarity of images. This increase enables 
the tracking of structures within the vessel wall through the pulse cycle. Resultantly, 
following aneurysm induction, we are able to monitor any changes in the composition 
and size of the vessel wall undergoes.  
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Figure	4-	Optimisation	of	ultrasound	M-mode	scanning.	(Top)	shows	a	cross-sectional	view	
of	the	aorta	with	clear	M-mode	trace,	enabling	defined	and	accurate	measurements.	Note,	
the	minimized	levels	of	distortion	enabling	a	clear	vessel	path	shown	as	deep	black	(Bottom)	
a	longitudinal	image	of	the	same	infrarenal	aorta	within	the	same	mouse,	with	a	very	noisy	
trace,	this	leaves	it	hard	to	distinguish	between	vascular	wall	structures	and	noise	signals.	
US	noise	is	shown	as	white	speckled	traces	within	the	vessel	path.	
3.9 RNA ISOLATION 
Analysis of tissues from both AAA model, as well as Biobank collaborative works,  
were collected and preserved in liquid nitrogen immediately following harvest in order 
to ensure maximum quality of RNA. Snap frozen tissues were labelled and stored 
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within a -80°C freezer until extraction of RNA was possible. Upon removal from the 
freezer, tissues were placed on ice and transferred to a worktop. Sample vasculature 
was then transferred using tweezers from labelled tubes to 500µl Eppendorf tubes. This 
was dipped in liquid nitrogen with some liquid placed inside the tube to ensure complete 
freezing. At this point, a mini pestle was used to crush the tissue into a powder that 
remained within the Eppendorf. This powdered substance was then suspended within 
Trizol prior to further mixing by pestle on ice. Pestles were removed and thoroughly 
washed with detergent overnight to ensure no contamination of samples. Following 
treatment of all samples with Trizol, all solutions were centrifuged to pellet cellular 
debris. Centrifugation was carried out for 10mins at max speed, prior to the supernatant 
being removed and placed within fresh sterile Eppendorf tubes, leaving behind all 
pelleted materials. Isopropanol (200µl) was then added to these tubes and shaken to 
precipitate RNA. All precipitated RNA was then pelleted by a further 10 minutes of 
centrifugation at max speed. Pellets were then washed using an ethanol gradient before 
being left to air dry for 10 minutes. Following this, the pellet was resuspended in sterile 
H20 and vortexed to ensure complete suspension.  
3.10 PCR 
Genes of interest, the most important markers of aneurysm and NE, were quantified by 
a series of PCR reactions. RT-qPCR enabled the relative quantification of each protein 
to be measured within both Tissue and Cell lysate samples following genetic material 
extraction from initial experimental tissues. The concentration of isolated RNA from 
tissues was quantified within each sample using the NanoDrop ND-1000 
spectrophotometer, operating at 260nm. Concentrations were recorded for each sample 
before solutions were made up to 100ng in 20μl. RNA was converted into cDNA at this 
stage, utilizing PCR reagents outlined in the Table 3. Primers were designed to 
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specifically identify the genes of interest, and sequence for each primer is shown in the 
Table 3. Housekeeping genes GAPDH and 18s were used to control for sample 
variance and allow for the assessment of sample quality. 
3.11 HISTOLOGY 
Upon completion of all aneurysm-modelling experiments, the aorta was dissected, with 
photographs being taken to document the phenotype produced by all models in each 
genetic background tested. A subset of these mice aortas was taken at random for 
histological analysis. Mouse aortas were flushed with 4% PFA injected into the left side 
of the heart upon initial dissection to remove all the majority of luminal blood. 
Following this, a finer dissection was carried out and the aorta was removed 
completely, including heart and kidneys down to the aortic bifurcation at the femoral 
artery region. These vessels were then placed within labelled cryovials submerged in 
PFA and left overnight. The following day these were transferred to a similarly labelled 
cryovial, this time with distilled water to rehydrate the samples before again being left 
overnight. Fine dissections under microscopic aides were used to strip away connective 
tissues and fat from the vessel before mounting. Tissues were mounted within either 
OCT or Paraffin dependant on the stains they were to be subjected to. For OCT sections, 
dry ice was placed within a polystyrene container to provide a flat cold surface. An 
OCT mould was placed onto the ice to cool, prior to OCT being poured in and the vessel 
orientated within. This was then allowed to fully freeze, before being transferred to a -
80°C freezer until the cutting of the samples. Paraffin tissues were treated similarly, 
with tissues embedded in paraffin and orientated as paraffin set within cooled moulds. 
Abdominal aorta sections were always orientated in a manner where the area of interest 
was cut first; which for the Calcium Chloride model was renal artery proximal aorta to 
first cutting surface and bifurcation section distal to the cutting surface, the suprarenal 
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portion closest to the cutting surface in AngII preparations and descending thoracic 
aorta first within BAPN models. Sections for all models were then cut to between 8-
12µm thickness and mounted on poly-l-lysine coated microscope slides.  
Immunofluorescence and immunohistochemistry staining were both employed to 
investigate the presence and localization of proteins relevant to the AAA and AD 
pathology, as well as the arrangement and structural differences that were seen 
respectively. Aortic sections were mounted onto poly-lysine coated slides following 
sectioning from with either paraffin or OCT frozen sections. Following mounting, 
sections were cleaned of mounting medium by washing or paraffin removal techniques. 
This consisted of washing the slides in PBS or the performing of antigen retrieval by 
heating methods. Following this, cells were then permeabilised with 250µl of 0.1% 
Triton in PBS for 3 minutes before washing in clean PBS. Blocking then occurred to 
minimize non-specific binding of antibodies, this was performed by incubating samples 
for 4 hours with blocking solution (5% BSA in PBS), followed by application of 
relevant antibodies for each protein being identified, enough to cover the sample. Slides 
were then placed within a humidified chamber and placed at 4 degrees overnight. The 
following day, slides were washed for 3 x 5mins in PBS, before incubation with the 
relevant secondary antibody for each protein. Secondary antibodies, specific to the 
species primary antibodies were raised in, were conjugated to a fluorophore so that 
antibody binding could be visualized and separately distinguished in double-stained 
samples. Secondary antibodies were incubated at room temperature for 90 minutes. 
Sections were also stained with DAPI in order to stain nuclear content for a further 10 
minutes following the secondary stain. This was the final step prior to a wash and 
application of a coverslip to each section. Slides that had been covered were stored 
within a dark box prior to imaging on the EVOS microscope. 3 sections were applied 
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to each slide with one section being guarded from Antibodies for control purposes; this 
was used to set control exposure settings on the EVOS and to account for 
autofluorescence. Images were taken on the EVOS system with control levels set for 
all image settings for each objective used.  
Immunohistochemistry techniques utilized included H&E, Sirus Red and Elastin 
staining. Slides were processed, sectioned and sectioning medium removed similarly to 
in immunofluorescence staining. Following these steps kits were used to stain for 
proteins and structures in accordance with information booklets provided. Following 
the completion of each staining protocol, slides were imaged using the GXM L3201 
fluorescence microscope and camera. Structures were visualised and settings adjusted 
manually, with consistent image settings used throughout imaging.  
Within elastin staining, quantification was utilised to determine the changes in the 
lamina arrangement with changes in distances between layers measured as a marker of 
degradation and medial damage. Using the GXM L3201 fluorescence microscope and 
camera, slides were analysed with micrometry performed on each slide to quantify the 
measurement from the inner to the outermost layer of elastin. These measurements were 
recorded both on-screen within the slide image, as well as recorded within an excel 
spreadsheet for statistical analysis.  
3.12 STATISTICAL ANALYSIS 
Statistical analysis was performed with the use of GraphPad Prism 7 software. All 
individual data-points were collated and subject to appropriate stats tests, based upon 
the sample size, data type and comparative groups. Assessment of distribution was 
assessed by the D’Agostino-Pearson omnibus K2 test. Where necessary statistical 
correction tests were also performed in order to get the most accurate p-value possible, 
where this is the case it will be stated within figure legends. A p-value of <0.05 was 
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considered to be significant in all test apart from proteomics data where a higher level 
of significance was used as a further cut off for identification of novel proteins 
implicated within the changes to pathological phenotype.  
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RESULTS	
4 EFFECT MODELS OF AAA HAVE ON GENE EXPRESSION WITHIN 
CELL CULTURE 
In order to examine the cellular processes induced during pathologies such as AAA, 
cell culture is utilized within many studies. Gene and protein expression within 
particular cell types relevant to the pathology being studied, in this instance SMCs, 
Endothelial and Macrophage cells. Application of AAA-inducing treatments similar to 
that utilized within AAA animal models can yield new information on the changes to 
expression levels in response to the stimuli within the different cell types. The two 
predominant animal models of AAA are the Ang II and CaCl2 models, these were 
therefore mimicked in vitro.  
 Calcium Chloride application to the aorta In Vivo leads to the calcification and 
degradation of the structural integrity of the vessel. Consequentially, this produces an 
aneurysm within the area of application. Many cells are involved within this process, 
with known depletion of vascular smooth muscle cells, infiltration of macrophages and 
changes in protein expression within the endothelium. Resultantly, these cell types were 
looked at to elicit whether they expressed markers of aneurysm, namely MMPs, as well 
as Neutrophil Elastase (NE), in order to establish the main cell line responsible for 
producing the AAA phenotype and whether any relationship was present with NE.  
 Angiotensin II perfusion is another common technique used to study AAA, 
where Ang II-associated increases in blood pressure result in the eventual expansion of 
the aorta over a period of 4 weeks. This expansion of the aorta can occur at various 
locations In Vivo. In Vitro, Ang II has been used to mimic the model in order to look 
into protein expression changes at the cellular level. Ang II was used to verify results 
95	
	
	
seen within CaCl2 experiments, ensuring that results were representative of the AAA 
phenotype rather than a result of model-specific changes.  
The same cell lines were studied both sets of In Vitro work. Cell lines studied consisted 
of human Smooth Muscle Cells (hSMCs), Human Umbilical Vein Endothelial Cells 
(HuVECs) and a mouse monocyte/ macrophage cell line (Raw 264.7). These were 
chosen due to their high similarity to cell types affected in the AAA pathology.  
 
4.1 MATERIALS AND METHODS 
Please refer to Chapter 3.1 for the materials and methods utilized within the following 
results chapter.  
4.1 RESULTS 
4.1.1	Neutrophil	Elastase	 is	up-regulated	by	exposure	to	Angiotensin	 II	and	high	
concentrations	of	Calcium	Chloride	in	hSMCs,	Raw264.7	and	HuVEC	cells	
Figure 5 showed that neutrophil elastase was upregulated in all cells in response to 
AngII, with sharp rises in expression following exposure for 4 hours or greater. The 
magnitude and timing of this expression change was cell type-dependent. HuVEC cells 
had the latest rise in NE expression, peaking at 2 days of exposure in all groups (Figure 
5A). In contrast, Raw264.7 cells (Figure 5B)  and hSMCs (Figure 5C) took far less 
time, with peaks seen at 4 hours and 1 day respectively, before NE expression dropped 
back down closer to basal levels. Similar trends were seen in cells response to CaCl2 
with Raw264.7 cells, having a premature peak in NE expression in comparison to other 
cell lines (Figure 5E). Highest concentrations of CaCl2, the concentration used within 
In Vivo experiments, produced consistently higher levels of NE expression across the 
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majority of time points. Largest increases were observed within HuVEC (Figure 5F) 
and hSMC (Figure 5D) cell lines within both sets of experiments.  
 
Figure	5-	Expression	of	Neutrophil	Elastase	across	three	cell	lines	at	various	time	points	and	
in	 response	 to	 the	 indicated	 concentrations	 (M/L)	 of	 Ang	 II	 (A,C,E)	 and	 CaCL2	 (B,D,F),	
respectively.	 (n=3)	 	A.	HuVEC	cells	 following	AngII	 treatment	(P>0.05),	B.	Raw264.7	cells	
following	AngII	 treatment	(P>0.05),	C.	hSMC	cells	 following	AngII	 treatment	(P>0.05),	D.	
hSMC	 following	 CaCl2	 treatment	 (P>0.05),	 E.	 Raw264.7cells	 following	 CaCl2	 treatment	
(P>0.05),	 and	 F.	 HuVEC	 cells	 following	 treatment	 by	 CaCl2	 (P>0.05).	 Note:	 the	 gene	
expression	levels	of	cells	with	respective	control	(vehicle)	treatments	were	normalised	to	1.0	
and	error	bars	 set	as	+/-	1	S.D.	ANOVA	 statistical	 testing	with	Bonferroni	 correction	 for	
multiple	analyses	was	used	within	the	analysis	of	this	series	of	experiments	
4.1.2	Exposure	of	Angiotensin	II	and	CaCl2	up-regulate	expression	of	MMP-9	in	hSMC	
and	HuVEC	cell	lines	
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MMP-9 was induced after prolonged exposure to AngII within both HuVEC and hSMC 
cell lines. Angiotensin II experiments caused a gradual rise in MMP-9 expression in 
both cell lines, with minimal change in expression in the first hours of exposure, rising 
at day one and hour 4 in hSMC (Figure 6A) and HuVEC (Figure 6B) cell lines 
respectively. Overall, Peak expression was seen at day 2. 
 
On the other hand, cells with short term of CaCl2 exposure produced marked increases 
in express of MMP-9 within the 0.5M groups, while the expression levels decreased 
below control when low concentrations (0.036M and 0.18M) were used within HuVEC 
cell lines. More specifically, CaCl2 experiments showed a stepwise expression pattern, 
increases in both duration of exposure and concentration caused marked augmentation 
to MMP-9 levels (Figure 6C and 6D). Highest expression was seen in the highest 
CaCl2 at all time points. All groups showed increases in MMP-9 level with extended 
incubation with CaCl2, this suggests both a dose a time dependance to MMP-9 
expression. 
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Figure	6-	Expression	of	Matrix	Metalloproteinase	9	in	hSMCs	and	HuVECs,	in	response	to	
varying	concentrations	of	AngII	and	CaCl2	 during	a	 timecourse	of	experiments	 (n=3).	 	A.	
hSMC	and	AngII	(P>0.05),	B.	HuVEC	and	AngII	(P>0.05),	C.	hSMC	and	CaCl2	(P>0.05)	and	D.	
HuVEC	and	CaCl2	(P>0.05).	Note:	the	gene	expression	levels	of	cells	with	respective	control	
(vehicle)	treatments	were	set	as	1.0	and	error	bars	set	as	+/-	1	S.D.	ANOVA	statistical	testing	
was	used	within	the	analysis	of	this	series	of	experiments	
4.1.3	 MMP-2	 expression	 is	 up-regulated	 in	 response	 to	 Calcium	 Chloride	 and	
Angiotensin	II	exposure	
MMP-2 expression was augmented within all AngII experiments and displayed a dose 
and time-dependent expression pattern in two out of three CaCl2 experiments.  
An increased level of MMP-2 expression in all three cell lines treated with different 
concentrations of Ang II was observed at Day2, however, peak expression varied 
between cell lines (Figure 7A-7C). In general, peak expression was observed at day 2, 
day 1 and 4 hours for HuVEC (Figure 7A), hSMC (Figure 7B) and Raw264.7 cells 
(Figure 7C), respectively. Small increases were observed at other time points within 
the majority of concentrations studied.  
CaCl2 experiments demonstrated similar expression trends to that of MMP-9 within 
MMP-2. HuVEC cells decreased in MMP-2 expression in all tested conditions (Figure 
7F), similar to the MMP9 expression observed in HuVECs treated with the lower two 
concentrations (0.036M and 0.18M) (Figure 7D). In hSMC (Figure 7D) and Raw264.7 
(Figure 7E) cell lines, highest expression levels were seen within the highest 
concentration groups at each time point, and augmentation of time produced further 
increases in MMP-2 expression. MMP-2 expression appears dose and time-dependent 
within hSMC and Raw 264.7 cells in response to CaCl2, however, HuVEC cells appear 
to be suppressed in their production under the same conditions.  
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Figure 7- Expression of Matrix Metalloproteinase-2 across three cell lines at various time points and in 
response to different concentrations of inflammatory stimuli (n=3). A. HuVEC cells following AngII 
treatment (P>0.05), B. Raw264.7 cells following AngII treatment (P>0.05), C. hSMC cells following 
AngII treatment (P>0.05), D. hSMC following CaCl2 treatment (P>0.05), E. Raw264.7cells following 
CaCl2 treatment (P>0.05), and F. HuVEC cells following treatment by CaCl2 (P>0.05). Note: the gene 
expression levels of cells with respective control (vehicle) treatments were set as 1.0 and error bars set 
as +/- 1 S.D ANOVA statistical testing was used within the analysis of this series of experiments.  
4.2	DISCUSSION	
Results for all In Vitro work produced insignificant results, largely due to the high 
variability of expression. No significant conclusions can be drawn from these results. 
ANOVA testing was performed on all groupsets to determine if there were distinct 
differences between them, a P-value of<0.05 was not reached within any testing. A 
Kruskal-Wallace test would also be appropriate given the type of data and quantity, 
however, ANOVA is used more widely in the literature.  
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In-Vitro exposure to CaCl2 was varied as to best assess which duration caused 
expression most akin to that of the aneurysmal phenotype seen within animal models. 
In-Vivo, exposure has been reported to range from 6 to 15 minutes. Resultantly, similar 
time-points were trialled, as well as longer durations of exposure in order to mimic the 
chronic pathology AAA. Exposure to CaCl2 was trialled up to and including the same 
timeframe as the AngII model, however, from a study of the literature, we decided that 
having a model previously performed and more akin to the In Vivo model would be of 
greater benefit to our study. 
In-Vitro exposure to Angiotensin II (AngII), is a much more well-established protocol 
and therefore less variation in conditions were needed to be trialled. Current literature 
was followed as a guideline of appropriate concentrations for use within 
experimentation.  
A time course of the varying effects differing concentrations has on expression of the 
relevant genes was carried out in both models. Utilising RT-qPCR, modulations in the 
gene expression were determined and compared.  
NE, MMP-2 and MMP-9 mRNA was detected within all cell lines, this follows on from 
publications supporting the production of these molecules in a variety of cell types, and 
modulated by CaCl2 and AngII treatment. From the data collected, it is not possible to 
determine whether NE has any regulatory role within the expression of MMP-2 and -9. 
However, with that being said the level of enzymatic activity or protein expression has 
not been detected and is a significant limitation within this study. Consequentially, this 
could be considered as an area of potential development within future cell culture 
experiments of this nature. Performing Western blot analysis or immunofluorescent 
staining upon treated cells would be some of the potential methods by which this could 
be achieved.  
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4.3	CONCLUSION	
In Vitro experiments based upon animal models are inconclusive and have not been 
able to determine a relation between NE and MMP expression, which is as yet not 
investigated within the AAA pathology. This was attempted to be studied within three 
cell types, with all gene-expression varied across time-points and concentrations of 
stimulant utilized. Further work is needed to elicit the full extent of this relationship 
and also its functional impact on the AAA pathology In Vivo. The next rounds of 
experimentation will address these issues in an attempt to address our primary aims and 
objectives.  
4.4. LIMITATIONS 
As mentioned briefly above in chapter 4.3, whilst efforts were made to identify the 
relation between NE and MMPs relevant to the AAA pathology, no successful 
conclusions were able to be drawn. As also identified above, further work is needed to 
overcome the limitations of this study, taking the initial work beyond gene expression 
analysis and onto analysis of protein levels within the same cell types. Further, the cells 
being utilised need to undergo greater levels of checks prior to utilisation for the 
experimentation. Whilst cell viability and health were checked by eye, under the 
microscope, further work needs to be carried out to verify cell state, such as senescence 
and cell viability to ensure the differences in the treatments and cell type have no 
significant impact on the cell number or health of the cells used within experimentation. 
In conclusion, there are a number of steps that should be taken within future 
experiments to ensure the full relationship between NE and MMP can be assessed.  
Beyond this, the cell types utilised within this study may be improved upon, with the 
origin of cells selected improved upon. Currently used HUVEC cells could be replaced 
by endothelial cells of aortic origin, similarly Raw 264.7 cells which are a Abelson 
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leukaemia virus transformed cell line derived from BALB/c mice and therefore 
alternatives may be more appropriate for the study of AAA. For instance, alternative 
cells used within the study of AAA and appropriate for usage here are THP-1 cells for 
studies focussed on human AAA. Furthermore, during this study HUVEC cells were 
derived from a single isolation and subsequent passages of cells and therefore whilst 
separate experiments were undertaken, the true N number for HUVEC experiments is 
and N of 1 due to the same original source, this may explain the extremely tight standard 
deviations observed.   
5 MRI SCANNING PROTOCOL DEVELOPMENT- CRITICAL ANALYSIS 
OF NEW TECHNIQUE COMPARED TO ULTRASOUND 
 
Abdominal	 Aortic	 Aneurysm	 (AAA)	 is	 one	 of	 the	 leading	 contributors	 to	 death	 in	 the	
western	world,	with	4-5%	of	men	over	65	being	affected	by	the	condition.	Relatively	little	
is	known	about	the	underlying	mechanism,	and	therefore	further	study	is	needed	to	elicit	
the	 cause	 and	 pathways	 contributing	 to	 the	 disease.	 Currently,	 Ultrasound	 (US)	 is	
considered	the	frontline	technique	for	monitoring	In	Vivo	progression	of	AAA	within	both	
Humans	and	animal	models.	However,	multiple	limitations	exist	with	US	scanning	of	small	
aortas.	This	work	aims	to	study	an	alternative	scanning	protocol	that	produces	a	more	
comprehensive	understanding	of	the	vascular	changes	throughout	animal	models.	To	do	
this	 we	 will	 be	 utilizing	 low	 field	 Magnetic	 Resonance	 Imaging	 (MRI),	 in	 order	 to	
determine	whether	more	reproducible	and	detailed	surveillance	of	changes	within	the	
aorta	can	be	achieved	when	compared	to	the	current	gold	standard.	
Using	a	1T	MRI	Scanner,	Gd-albumin	blood-pool	agent	and	semi-automated	processing,	
reproducible	volumetric	measurements	of	the	infrarenal	aorta	and	identification	of	AAA	
were	obtained	 in	10	mice	 infused	with	angiotensin	 II	 for	 four	weeks.	Compared	 to	US	
103	
	
	
scanning,	MRI	scanning	provided	a	much	clearer	image,	more	accurate	measurement	of	
small	infra-renal	aortas	with	higher	reproducibility,	and	discovered	a	higher	incidence	of	
AAA.	Importantly,	volumetric	measurements	of	aortas	is	only	possible	with	MRI	scanning,	
which	is	a	key	determinant	for	predicting	AAA	rupture,	representing	a	potential	new	gold	
standard	for	AAA	prognosis.	
Monitoring	of	the	AAA	Pathology	and	other	similar	aortic	abnormalities	can	be	achieved	
utilising	this	protocol,	yielding	an	enriched	dataset	in	comparison	to	the	most	commonly	
utilised	US.	
	
As	 previously	 mentioned,	 Abdominal	 Aortic	 Aneurysm	 (AAA)	 is	 the	 focal	
dilatation	of	the	Aorta.	Predominantly	situated	in	the	infra-renal	segment(1),	AAA	
is	a	 localised	weakening	of	 the	vessel	wall	which	makes	 it	prone	to	rupture(2).	
This	 pathology	has	 a	 high	mortality	 rate	 as	 a	 result	 and	 affects	 4-5%	of	males	
globally	 and	 a	 smaller	 proportion	 of	 females	 in	 the	 65	 years	 old	 and	 above	
population	 also(3).	 The	 incidence	 of	 AAA	 is	 increased	 with	 Coronary	 Artery	
Disease	(CAD)(4),	family	history	and	smoking(4),	amongst	others.	
The	 pathological	 characteristics	 of	 AAA	 include	 collagen	 and	 elastin	
dysregulation(8),	 chronic	 inflammation(9),	 smooth	 muscle	 apoptosis(10)	 and	
breakdown	 of	 the	 extracellular	 matrix	 in	 the	 surrounding	 areas	 of	
vasculature(11).	The	alterations	lead	to	the	expansion	of	the	vessel	beyond	that	of	
the	normal	aorta,	sequentially	weakening	the	vessel	and	consequentially	increase	
the	 probability	 of	 aortic	 rupture,	 and	mortality	 at	 the	 same	 time.	 Resultantly,	
screening	 programmes	 have	 been	 put	 in	 place	 in	 order	 to	 discover	 rapidly	
expanding	vessels	early,	in	order	to	minimise	the	chances	of	death.	In	line	with	the	
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introduction	of	screening	programmes,	death	rates	as	a	consequence	of	AAA	have	
fallen	in	the	UK(179).	From	such	studies,	the	identification	of	numerous	factors	
influencing	 the	 probability	 of	 rupture	 has	 become	 apparent,	 these	 include	 the	
aneurysmal	 maximum	 diameter,	 aneurysmal	 volume,	 location	 and	
gender(180,181).	Some	of	these	variables	were	already	known	to	be	risk	factors	
for	the	AAA	pathology,	however,	volume	is	an,	at	present,	underutilised	diagnostic	
tool.	For	the	most	part,	current	clinical	practice	relies	upon	the	widely	installed	
base	of	US	scanners	to	identify	patients	that	would	benefit	from	higher	resolution	
modalities	such	as	CT	or	MRI.	Consequently,	translating	factors	as	identified	above	
by	Tang	et	al(180).	as	well	as	Hatakeyama	et	al(182).	into	the	clinics	could	result	
in	improved	diagnostic	abilities	with	regards	to	risk	of	rupture.	US	is	unable,	at	
present,	to	implement	these	changes,	with	volumetric	measurements	beyond	that	
of	 the	 capabilities	 of	 most	 US	 facilities,	 with	 limitations	 to	 simple	 diametric	
quantification,	instead	of	the	proposed	volumetric	change	which	is	put	forward	as	
a	potential	new	gold	standard	for	AAA	prognosis	by	Tang	et	al(180).	
Magnetic	Resonance	Imaging	(MRI)	scanning	is	an	alternate	scanning	method	to	
US,	 that	 function	 by	 reconstructing	 a	 hydrogen	 signal	 that	 can	 be	 altered	 by	
scanning	 program	 parameters	 to	 give	 clear	 images	 of	 internal	 structures	 non-
invasively.	Optimisation	of	a	scanning	program	can	increase	the	clarity	of	specific	
tissue	types,	such	as	the	usage	of	a	blood-pool	contrast	agent.	Within	this	study,	
we	 use	 such	 agents	 to	 highlight	 the	 aorta	 and	 the	 luminal	 changes	 that	 occur	
within	it	over	time.	Benefits	and	drawbacks	of	the	utilisation	of	MRI	in	comparison	
to	US	are	outlined	later	within	the	discussion	of	this	paper.		
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The	 pathological	 characteristics	 of	 AAA,	 as	 mentioned	 above,	 lead	 to	 the	
production	 of	 a	 progressively	 expanding	 aneurysmal	 phenotype.	 One	 way	 to	
uncover	such	changes	in	vivo,	non-invasively,	is	by	molecular	imaging.	However,	
this	 requires	 the	 development	 of	 a	 suitable	 imaging	 agent	 and	 protocol.	 An	
example	 is	 the	 elastin	 binding	 MR	 imaging	 agent	 (ESMA)(181).	 Alternatively,	
anatomical	 imaging	 may	 be	 employed	 to	 visualise	 and	 quantify	 disease	
progression	 with	 the	 benefit	 of	 an	 easier	 implementation	 in	 other	 labs.	 This	
approach	has	been	taken	in	this	study.	
Among	 the	 various	 anatomical	 imaging	 modalities,	 US	 scanning	 has	 been	 the	
preferred	method	for	in	vivo	monitoring	of	AAA	in	preclinical	research,	and	high	
field	MRI	studies	have	also	been	reported(183,184).	US	is	currently	the	preferred	
method	within	the	clinical	setting	due	to	its	low	cost	and	speed.	These	techniques	
enable	 tracking	 of	 macroscopic	 changes	 to	 the	 aorta,	 predominantly	 by	
quantifying	the	size	of	the	lumen	and	alterations	to	the	vessel	wall	path	away	from	
expected	dimensions.	Both	modalities	have	been	employed	and	adapted	 in	 this	
paper.	
US	 is	 a	 common	 method	 of	 detection	 and	 tracking	 of	 mouse	 anatomy,	 where	
tissues	 such	 as	 smooth	muscle	 and	 organs	 create	 different	 strength	 signals	 in	
scans	in	comparison	to	alternately	composed	substances	e.g.	blood.	Advantages	
include;	relatively	low	cost	of	the	equipment	and	fast	US	scanning.	Disadvantages	
are	 that	 (a)	 additional	 time	 is	 needed	 for	 preparation	 of	 fury	 mice,	 with	 US	
requiring	shaving	around	the	area	of	interest;	(b)	time	is	needed	to	find	the	probe	
angle	 for	 the	 least	obstructed	view	of	 the	aorta;	 (c)	 the	 field	of	view	of	a	high-
resolution	 ultrasound	 is	 relatively	 small	 and	 localised;	 (d)	 the	 data	 is	 easily	
106	
	
	
influenced	by	user	technique	i.e.	suffers	from	inter-operator	variability	and	thus	
lacks	 reproducibility	 between	 labs;	 (e)	 similarly,	 the	 data	 interpretation	 is	
performed	by	 the	operator	which	 increases	 the	 chance	of	operational	bias	and	
misdiagnosis(185).	 Although	 such	 misdiagnosis	 could	 be	 minimised	 by	
verification	of	all	scanning	measurements	by	double	measurement	of	each	scan,	
utilising	 VevoLabs	 software,	 an	 improved	 alternative	 imaging	 technique	 is	
urgently	 needed	 in	 order	 to	 achieve	more	 objective,	 reproducible	 and	detailed	
surveillance	of	changes	within	 the	aorta	over	weeks,	or	even	 longer	within	 the	
clinical	setting.	
In	this	chapter,	we	present	the	use	of	low-cost	imaging	modalities	US	and	1	T	MRI	
with	commercially	available	contrast	agent	to	scan	and	monitor	the	aorta	in	AAA	
mouse	models,	which	is	directly	translatable	to	the	clinical	setting.	Comparison	
between	3D	US	and	MRI	imaging	is	beyond	the	scope	of	this	paper.	3D	US	scanning	
is	a	relatively	new	technology	with	huge	potential(186),	however,	comparatively	
few	 facilities	 currently	 posses	 such	 scanning	 capabilities.	 	 Aneurysms	 are	
visualized	and	their	anatomical	changes	over	time	quantified	via	MRI	images	by	
custom-built	semi-automated	analysis.	Use	of	analysis	outlined	in	this	paper	could	
lead	to	improved	surveillance	of	AAA	patients	and	increase	the	predictability	of	
AAA	rupture.		
5.1 METHODS 
5.1.1 Animal Husbandry 
Animals	were	housed	according	 to	 the	parameters	set	out	within	 the	materials	
and	method	chapter	above	(Chapter	3.2).		
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5.1.2 AngII-induced AAA 
To	model	the	AAA	phenotype	8-week	old	ApoE-/-	mice	of	mixed	gender	underwent	
AngII,	dissolved	in	saline,	infusion	using	Alzet	Osmotic	Pumps	(Charles	River)	to	
infuse	1.44mg/kg/day	(Sigma)	for	28	days.	Pumps	were	implanted	subdermally	
into	the	dorsal	neck	region,	under	sterile	surgical	conditions.	Mice	were	placed	
under	anaesthesia	by	isoflurane	carried	in	oxygen.	The	small	incision	is	closed	by	
discontinuous	suture	using	3.0	Vicryl.	Following	surgery,	mice	were	individually	
housed	 and	 returned	 to	 chow	 diet	 and	 water	 ad	 libitum	 for	 the	 duration	 of	
experiments.	 Sham	 animal	 procedures	 had	 been	 carried	 out	 previously,	 and	
expansion	 of	 the	 aorta	 deemed	 negligible	 over	 the	 same	 time-course.	 Animals	
were	weighed	 prior	 to	 pump	 implantation	 and	 at	 weekly	 intervals	 during	 the	
procedure,	 loss	 of	 weight	 was	 seen	 in	 response	 to	 AngII	 and	 no	 correlation	
between	weight	and	aortic	size	was	observed.		
5.1.3 Ultrasound Scanning 
Ultrasound	was	performed	weekly,	with	baseline	measurements	being	taken	prior	
to	pump	implantation	and	continuing	throughout	the	duration	of	the	experiments,	
totalling	 5	 US	 scans	 per	 mouse.	 Mice	 were	 sedated	 by	 gaseous	 anaesthesia,	
isoflurane	vaporised	in	oxygen	as	a	carrier.	Following	sedation,	all	mice	had	all	
hair	on	their	stomach	removed	by	hair-removal	cream	(Veet)	before	being	placed	
on	 a	 heated	 ultrasound	 platform.	 Paws	 were	 taped	 down	 to	 sensor	 pads	 to	
monitor	heartbeat	throughout	the	experiments.	Pre-warmed	ultrasound	gel	was	
then	 applied	 to	 the	 newly-bald	 area	 before	 the	 ultrasound	 probe	 (MX550D,	
VisualSonics)	 was	 mounted	 and	 placed	 over	 the	 animal’s	 abdomen.	 The	 Vevo	
3100	 was	 used	 to	 perform	 all	 ultrasound	 scans	 and	 analysed	 with	 VevoLabs	
analysis	 software.	 Measurements	 were	 taken	 in	 both	 longitudinal	 and	 cross-
108	
	
	
sectional	 planes	within	 the	 Infrarenal	 portion	 of	 the	 aorta	within	 each	mouse.	
Diametric	 changes	 were	 quantified	 in	 the	 cross-sectional	 plane	 in	 a	 Catherine	
wheel-like	fashion	to	account	for	non-uniform	expansion	of	the	vessel	(see	Figure	
2).	 These	 were	 then	 compared	 to	 control	 scans	 for	 percentage	 expansion	
measurements.		
5.1.4 MRI Scanning 
MRI scanning was performed once before pump implantation (baseline) and once after 
pump removal and recovery from surgery, typically 2-3 days after the last US scan. The 
chosen pump model was not MRI compatible and therefore had to be removed before 
MRI scanning after AAA induction. Note: MRI compatible versions of Alzet pumps 
are not commercially available but in principle can be produced by replacing the steel 
rod regulator with plastic tubing. However, we believe that validation would be 
required that this modification does not interfere with pump flow rates and this study 
was simplified by using the original pumps instead. For each MRI scan, the mouse, 
average weight of 27g, was sedated by isoflurane in oxygen, injected into a lateral tail 
vein with 85 µl of Gd-Albumin (20 mg/mL, BioPAL USA, diluted with saline) and 
immediately placed on the MRI bed (Bruker BioSpin MRI, Germany) equipped with 
isoflurane anaesthesia, water-heating, respiration monitoring, controlled to 30-40 bpm 
(SA Instruments, USA), and solenoid whole-body RF coil. The bed was then inserted 
into the 1 T permanent magnet (Aspect Imaging, Israel) coupled to the ICON MRI 
console controlled by Paravision 6.0 software (Bruker). After scanner preparations, a 
fast low angle shot (FLASH) based localizer was acquired, a 3D scan volume placed 
over the whole abdominal area, and a T1 weighted 3D FLASH image acquired with 
echo time 4 ms, repetition time 30.6 ms, flip angle 40°, 8 dummy scans, image size 
76x100x58 pixels, field of view 23.8x30x17.5 mm, isotropic 0.3 mm voxels, total 
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acquisition time ca. 10 min 36 secs. Scans were prospectively respiration gated to avoid 
motion artefacts and improve image quality. 
Use of 1T MRI scanning equipment limited the resolution of images produced, 
however, imaging was optimised to provide sufficient quality reconstructions so aortic 
volume could be accurately and reproducibly measured. Contrast increased the 
accuracy of this protocol as lumen boundaries were much more distinct, in comparison 
to pre-contrast scans. Alternative scanning setting were also tested to find the best 
settings for scanning. Contrast consistently increased clarity and precision of scans and 
subsequent measurements,  
The reconstructed MRI images (Paravision) were analysed in two steps in VivoQuant 
(Invicro, USA). First, data were preprocessed by a custom-written script performing 
bias field correction17 (iterative Otsu with downsampling factor 2, max. iteration 
50x50x50, converging threshold 0.5, control points 2x2x3, spline order 3) and image 
reorientation. Then, the infrarenal aorta was manually segmented into transaxial 2D 
slices between the lower renal artery and the bifurcation of the aorta into the femoral 
arteries. This dataset consists of 53 total slices compared to USs single slice, with a 
fixed smaller region of interest being selected. Resultantly this allowed for continuity 
between scans and controls for difference in aortic size at different parts of the aortic 
tree. 
	
5.2 RESULTS 
5.2.1 Gd-Albumin Increases clarity of scans and improves the accuracy of scan interpretation 
 
The	 use	 of	 vascular	 contrast	 agent	 Gadolinium	 labelled	 albumin	 increased	 the	
clarity	of	the	vessel	lumen	by	increasing	the	signal	in	blood-rich	areas.	As	seen	in	
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Figure	8	 initial	scans	produced	obscure	and	vague	outlines	of	the	aorta	 lumen,	
however	with	the	introduction	of	this	blood	pool	contrast	this	was	rectified	and	
more	typical	clear	lumen	demarcations	were	evident.	With	the	use	of	Gd-Albumin	
precise	quantification	of	the	infrarenal	aorta	became	possible,	and	the	possibility	
of	signal	gated	readings	becomes	possible.		No	side	effects	were	evident	from	the	
use	 of	 contrast	 reagents	 within	 any	 experimental	 procedure	 performed.	 No	
adverse	effects	are	commonly	noted	within	the	literature	on	this	subject	either,	
thus	making	the	procedure	relatively	safe	and	similar	in	severity	of	US	scanning	
techniques.		
	
Figure	8-	Representative	 images	of	 imaging	optimization,	with	each	 image	 showing	 the	
development	of	the	protocol	as	outlines	of	the	aorta	become	clearer	(sequentially	from	Top	
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to	Bottom	and	Left	to	Right.	White	Arrows	indicate	the	Aorta	in	each	cross-sectional	image,	
with	original	images	obtained	from	VivoQuant	analysis	software.	
5.2.2	Ang	II	infusion	produces	a	significant	expansion	in	abdominal	aorta	
measured	quantitatively	by	ultrasound	and	MRI		
	
Figure	9-	Composite	image	of	MRI	and	US	typical	images.	Top	left,	typical	3D	reconstruction	
image	for	pre-AngII	scan.	Top	left	and	right,	typical	3D	reconstruction	image	of	the	same	
mouse	for	pre-	and	post-AngII.	Bottom	left,	Longitudinal	aortic	US	scan	with	aneurysm	in	
the	3rd	week	of	AngII	infusion.	Bottom	right,	Cross-sectional	US	scan	with	Catherine	wheel	
measurement,	displaying	the	technique	of	diameter	measurement	used.	
A	total	of	10	mice	underwent	MRI	scans	of	their	aorta,	all	of	which	consequentially	
received	AngII	infusion	of	1.44mg/kg/day	for	28	days	before	undergoing	a	second	
scan.	 All	 10	 mice	 showed	 a	 marked	 increase	 in	 infrarenal	 volume,	 following	
similar	trends	to	that	of	US	scans.	Aneurysmal	enlargements	within	scan	analysis	
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were	 detected	 by	 comparison	 to	 each	 respective	 baseline	 control	 scan.	 Use	 of	
contrast	reagents	enabled	easy	identification	of	the	aorta	and	production	of	ROI’s.	
The	scanning	technique	was	sensitive	enough	to	pick	up	relatively	small	changes	
within	the	aorta,	making	it	appropriate	for	use	within	the	study	of	AAA.	All	animals	
showed	to	have	expansion	of	the	aorta,	not	all	had	aneurysms	as	defined	by	an	
increase	of	50%	in	infrarenal	aorta	diameter	measured	by	US	and	aorta	dissection	
(see	Table	4	and	Figure	9).	
Table	4-	Summative	Table	of	Results	following	the	implementation	of	the	Ang	II	procedure.	
Comparison	of	monitoring	using	all	modalities	possible,	namely	MRI	in	both	2D	and	3D	as	
well	as	post-mortem	dissection	to	confirm	diagnoses.	
	
5.2.3	Use	of	MRI	scanning	can	produce	3D	reconstructions	of	the	abdominal	aorta	
and	subsequent	aneurysms	
Following	MRI,	scans	are	performed	and	processed	in	VivoQuant.	This	software	
can	 automatically	 produce	 a	maximum	 intensity	 projection	 (MIP)	 in	 3D	 of	 the	
selected	scan	area	(Figure	9	top	panels).	Within	each	scan,	you	are	able	to	view	
results	within	3	planes	as	well	as	how	this	relates	to	the	3D	MIP.	By	selecting	ROIs	
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you	are	also	able	to	highlight	relevant	areas	within	both	sectional	scans	and	3D	
MIP	reconstructions.	This	functionality	allows	for	measurements	of	the	Infrarenal	
aorta	 in	 both	 2D	 and	 3D.	 Both	 direct	 measurements	 of	 aortic	 diameter	 are	
possible,	as	well	as	volumetric	measurements	of	the	same	vessel.		
	
	
Figure	10-	Top-	Images	depicting	how	Otsu’s	iteration	analysis	can	outline	and	quantify	the	
aorta	in	a	semi-automated	fashion	following	basic	user	training.	Red	indicates	the	freehand	
operator-defined	potential	aortic	area.	Green	indicates	the	true	aortic	region	as	determined	
and	optimized	by	Otsu’s	iteration	analysis.	Bottom-	Inter-operative	variability	highlighting	
similarities	between	datasets	(P=	0.3602,	paired	two	tailed	t-test	)	
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5.2.4	Semi-automated	format	of	MRI	post	optimisation	allows	for	low-level	
training	to	scan	the	aorta	
Minimally	 trained	researchers	were	able	 to	perform	MRI	scanning	and	achieve	
sufficient	quality	outcomes	as	induction.	Training	on	how	to	set	basic	parameters,	
such	 as;	 area	 of	 interest,	wobble	 calibration,	 localiser	 and	 quantity	 of	 contrast	
reagent,	was	undertaken	and	 following	 this	 independent	operation	of	 scanning	
was	able	to	be	achieved	(Figure	10).	Following	on	from	this	the	processing	of	the	
MRI	files	and	identification	of	the	aorta	within	all	subsequent	scans	were	carried	
out.	The	 interpretation	of	 scans	 took	place	on	a	post-analysis	computer,	where	
further	training	took	place	for	analysis.	Again,	this	training	was	basic	and	largely	
comprised	of	anatomy	and	VivoQuant	software	training.	
5.2.5	Proposed	AAA	definition	for	MRI	scanning	
By utilising our optimised MRI scanning protocol, aortic expansion after exposure to 
AngII for four weeks is easily identified (Figure 12). The average increase in infrarenal 
volume was 33% above that of baseline as measured by MRI scanning.  Since the MRI 
analysis protocol measures infrarenal volume change, the current definition of an 
aneurysm is not compatible. Current guidelines define an AAA as “a vessel diameter 
50% greater than expected or its previously determined size”, this is incomparable to 
the measurements taken by the MRI as aneurysms occur in many forms, however, most 
are saccular or fusiform aneurysms, and therefore are limited to a relatively small region 
of the vessel. Resultantly, as the volumetric measurements are taken over a whole 
segment, only part of which is aneurysmal, the volume in many cases will not reach 
this 50% increase threshold. Consequently, ‘the 50% increase threshold’ cannot be used 
to define an AAA in the volumetric measurement by MRI, and the definition of an 
aneurysm will have to be reassessed when a vessel is quantified. Instead, we observed 
115	
	
	
an excellent agreement between the volumetric data measured by MRI and the final 
aortic dissection data. Importantly, based on the AAA incidence observed from aorta 
dissection, we could set a '20% increase of aortic volume' measured by MRI as a 
‘threshold’ to define an AAA in MRI scanning, which results in 100% agreement 
between two methods (aorta dissection and MRI) in identifying AAA incidence. This 
threshold was determined by assessment of dissection and comparative analysis of 
accompanied scans. This value falls from traditional 50% cut-offs due to the length of 
the expansion and total infrarenal aorta being taken into account within this instance. 
In essence, as the whole infrarenal aorta is rarely effected and therefore would decrease 
the overall expansion percentage, this has been accounted for within the cut-off value. 
By utilising the 20% as a cut-off we are able to highlight incidences of significant 
remodelling, the protocol may later be updated to isolate solely the area of expansion 
however this level of sophistication is yet to be achieved(Figure 11) (Table 4). 
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5.2.6	Measurements	of	aorta	expansion	by	MRI	and	US	are	comparable		
When	 comparing	 MRI	 and	 US	 measurements,	 the	 overall	 trend	 was	 similar,	
however,	 some	 discrepancies	 were	 seen	 between	 the	 two	 (Figure	 11).	
Measurement	 units	 for	 each	 differed,	 with	 MRI	 involving	 volumetric	
measurements	and	 therefore	quantified	 in	mm³,	 in	 comparison	 to	US	diameter	
measurement	quantified	 in	mm.	Resultantly,	 as	 the	overall	 length	of	 infrarenal	
aorta	 differs	 between	 animals	 it	 is	 hard	 to	 quantify	 how	 similar	 these	 two	
modalities	are	in	their	results.	Consequently,	percentage	expansion	was	used	to	
monitor	the	changing	of	the	vessel	from	in	both	techniques.	Data	shown	in	Figure	
11-Top	 Right	 revealed	 a	 good	 agreement	 between	 the	 two	 techniques	 was	
Figure	11-	Comparison	of	 infrarenal	aorta	expansion	(percentage)	measured	by	US	and	
MRI.	Measurements	for	each	mouse	are	given	and	comparison	for	each	mouse	within	each	
form	of	measurement	are	presented.	(Top	Left)	Correlation	between	2D	(mm)	and	3D	(mm3)	
MRI	 measurements,	 with	 distinct	 Pre	 and	 Post-	 AngII	 exposure	 evident,	 r2=	 0.5467,	 P=	
0.0005.	(Top	Right)	Percentage	change	in	aortic	size,	as	measured	volumetrically	by	MRI	
(mm3)	and	diametrically	by	US	(mm),	r2=	0.6003,	P=	0.0142.	(Bottom	Left)	Bland	Altman	
plot	displaying	 the	 relative	difference	between	US	and	3D	MRI	measurement	percentage	
change.	(Bottom	Right)	Comparative	Graph	of	2D	Measurements	performed	by	both	MRI	
and	US	(mm),	r2=	0.6487,	P=	0.0027.	
117	
	
	
observed.	
	
		
	To	verify	one	technique	against	the	other,	2D	sections	from	Infrarenal	aortic	scans	
were	 taken	 and	 measured	 for	 vessel	 expansion.	 These	 comparisons	 were	
performed	on	scans	from	the	same	mouse	at	the	same	time-point	and	within	the	
same	region,	using	biological	landmarks	for	reference.	Resultantly,	2D	percentage	
measurements	could	be	generated	and	compared	across	the	two	modalities.	As	is	
evident	from	the	resulting	graph,	there	are	very	similar	trends	seen	across	the	two	
datasets	(Figure	11).	Classification	of	aneurysmal	vessels	by	2D	measurements	
were	improved	(6	aneurysmal,	3	non-aneurysmal)	with	expansion	trends	within	
other	vessels	showing	a	similar	trajectory.	Overall,	expansion	rates	were	highly	
comparative	 between	modalities.	 3D	 analysis	was	 used	 to	 further	 enhance	 the	
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Figure	 12-	 Top	 left-	 Percentage	 Change	 of	 aortic	 diameter	 (US)	 and	 volume	 (3D	MRI)	
respectively,	 with	 current	 50%	 threshold	 for	 AAA	 marked	 for	 US	 and	 suggested	 20%	
similarly	for	3D	MRI	illustrated	with	a	dotted	red	line.	Top	Right-	Aortic	Volume	Measured	
by	3D	MRI,	with	paired	data	change	shown	Pre	and	Post	exposure	to	AngII.	Bottom	Left-	
Comparison	of	3D	MRI	percentage	expansion	and	dissection	outcomes	for	presence	of	AAA.	
N=9	animals,	scanned	both	before	and	after	exposure	to	AngII	for	four	weeks			
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dataset,	 giving	 greater	 information	 on	 the	 changes	 occurring	 to	 the	 vessel.	 As	
outlined	 earlier,	 volumetric	 changes	 could	 provide	 important	 information	 on	
rupture	 risk	 and	 therefore	 verification	 as	 to	whether	 this	 is	 possible	 within	 a	
mouse	model	would	be	seen	as	a	step	forward	for	AAA	monitoring.		
Although	 largely	good	agreement	between	 the	 two	 techniques	was	observed,	a	
clear	disagreement	was	also	observed	between	them	in	term	of	the	AAA	incidence.	
Particularly,	 we	 observed	 one	 animal	 displayed	 a	 very	 high	 aorta	 expansion	
(>50%	 increase)	 measured	 by	 MRI,	 while	 exhibited	 a	 subtle	 change	 (<10%	
increase)	 measured	 by	 US.	 This	 could	 be	 due	 to	 either	 US	 operational	 error,	
missing	 the	aneurysm	and	 therefore	 the	enlargement.	Alternately,	 if	 this	was	a	
diffuse	 AAA,	 small	 changes	 to	 the	 diameter	 but	 prolonged	 areas	 of	 the	 vessel	
affected	could	increase	the	volume	by	a	far	higher	percentage	than	the	increase	
seen	in	diameter.	
	
	
5.3	Discussion	
Current	clinical	protocols	of	US	are	limited,	and	this	update	in	MRI	procedure	may	
now	 allow	 for	 utilisation	 of	 low-field	 MRI	 to	 provide	 greater	 detail	 in	 a	
reproducible	and	affordable	manner.	Current	scanning	of	the	Infrarenal	aorta	may	
need	to	be	adapted,	with	scan	area	extended	to	include	suprarenal	regions.	This	is	
possible	by	expanding	the	region	of	interest	or	performing	a	secondary	scan	for	
the	alternate	area.	With	a	change	 in	volume	being	an	 indicator	of	AAA	rupture,	
with	 further	 study,	we	 could	 determine	 a	 volume	 increase	 threshold	 by	which	
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aneurysms	are	classified	as	at	risk	of	rupture		(180).	This	would	be	beneficial	in	
the	 clinic	 as	 with	 semi-automated	 quantification,	 this	 could	 lead	 to	 basic	
preliminary	diagnostic	markers	and	prognosis	indicators,	similar	to	that	seen	with	
blood	test	biomarkers	or	ECG	traces.		
Moreover,	if	the	volumetric	measurement	by	MRI	is	to	be	utilised	as	a	clinical	or	
even	research	tool,	quantification	in	both	a	2D	and	3D	format	could	result	in	the	
most	comprehensive	analysis	method,	and	by	doing	this	allows	for	detection	and	
monitoring	of	both	diffuse	and	saccular	enlargements	of	the	vessel.	Currently,	if	
you	 were	 to	 use	 ‘the	 50%	 rather	 than	 the	 20%	 expansion	 threshold’,	 a	 large	
number	 of	 false-negative	 outcomes	 would	 be	 produced.	 It	 is	 possible	 that	 a	
redefined	 area	 could	 be	 used,	 post-secondary	 scanning,	 where	 retrospective	
measurement	of	a	specific	adjustable	area	within	control	scans	and	measurement	
of	equivalent	areas	within	follow-up	scans	takes	place.	This	would	only	be	possible	
within	preclinical	studies.	
As	mentioned	above,	there	is	the	possibility	for	this	protocol	to	be	scaled	up	to	the	
clinical	setting.	This	work	within	small	rodents,	utilising	a	1T	MRI	scanner,	would	
be	 directly	 translatable	 to	 the	 clinical	 setting	 if	 an	 alternate	 contrast	 agent,	
approved	 for	 human	 use,	 could	 replace	 the	 Gd-Albumin	 bolus	 administered	 to	
each	 mouse.	 These	 agents	 are	 widely	 available	 and	 already	 in	 use	 within	 the	
clinical	setting.	Alternately,	the	use	of	RF	pulses	to	generate	contrast	within	more	
powerful	 MRI	 scanners	 could	 also	 produce	 similar	 results,	 a	 functionality	 not	
possible	 within	 the	 1	 T	 scanner	 utilised.	 	 Possibilities	 for	 this	 include	 other	
gadolinium-based	agents	as	well	as	alternate	albumin	binding	contrast	agents,	as	
exemplified	within	 studies	 discussed	 by	Habets	 et	 al.(187),	 however,	 alternate	
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lower	molecular	weight	contrasts	could	be	utilised	as	clearance	within	humans	is	
much	lower	than	rodents.	
MRI	produces	images	reconstructed	from	the	hydrogen	signal	that	is	modulated	
by	several	effects	(local	hydrogen	concentration,	structure,	T1	and	T2	relaxation	
times,	etc.)	and	several	experimental	parameters,	such	as	magnetic	field	strength,	
pulse	 sequence,	 scan	 parameters	 e.g	 repetition	 and	 echo	 time,	 to	 name	 a	 few.	
Image	contrast	can	be	enhanced	by	the	injection	of	a	contrast	agent.	Advantages	
compared	 to	 US	 are	 that	 (a)	with	 a	 given	 protocol	 (like	 a	 chosen	 set	 of	 pulse	
sequence	parameter	values)	the	acquisition	is	 fairly	user-independent	and	thus	
reproducible;	 (b)	 the	 positioning	 of	 the	 animal	within	 the	 RF	 coil	 is	 relatively	
stable	and	has	little	influence	on	the	image	quality	as	long	as	the	area	of	interest	
is	approximately	in	the	RF	coil	centre;	(c)	a	larger	area	(even	whole-body)	can	be	
imaged	with	high	spatial	resolution.	Subsequent	detailed	image	analysis	can	then	
extract	robust	measurements	of	AAAs.	Disadvantages	and	our	solutions	to	them	
are	that	(a)	MRI	systems	and	their	maintenance	are	expensive,	but	a	low	cost	1	T	
MRI	system	can	produce	reliable	and	reproducible	data,	as	outlined	in	this	study.	
(b)	Time	and	effort	is	required	to	optimise	the	imaging	protocol,	however,	this	is	
a	one-off	development	effort	with	time	being	minimised	by	building	upon	already	
existing	protocols.	(c)	Contrast	agent	may	have	to	be	administered,	however,	this	
was	a	simple	intravenous	injection	minutes	before	image	acquisition,	we	observed	
no	side	effects,	and	the	cost	was	acceptable.	Furthermore,	if	RF	pulses	were	used	
to	generate	contrast	in	more	powerful	scanners,	this	would	not	be	necessary.	(d)	
Subjects	need	to	be	permitted	to	enter	the	magnetic	field,	however,	in	this	study,	
the	 surgically	 inserted	osmotic	 pumps	 for	 continuous	 release	 of	Angiotensin-II	
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were	not	MRI	compatible	so	MRI	could	only	be	done	before	pump	insertion	and	
after	 their	 removal.	 (e)	 Image	 acquisition	 is	 more	 time	 consuming	 than	 US	
scanning,	although	with	optimisation	of	 scans	 this	 time	discrepancy	 is	minimal	
and	a	richer	data	set	is	obtained.	(f)	Image	analysis	may	be	time-consuming	and	
introduce	operator	variability.	To	address	this	 final	point,	 the	design	of	a	semi-
automated	process	by	which	quantification	of	the	aorta	could	occur	quickly	and	
easily	with	minimal	training	took	place.	VivoQuant	(Invicro	LLC,	Boston)	enabled	
the	 semi-automation	 of	 quantification	 steps,	 utilising	 the	 increase	 in	 signal	 in	
aortic	 areas,	 largely	 due	 to	 the	 contrast	 used.	 In	 order	 to	 implement	 gating	
thresholds,	 for	 the	 identification	 of	 the	 aorta,	 segmentation	 through	 image	
thresholding	took	place.	This	takes	advantage	of	the	grey	levels	within	an	image	
and	is	particularly	good	at	differentiating	an	object	from	background.	It	is	fast	and	
computationally	 simple.	 Otsu’s	 method,	 the	 method	 chosen	 to	 calculate	 the	
thresholding	in	this	study,	uses	integration	to	find	the	global	minimums(188).	This	
means	that	Otsu’s	method	could	be	used	for	unsupervised	computation	with	no	
prior	knowledge	of	grey	levels	of	the	object.	This	allows	for	a	mathematical	strict	
way	to	calculate	 the	 thresholding	 from	a	given	histogram.	Following	this,	 there	
were	no	significant	differences	found	between	the	sequential	analysis	of	the	same	
dataset	by	multiple	operators,	as	depicted	in	Figure	10.		
AAA	 are	 typically	 located	 in	 mice	 pararenal	 and	 in	 humans	 more	 specifically	
infrarenal	aortic	locations.	Ultrasound	is	able	to	scan	both	areas	of	the	aorta	when	
adjusting	the	angle	and	orientation	of	the	probe	to	avoid	other	tissues	masking	a	
clear	view	of	the	aorta.	However,	this	adjustment	can	restrict	the	field	of	view	such	
that	small	expansions	like	saccular	aneurysms	may	be	missed.	This	carries	the	risk	
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of	incorrect	AAA	quantification	and	even	misdiagnosis.	Another	limitation	of	US	is	
that	the	orientation	of	the	acquired	images	varies	somewhat	for	each	individual	
scan	 in	 the	 same	 subject.	 Thus,	 surveillance	 scans	 over	 time	 compare	 slightly	
different	views	of	the	aorta.	This	makes	the	diagnosis	less	precise	and	more	subtle	
changes	may	 be	 invisible.	 Observed	 changes	 in	 vessel	 size	may	 be	 an	 artefact,	
producing	a	false	positive,	caused	by	the	limited	reproducibility	of	scans.	Similarly,	
the	aorta	diameter	can	change	rapidly	along	the	blood	vessel	even	within	healthy	
mice,	or	generally	in	diffuse	aneurysms	also	in	humans.	Moving	the	US	probe	along	
the	aorta	by	few	millimeters	then	has	a	significant	impact	on	the	measured	aorta	
diameter.	The	result	of	each	scan	is	hence	associated	with	a	considerable	error	in	
such	 cases.	 Resultantly,	 MRI	 gives	 an	 alternative,	 solving	 a	 number	 of	 the	
previously	mentioned	operational	errors	that	can	occur.	MRI	gives	you	a	rich	3D	
dataset,	this	can	give	all	quantitative	US	data	values,	with	additional	information	
about	the	surrounding	regions	of	the	vasculature	and	changes	in	the	form	of	the	
overall	vessel	being	captured.	
Alternate	scanning	methods	that	could	produce	similar	datasets	were	considered,	
such	 as	 Computed	 Tomography	 (CT).	 However,	MRI	 is	 superior	 to	 CT	 for	 soft	
tissue	 imaging	 and	 (unlike	 CT)	 produces	 the	 images	 using	 non-ionising	
radiation(185).	Large	areas	of	the	mouse	can	be	imaged	in	a	single	scan,	allowing	
better	understanding	of	the	effects	of	AAA	models	on	the	full	organ	system,	as	well	
as	giving	anatomical	references	that	will	aid	definition	of	the	aorta	in	the	mouse.	
MRI	also	allows	high-resolution	imaging	and	small	structures,	such	as	the	aorta,	
and	potential	aneurysms	are	distinguishable	on	a	low	field	MRI.	
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5.4	Conclusion	
Ultimately,	this	technique	allows	users	to	monitor	aneurysms	in	an	unbiased	and	
reproducible	manner,	with	the	use	of	relatively	low-field	MRI	technology,	making	
it	a	new	option	within	the	study	of	AAA	and	other	such	diseases.	
Quantitative	 imaging	with	 low-field	MRI	 is	now	possible	 for	study	of	vessels	as	
small	 as	 a	 mouse	 aorta.	 Changes	 as	 small	 as	 a	 fraction	 of	 a	 millimetre	 are	
detectable	 with	 the	 use	 of	 a	 blood-pool	 agent.	 There	 is	 the	 potential	 for	 this	
technique	to	be	scaled-up	into	clinical	use.		Using	this	method	and	low-powered	
setup,	 far	 more	 in-depth	 study	 of	 the	 aorta	 could	 occur,	 with	 lower	 levels	 of	
training	 and	 equipment	 experience	 needed.	 Data	 generated	 is	 of	 superior	
reliability	 and	 accuracy,	 than	 that	 of	 currently	 utilised	 2D	 ultrasound	 data,	 as	
quantification	area	 is	much	more	 tightly	controlled	and	 therefore	all	 scans	and	
measurements	can	be	taken	in	precisely	the	same	region.	3D	reconstruction	of	the	
aorta,	 as	 well	 as	 multi-plane	 viewing	 options,	 furthermore	 gives	 you	 a	 visual	
representation	 of	 the	 whole	 vessel	 in	 comparison	 to	 cross-sectional	 images	
provided	 by	 US.	 With	 this	 added	 information,	 improved	 scanning	 and	
quantification	 of	 each	 vessel	 and	 its	 changing	morphology	 could	 contribute	 to	
improved	diagnosis	for	potentially	lethal	events,	most	notably	AAA	rupture.		
6	NE	DEFICIENCY	IS	PROTECTIVE	AGAINST	AAA	INDUCTION	
BY	CALCIUM	CHLORIDE	
AAA is an aortic pathology that affects a significant portion of the population, largely 
of the male and ageing demographic, with large studies reporting 4-5% of males 
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affected, a figure that can increases to around 8% of men over 65 according to alternate 
studies(189). The most commonly affected region of the aorta within the human 
condition is the infrarenal aorta, with expansion occurring between the renal arteries 
and femoral bifurcation. A number of animal models were used to model the pathology 
of AAA, however, the CaCl2 model of AAA procedure is one of the most specific in 
terms of regionality. Within the protocol, CaCl2 is applied directly to the adventitia of 
the vessel, with this applied area being selectively affected by consequent changes. The 
application of CaCl2 leads to localized triggering of inflammation by the activation of 
MMPs via divalent cationic activation. The activation of MMPs leads to cleavage of 
extracellular matrix proteins such as collagen and elastin, the cleaved bi-products cause 
inflammatory cell recruitment and activation whilst MMPs alternate effects on 
transcription factors such as NFkB as well as the activation and release of pro-
inflammatory cytokines which again(190), in turn, promotes the inflammatory 
environment causing the destruction and degradation of the vessel wall. One significant 
benefit of this model is the localization of the inflammation, mimicking the human 
pathology unlike the Ang II model, which causes systemic changes to the animal in 
order to produce a less localized but more aggressive aneurysm phenotype. Whilst both 
have their place in AAA research, it could be argued that they represent different phases 
of the pathology, with the CaCl2 model mimicking the chronic stable phase that is the 
predominant phenotype seen within AAA monitoring and investigations. As a result, 
this model does not result in rupture, and there have not been any reported cases of 
rupture being the cause of death within this procedure when used alone, however, when 
used in combination with an elastase or collagenase infusion rupture has been reported. 
The CaCl2 model has been championed and most extensively carried out by the lab of 
Dr J Golledge. This has led to extensive progression within the understanding of the 
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AAA field. Large advances in the understanding of inflammatory markers, structural 
remodelling and specific cellular involvement within the development of AAA have 
been thanks to the use of the CaCl2 model.  
This round of experimentation will produce a deeper understanding of NEs role within 
both the initiation of AAA, as well as the chronic inflammatory stable phase of the 
pathology. NE already has a known role within NET formation and a role of NETosis 
within AAA has been put forward; suggesting NE will play a role within the overall 
pathology. However as yet, this role is undefined, and its influence is even less clear. 
Beyond AAA NE is known as a driver of pathology within COPD, with functionality 
in the degradation of elastin and destruction of the lung and consequentially the 
potential for NE to play a similar role within AAA is high. Furthermore, NE already 
has a known role within atherosclerosis, with knockout of the enzyme by 
pharmacological and genetic means inhibiting experimental induction of 
atherosclerosis(167). Particular attention will be paid to the changes to the structural 
changes that are produced between Control and NE knockout mice, as this is the area 
in which NEs known functions are predicted to have the greatest degree of influence.  
6.1 MATERIAL AND METHODS:  
Please refer to Material and Methods chapter previously for an in-depth overview of 
general materials and methods utilized in this round of research. 
6.1.1 CALCIUM CHLORIDE MODEL OF ANEURYSM 
A Pilot study comparing Wild type (ApoE-/-/NE+/+) to NE Knockout (ApoE-/-/NE-/-) 
mice subjected to CaCl2 induced-AAA procedures was carried out as previously 
described by Wang et al. (84). Briefly, CaCl2 was administered at 0.5M for 2x7mins 
(Sigma Aldrich), under general anaesthetic (gaseous isoflurane), directly to the aorta 
within the Infrarenal portion of the aorta halfway between the renal arteries and femoral 
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bifurcation, as seen in Figure 13. Measurements of this area were taken, by abdominal 
Ultrasound scanning technique, prior to surgery and repeated at various time-points 
following the operation to monitor the expansion of the vessel over time. The use of 
Ultrasound minimises the number of animals used, in accordance with the 3Rs. 
A follow-up study comparing the same two groups of mice, undergoing the same 
treatment was carried out. Initial Infrarenal measurements were made using Magnetic 
Resonance Imaging (MRI) in place of Ultrasound and repeated biweekly to monitor the 
changes in the aorta. At week 6 all animals were finally scanned, before being culled 
and dissected for analysis of tissues.  
 
 
Figure	13-	Schematic	of	the	Calcium	Chloride	model	of	aneurysm	procedure,	outlining	the	
various	 steps	 of	 surgery	 and	 the	 end	 result.	 A-	 Sketch	 of	 mouse	 orientation	 and	 region	
effected	 within	 the	 procedure.	 B-	 Step-wise	 time	 points	 from	 isolation-	 application-	
dissection	 of	 the	 infrarenal	 aorta.	 White	 arrows	 indicate	 area	 of	 calcium	 chloride	
application,	Black	arrow	indicates	the	same	area	and	identification	of	AAA	
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6.2	RESULTS	
6.2.1	MRI	monitoring	of	Calcium	Chloride	Model	of	AAA	shows	altered	
expansion	trends	with	NE	Knockout	and	Control	Mice	
 
The CaCl2 Model was employed and monitored in a time-course fashion over the 6-
week time period that the protocol lasts. Mice were scanned in accordance with 
scanning protocol in the 2 days prior to the commencement of the CaCl2 model. 
Following on from this time point, mice underwent the procedure and were scanned bi-
weekly. This enabled the identification of the specific time point at which the vessel 
underwent the greatest level of change. As we can see from scanning, the rate at which 
the vessel diameter expands significantly increases after the 4th week of the procedures 
induction. Within the first month, there is low-level changes to the vessel and gradual 
expansion before a more significant and exaggerated change at the 4-week stage. This 
trend was replicated within both experimental groups, with NE knockout mice rising 
earlier however not reaching the same peak at week 6 when compared to the Control 
group. 
Whilst the infrarenal (IR) volume of the aorta was similar between the two groups at 
week 0 of experimentation, this was not the case following AAA induction with the NE 
knockout group expanding on average at a quicker rate than Controls. However, from 
the week 4 point onwards Control mice experience a later rise in aortic diameter 
increase with the gap between the two experimental groups growing drastically from 
week 4 to 6. Expansion of the IR volume was almost three times greater within the 
Control group when compared to the NE knockout group. An increase of 0.3 mm3 was 
witnessed within the NE Knockout group as opposed to 0.92 mm3 seen in Control 
groups, this average expansion was an increase of 9% and 29.4% respectively. However 
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no significant difference was observed between the two groups when compared (Figure 
14). Comparatively, the incidence of AAA was shown to significantly differ between 
the same two groups (Figure 15). 
  
Figure	14-	Comparison	of	percentage	aortic	expansion	within	CaCl2	treated	mice	of	the	WT	
Control	genotype	and	NE	Knockout	genotype	(P=0.0988,	Unpaired	t-test,	error	bars	display	
+/-	1	S.D,	Largest	Horizontal	bar	represents	the	mean	percentage	expansion	in	each	group	
N=7	WT	Control	and	N=5	NE-/-)	
129	
	
	
 
Figure	15-	Incidence	of	aneurysm	following	CaCl2	treatment	as	measured	and	determined	
by	MRI	analysis	of	all	animals,	comparing	aortic	scans	at	week	0	and	week	6	of	aneurysm	
protocol.	WT	Control-	5	out	of	7,	NE-/-	-	0	out	of	5	(P=0.0278,	Fishers	Exact	Test)	
6.2.2	Ultrasound	analysis	of	the	aorta	verified	results	seen	with	MRI,	with	larger	
increases	in	aortic	diameter	seen	within	Control	mice	compared	to	NE	knockout	
mice	
 
Similarly to MRI analysis, US scanning was performed in the days prior to the CaCl2 
model being carried out.  Following the procedure, scans were performed biweekly 
with images taken in many ultrasound-scanning modes and saved for future analysis. 
This enabled the identification of both functional and structural changes in the vessel 
over the time course. Diametric quantification by means of US is the current clinical 
guideline for diagnosis and director of management for AAA. US results displayed 
expansion was present within both Control and NE knockout groups, however, the rise 
seen within Control mice was on average four times that seen within NE Knockout 
mice. Average expansion of 0.10mm and 0.41mm were quantified within NE Knockout 
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and Control mice respectively, with measurements being taken within the same 
scanning period and analyzed in a blinded fashion to minimize any operator bias. This 
expansion was equivalent to 14.4% expansion of the aorta in NE Knockout mice and 
51.5% within WT Controls (Figure 16).   
 
Figure	16-	Percentage	Expansion	of	mouse	aortas	 following	US	scanning	at	week	0	and	
week	 6	 of	 CaCl2	 treatment.	 Largest	 Horizontal	 bar	 represents	 the	 mean	 percentage	
expansion	in	each	group	(P=0.0324,	Mean	+/-	1	S.D,	Unpaired	t-test	N=	Control-	7,	NE-/-	-5)
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Figure	17-	Incidence	of	AAA	as	determined	by	US	scanning	techniques	at	week	0	and	week	
6	of	CaCl2	treatment.	Largest	Horizontal	bar	represents	the	mean	percentage	expansion	in	
each	group	(P=0.0278,	Fishers	Exact	Test,	N=	Control-	7,	NE-/-	-	5)	
6.2.3	Aortic	pulsatility	change	was	not	significantly	different	between	Control	and	
NE	knockout	mice	6	weeks	post-application	of	Calcium	Chloride	
During scans at week 0 and final scans at week 6, the vessel’s pulsatility was assessed, 
with the pulsatility being determined by tracking the movement of the aortic wall within 
the heartbeat cycle at both instances. M mode traces of each scan were assessed using 
VevoLabs analysis software, with video traces of the infrarenal aortic wall enabling 
quantification by tracking maximum and minimum diameters and calculating results 
from these measurements. Within the two groups, there were significant increases in 
pulsatility within the Control group, with all animals pulsatility increasing across the 
6-week period. This was not the case within NE Knockout mice with some mice 
displaying a decrease in the same characteristic (Figure 18), however generally this 
measurement also increased across the time period similar to that of Control mice. 
Although predominantly an increase was found within both cohorts the difference 
observed within Control group was far greater than those of the NE knockout animals. 
NE Knockout mice only increased negligibly, 3.3%, whereas Control mice increased 
by 43.9%.  
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Figure	18-	Changes	in	Pulsatility	of	vessels	following	CaCl2	treatment	(P=0.588,	unpaired	t-
test,	mean	 +/-	 1	 S.D,	 N=	 Control-	 7,	 NE-/-	 -	 5).	 Each	 aorta	was	measured	 at	maximum	
expansion	 and	 minimum	 contraction	 over	 3	 heartbeat	 cycles	 whilst	 mice	 were	 under	
sedation	to	a	specific	heart	rate	range	and	temperature.	
6.2.4	Dissection	of	Control	and	NE	Knockout	mice	replicate	findings	of	both	MRI	
and	US	modalities,	with	expansion	seen	more	prominently	within	Control	animals.		
 
Following the completion of the 6-week CaCl2 protocol, all mice were culled via 
Schedule 1 methods. Following this, mice were immediately grossly dissected with the 
vasculature isolated and removed from the carcass. Removed vasculature was then 
finely dissected, with images taken.  
Within dissections, the infrarenal region of the vessel was the most remodelled portion, 
with evidence of the direct and localized application of CaCl2 to the exterior of the 
vessel obvious within many vessels. Expansions were seen in Control mouse vessels in 
the mid infrarenal aorta, however, no similar expansions were seen within the NE 
Knockout mice. The predominant effect of the CaCl2 procedure was the observed 
change in luminal path which was evident under closer inspection and easier to 
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visualize whilst blood was still present within the vessel. This was seen as an expansion 
in a highly localized area of the aorta, as seen in Figure 19.  
 
Figure	19-	Representative	differences	in	aortic	morphology	as	displayed	by	dissection	
images.	WT	Control	mice	had	observed	expansions	in	the	region	of	CaCl2	application	(Left,	
blue	arrow	indicating	a	region	of	expansion),	whereas	no	significant	increases	were	seen	
within	the	same	infrarenal	portion	of	NE	Knockout	mice	(Right)	
No mice showed any signs of expansion or vessel remodelling in regions not treated 
with CaCl2, with all vessels displaying a clean, uniform and continuous vessel wall in 
shape and cellular appearance when inspected under a microscope.  
 
6.2.5	RNA	analysis	of	dissected	aortas	display	differential	expression	of	MMPs	
within	NE	Knockout	mice	
 
Tissues generated from the Calcium Chloride procedure were taken, following fine 
dissection, for utilization within RNA analysis. RNA analysis allows for a snapshot of 
gene expression changes within tissues that have undergone different treatments or in 
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this instance when of differing genotypes in response to the same treatment. In order to 
preserve the RNA within tissues, all fine dissection occurred immediately, and each 
respective dissected aorta snap-frozen prior to processing.  
Consequent RNA analysis by qPCR outlined clear differences and similarities in the 
expression of particular cell types, proteins and enzymes. Observations included the 
significant loss of MMP2 in line with NE (p<0.05) (Figure 20), in comparison to 
expression of MMP8 where there was no significant, changed seen across the aortas 
isolated (N=3 per group). Similarly, markers for endothelial cells (CD144) were also 
found to be comparable between Control and NE Knockout groups. 
 
 
6.3 DISCUSSION AND LIMITATIONS 
Throughout this Chapter, studies to elicit whether NE contributes to the AAA pathology 
and how it takes its effect was undertaken. Consistently within experiments, there is 
evidence to suggest NE may play a role within the production of AAA within the CaCl2 
model, as changes in expansion and incidence rates within AAA models indicate. 
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Figure	20-RNA	analysis	results	of	q-PCR	from	WT	Control	and	NE	Knockout	Aortas	following		
CaCl2	treatment	at	week	6	of	the	protocol.	NE,	MMP2	and	MMP8	have	observable	reductions	in	
levels	between	the	WT	and	NE-/-	groups,	whereas	CD144	shows	no	change.	N=3	per	group,	
mean	+/-	1	S.D	
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However, due to the number of animals utilised within this study remains relatively 
low, these outcomes are preliminary and require validation by increase in the N number. 
Furthermore, changes in RNA analysis results between the two groups point towards 
MMP difference being influential, suggesting a link between NE and MMPs, possibly 
similar to that discussed within the COPD condition. Again, further investigation is 
needed to understand the full impact of NE and the mechanisms by which NE produces 
an effect due to a limited number of repetitions. The observed effect is dissimilar to a 
pilot study which utilized the elastase model of AAA-induction(142), however 
considering the use of an elastase to replace another elastase, I feel this is not surprising, 
and with further study, the argument for that paper to be disregarded will be 
strengthened. Beyond this, inhibition of NE has previously been observed to decrease 
the levels of circulating cholesterol within animal studies(167). Consequently, reduced 
levels of circulating cholesterol, reduced inhibition of cholesterol efflux from 
macrophages and consequent decreased levels of atherosclerosis and inflammation 
would have a beneficial impact on AAA incidence and could explain the outlined 
decrease in pathology incidence. 
Although some evidence to suggest a role within AAA was identified, serious 
limitations of some experimentation exists. With reference to qPCR results outlined 
within Figure 20, the detection of NE was unexpected, as all mice were subject to 
repeated genotyping. This could imply the jeopardization of sterility and consequent 
contamination. The insertion of the neomycin selection cassette into exon 2 has 
historically led to no protein expression, this was confirmed with no evidence of 
significant NE staining within relevant NE knockout samples and genotyping of mice 
at birth. Verification of this should however be carried out in order to reassess the 
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source of NE material prior to the acceptance of results stemming from this specific 
aspect of experimentation.  
Further to this, the results discussed above within this chapter require validation and an 
improved understanding of the mechanism by which the potential effects are occurring. 
For instance, there is a definite need for further clarification of the effect brought about 
by loss of NE within this AAA model. Techniques such as histological staining are 
needed to be undertaken prior to concrete conclusions being made.   
6.4 CONCLUSION 
Throughout this chapter, we have started to understand the role of NE within AAA. 
Experiments in some instances did not reach significance. These prelininary results 
suggest inhibition of NE is protective against the induction of AAA. RNA analysis of 
end-stage tissue led to the observation of a reduction in MMP expression with loss of 
NE, this could be a potential mechanism by which loss of NE exerts its effect. Further 
work is therefore required to verify these results with the use of an alternate model of 
AAA. 
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7-	NE	GENE	INACTIVATION	IS	PROTECTIVE	AGAINST	
INDUCTION	OF	AAA	BY	ANGIOTENSIN	II	
 
Whilst previous experimentation has eluded to NEs role within AAA, both within in 
vitro and in vivo, confirmation with a further animal model that is considered the most 
comprehensive is required before definitive conclusions are drawn. Currently both cell 
culture experiments and the calcium chloride model point towards NE playing a 
significant role within the modulation of AAA-associated markers and generation of 
AAA itself.  
The Angiotensin II model of AAA is a widely used procedure, previously unused within 
our laboratory group. Ang II is infused via an osmotic pump, over a 28-day period, 
positioned within the sub-dermal pouch of the rodent. Early on in this time period, the 
infusion of the agent causes activation of the AT1a receptor and consequential 
significant increase in blood pressure of the animal; this is a commonly observed risk 
factor for AAA and occurs within the first few days with results lasting the duration of 
the time course. Over the next month, vascular remodelling occurs within the recipient 
animals. Included in this remodelling is cardiac hypertrophy and, of most interest in 
this investigation, aneurysms. Aneurysms- the enlargement of a vessel by 50% or 
greater beyond that of a healthy vessel, can be witnessed in as much a 70% of animals 
undergoing 28-days of Ang II infusion, dependent upon operator. The location of these 
enlargements most commonly occur in the suprarenal or thoracic portion of the aorta, 
however, they can bridge the renal arteries and form a fusiform aneurysm in severe 
instances. With the expansion of the vessel come a number of risk factors for mortality, 
these include both aortic dissection and rupture. Aortic Dissection is the splitting of the 
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vessels intima away from the medial and adventitial portion of the vessel resulting in 
the production of a false lumen. Aortic Rupture has even further complications, where 
the luminal contents break through the weakened and expanded vessel wall. Rupture 
results in death in approximately 80% of cases where the sufferer is not already in 
medical care. These expansions and changes can be a result of changes in flow within 
the vessel, as well as inflammatory cell infiltration and degradation of the vessel wall. 
All of these factors have known roles within the initiation and progression of AAA and 
are present within the tissues generated from the Ang II model. NE may have roles 
within some of these processes and potential to impact the pathology, with already 
reported roles of NE within the cleavage of ECM proteins. Resultantly, use of the Ang 
II model of AAA upon a NE knockout background could elicit further information that 
aids in unravelling the AAA initiation and development process or even provide a drugs 
target for the pathology.  
This model differs from the previously utilized CaCl2 model, with the model mimicking 
a different phase and severity of aneurysm. Whilst the CaCl2 model replicates the stable 
chronic phase of the condition, the Ang II model produces the more acute dissection 
and rupture-prone phase of the pathology. As a result, the results are occasionally 
dissimilar if the aspect being investigated is relevant only within a particular phase of 
the process. However, both models have the ability to produce significant 
advancements in the understanding of the mechanisms underlying AAA. 
Following similar AAA studies that utilized the Ang II model procedure, the field has 
moved on hugely. The role of MMPs and TIMPs in AAA were outlined by utilization 
of this model, as well as inflammatory signalling mechanisms such as Toll-like 
Receptors, micro RNAs involvement within AAA and even drug trials for inhibition of 
AAA before progression to human trials. Resultantly, this can be viewed as a gold 
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standard within the field for mimicking the disease and consequentially should yield 
the largest insight into the role of NE within the pathology, in turn answering one of 
our main hypothesis. Predominantly this round of experimentation is aimed to answer 
the research question of how is NE implicated within AAA. This will be addressed by 
the use of genetic knockout of NE within the animal model, as well as the use of 
subsequent tissues generated to look at the changes in further proteins with the use of 
histological staining and RNA analysis.  
7.1 MATERIAL AND METHODS:  
For detailed information on the Materials and Methods utilized within these chapters 
experiments, please refer to the Materials and Methods chapter above. 
7.1.1Proteomics analysis 
Proteomics analysis was performed to elicit and identify underlying mechanisms of any 
changes seen within the aneurysm model experiments. As NE is an enzyme produced 
predominantly by circulating blood cells, cells that can cross into the vasculature, the 
enzyme can interact with a number of cell-types and therefore has a wide scope for 
potential influence. Resultantly we employed a fractional extraction of the proteins to 
narrow down the areas in which NE was exerting its effects. Following in the footsteps 
of Didangelos et al. (11), the aortic tree of mice treated with AngII for 14 days, 
administered by osmotic pumps, was finely dissected before being processed. Two 
groups of mice were administered the same AngII treatment over the same time period, 
with Control Mice and NE knockout mice undergoing experimentation. Following 
treatment of mice with AngII and fine dissection of the aortic tree, the vessel was finely 
diced and placed into separate cryovials for fractional protein separation, in accordance 
with the Didangelos protocol(11). This protocol separates the sample into three protein 
subsets, with the three portions consisting of; loosely bound novelly synthesized 
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proteins, intracellular protein content and finally, extracellular matrix proteins. NE has 
the possibility to influence all three of the fractions, with results providing the basis for 
further experimentation to verify the results and their effects on the AAA phenotype.  
Following the isolation of the three protein fractions, these are taken for proteomic mass 
spectrometry analysis. Protein samples were run on a self-made 10% acrylamide gel 
and stained by Coomassie blue staining to reveal all protein bands. This separates the 
proteins from the extraction buffers, removing impurities from the samples. Each 
protein lane was then cut and placed within sterile Eppendorf vials, before 
trypsinisation to remove the proteins from the gel. Following separation from the gel, 
proteins were dissolved in 10mM Urea and 0.05% SDS/ ammonium bicarbonate at pH 
8, samples were then incubated for an hour at 50degrees. Following this, iodoacetamide 
was added and incubated for a further hour, at 21degrees. This left samples reduced and 
alkylated. Samples were then diluted to 1.2M urea/ 0.01% SDS. Trypsin was added to 
this mixture at a 1:50 ratio before overnight incubation at 37degrees. Mixtures were 
consequently dried in a SpeedVac, removing volatile salts and later re-dissolved in 
100µl of 0.1% AcN/formic acid. Protein solutions were separated using an ABI 140C 
HPLC binary pump, with an SCX column. Elution gradient was 0%B to 20%B in 
30mins and 20% to 100% B in 22mins. A consisted of 25% AcN/0.1% formic acid, 
with B 500mM KCl, dissolved within A at 20µl/min, with collection of fractions 
occurring at each minute. Reversed-phase liquid chromatography electrospray tandem 
mass spectrometry was subsequently undertaken.  
 Peptides present in the protein elution fraction were separated by nanoLC and 
sequenced using online tools (ESI-MS/MS). Eluted peptides were detected and 
sequenced by Q-tof equipment (Waters, Micromass, Manchester, UK) with a nanoESI 
ion source. MS/MS processing of all spectra was carried out using MassLynx software. 
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This produced the peak list, used to identify the proteins present. This was identified 
using the NCBI murine database. Mascot software (Matrix Science, UK) alongside 
Daemon software (Matrix Science). Results were then imported into an Excel 
spreadsheet for interpretation, this was considered significant when a Mascot score was 
greater than 25, in accordance to the method utilised within papers such as Naba et al. 
(191)  . Mascot scores are used similarly to P-values, in the sense that they are used as 
a measure of likelihood that the result of the reading occurred by chance. A cut-off of 
25 is used in this instance to have a high threshold by which the protein reading must 
improve upon in order to be considered as significant. This score is relative to how well 
the assessed ion MS/MS spectrum relates to the stated peptide it is being compared 
against. Through the use of a 25 cut off the level of false-positive results significantly 
falls. Identified proteins within the searches were then used to direct further works, such 
as western blot and histological analysis of AAA model samples.  
7.2 RESULTS 
7.2.1	Blood	Pressure	changes	following	Ang	II	administration	was	comparable	
between	groups	
 
The mechanism by which Ang II exerts its predominant effect of raising blood pressure 
in order to produce hypertension and latterly AAA is via the AT1a receptor. Other side 
effects of Ang II exposure exist and can impact the AAA pathology to a lesser extent, 
however, these are of less importance within this study as the AT1a receptor is widely 
accepted as the predominant mechanism of AAA causing hypertension within this 
model. Monitoring blood pressure change was imperative as the relation between NE 
and blood pressure regulation is currently unknown. Consequentially any alterations to 
the AAA phenotype seen with NE knockout mice could be a result of inhibition of 
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blood pressure by NE, compared to an actual role in inhibition of the pathological 
process and phenotype formation.  
 Tail-cuff blood pressure monitoring methodology was utilized, with 10 repeat 
measurements taken daily on 3 days in a week, before being averaged, removing 
outlying or interrupted readings. This procedure was repeated both the week before 
Ang II pump insertion, as well as during the second week of Ang II exposure. As is 
evident within the Graph below, significant increases in both systolic and diastolic 
blood pressure were recorded within both Control and NE knockout mice. Blood 
pressure increases were highly comparable between the Control and NE Knockout 
groups, with no significant difference was seen at any stage. Initial blood pressure 
values were minimally lower within the NE knockout cohort, however, failure to 
produce any significant difference between the NE knockout and control groups. 
 
Figure	21-	Average	changes	in	systolic	and	diastolic	blood	pressure	in	a	cohort	from	the	
experimental	group	of	mice	following	Ang	II	treatment	as	measured	by	tail-cuff	analysis	at	
week	0	and	week	2	of	the	Ang	II	protocol.	Results	achieved	by	taking	10	readings	per	day,	
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for	3	days	per	time	point	per	animal.	N=	3	per	group	(Systolic	p=0.179,	Diastolic	p=0.466,	
Unpaired	t-test,	mean	+/-	1	S.D.)		
	
7.2.2	Changes	in	flow	are	seen	from	week	two	after	Ang	II	administration	within	
Control	animals,	but	no	significant	change	is	visible	within	NE	knockout	mice	
 
          The use of Ultrasound to measure vessel dimensions and flow has been widely 
used within the cardiovascular field, both in research and clinically for many years. As 
a new technique being established within our research group, many scans were 
undertaken to learn and optimize imaging of the vessel in order to monitor the induction 
and progression of AAA over the 4 week period that the Ang II procedure is carried 
out, and one week prior for control baseline measurements. Ultrasound enables the 
visualization of flow with an algorithm attributing a colour to a certain velocity of flow, 
producing a colour image that visualizes the velocity of flow and the changes to this 
velocity that occur across a US image. Major arteries such as the aorta in healthy 
physiology are pulsatile, with flow being highly pressured and progressing in a laminar 
formation. This forms a target like signal, as the resistance of the wall slows the adjacent 
blood, whereas the centre of the vessel progresses unimpeded. However, in specific 
areas such as the aortic arch and also within areas of remodelling and pathology, this 
laminar flow is highly disrupted becoming turbulent. This turbulence can have adverse 
effects to the surrounding vessel and has been evidenced to contribute to pathologies 
such as AAA and atherosclerosis. Furthermore, the flow of a vessel can exemplify the 
health status of a vessel. For instance, with the example of aortic dissection and AAA 
where a false lumen can be created this can be clearly visualized within US scans. 
Within the pathology, where a break in the intimal layer allows blood to flow into the 
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medial space and pool within the area, large amounts of remodelling occurs and is a 
sign of worsening prognosis. Similar qualitative and quantitative assessments will be 
made and comparisons drawn between the Control and NE knockout groups across the 
entire timeline of Ang II treatment. Control scans prior to Ang II administration will be 
carried out and subsequent biweekly assessment of the aorta within each animal at 
numerous reproducible locations and in both cross-sectional and longitudinal planes, 
this enables a thorough time course overview of the changes the Ang II model has upon 
the aorta within mice, as well as the difference NE knockout elicits to the same process.  
 
Figure	22-	Colour	Doppler	analysis	displaying	the	progressive	changes	in	colour	doppler	
image	signatures	at	the	various	stages	of	aneurysm	development	within	WT	Control	and	NE-
/-	Mice.	Arrow	indicates	the	aorta	in	each	image,	top	row	is	cross	sectional	view,	bottom	row	
shows	 the	 same	mouse	as	 top	 row	but	 in	 longitudinal	plane.	A&D-	Healthy	 laminar	 flow	
displayed	 by	 a	 target-like	 appearance	 in	 Doppler	 reading,	 identified	 by	 an	 arrow,	 seen	
within	both	WT	and	NE-/-	mice	at	week	0,	images	from	a	WT	control	pre-implantation	of	
Angiotensin	pump.	B&E-	WT	mouse	4	weeks	post-Ang	II	pump	implantation,	disturbance	of	
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the	clear	vessel	outline	and	laminar	flow	signature,	with	accompanied	enlargement	of	the	
vessel.	Disturbance	of	laminar	flow	observed	with	non-central	peak	in	reading.		Complete	
separation	of	flow	with	production	of	a	false	lumen	shown	by	complete	alteration	in	doppler	
signature	 with	 separation	 of	 blue	 and	 red	 signal.	 C&F-	 NE-/-	 Week	 4	 post-pump	
implantation,	 no	widespread	 or	 notable	 change	 from	 images	 A&D,	with	 similar	 doppler	
signal	visualized	and	observed	within	all	mice.			
Within the study of Control mice and NE knockout mice, flow was consistently seen to 
be altered within Control animals however this change was minimized within 
comparable NE knockout mice. Laminar flow, represented by a target like image, was 
repeatedly found within all mice within Control scanning (Figure 22, A and D). At the 
2-week stage of Ang II infusion, no change was seen within the NE knockout mice 
population, however, occasional early changes and distortions to laminar flow were 
identified within Control mice. Most commonly this was visualized in the pararenal 
portion of the vessel. Moving onto the end-stage 4-week point of Ang II infusion, small 
deviations from normal were seen, with NE knockout mice not displaying any 
significant changes in flow pattern when measured using Colour Doppler (Figure 22, 
C&F). However, the early changes witnessed at the 2-week stage within Control mice 
were exacerbated within Control mice at week 4 (Figure 22, B&E). The proportion of 
scans that showed early signs of remodelling had increased, and beyond this, a 
significant portion of the cohort had developed further with remodelling progressing 
into significant changes and in the case of 2 animals the production of a false lumen 
(Figure 22, B&E). This production of a false lumen resulted in significant turbulence 
as witnessed within the longitudinal section of imaging and the production of a 
secondary lumen with extremely low velocities of flow in cross-sectional planes.  
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7.2.3	PW	Doppler	results	show	changes	in	pulse	waves	within	both	groups	 
Alongside the use of Colour Doppler, the use of Pulse Wave Doppler allows the 
quantification of vessel pulsatility and visualization of the variability of a vessels blood 
flow over time. PW Doppler produces a trace of flow velocity at a particular point in 
the vessel over a period of time, producing a wave trace which displays the variability 
of the blood flow velocity over that set period. Different vessel characteristics such as 
size, pressure and health of the vessel alter the wave produced. From this wave, we are 
able to tell many things that can give a further insight into the health of the vessel and 
therefore this will be used as an indicator of disease progression as animals are 
monitored over the 4-week Ang II infusion period. Ultrasound analysis software can 
produce automated readings and values for factors such as vessel plasticity as a product 
of the PW characteristics; this also can give an indication of the level of remodelling or 
deterioration seen within a vessel when repeatedly measured in a time-course manner. 
 
Figure	23-	Colour	Doppler	and	PW	Doppler	analysis,	displaying	representative	changes	to	
both	the	colour	doppler	and	PW	doppler	measurements	at	different	stages	of	the	aneurysmal	
phenotype	within	WT	Control	mice.	Progressive	 changes	 range	 from	untreated	 (Left),	 to	
early	changes	at	week	2	(Centre)	and	Late	stage	of	AAA	(Right)	
Within the experimental groups' baseline, PW waves were highly similar and consistent 
with literature images. High peaks in vessel velocities followed by a sharp fall-off but 
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no backflow was seen within both Control and NE knockout groups at week 0. 
Following the administration of Ang II vessel readings significantly changed, with large 
levels of deviation from the healthy stereotypical PW wave seen within Control 
experimental mice, most predominantly within the highly remodelled vessels. At week 
4 NE knockout mice had minor changes to the PW Doppler trace, with less sharp fall 
off after the velocity peak within the trace. Comparatively, Control mice showed an 
altered PW wave, with backflow present in most extensively remodelled vessels 
(Figure 23, right panel). The loss of the aortic flow signature in Control vessels at week 
4 is a sign of deteriorating vascular health.  
7.2.4	Both	Aortic	Diameter	and	Infra	renal	volume	are	significantly	increased	
following	4	weeks	of	Ang	II	treatment		
 
             The Ang II model of AAA is a well-established technique that replicates the 
acute expansion and dissection phase of the aneurysmal pathology. The administration 
of Ang II and tracking of the changes to the abdominal aorta was made possible by use 
of both Ultrasound and MRI scanning techniques. Ultrasound enabled the detailed 
tracking of changes to aortic diameter, whilst MRI allows for volumetric measurement 
of the entire selected portion of the aorta at each time point.  
 Within Ultrasound analysis, mice were scanned prior to implantation of the 
osmotic pump and then biweekly following the insertion. As an aneurysm is defined as 
the enlargement of a vessel to greater than 50% of its original diameter, all 
measurements were taken and compared to relative control measurements. At week 0 
infrarenal diameter measurements within both groups were comparable and a healthy 
outline of the vessel was observed within all mice across both Control and NE knockout 
groups. At week 4 the two groups have highly differing results, with the average 
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expansion within Control groups being around 70% above control scans compared to 
the 5% increase seen within NE knockout groups.  
 MRI results and scanning protocols were highly similar, however, due to the 
osmotic pump containing a metal rod, no week 2 measurement were taken and final 
scans were carried out following the removal of the pump. Volumetric expansion was 
diminished in comparison to diametric increases, however. When analyzing week 4 
MRI measurements, average volume expansions within the Control group were around 
35% increase, compared to the 5% of the NE knockout contingent. Variability of 
expansion seen was much larger within the Control aortas measured in comparison to 
NE counterparts.  
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Figure	24-	Comparative	graphs	displaying	the	Volumetric	differences	between	WT	Control	
and	 NE	 Knockout	 groups	 following	 Ang	 II	 protocols.	 Top-	 displays	 differences	 between	
groups	as	measured	by	MRI	(P=<0.0001,	unpaired	t-test).	Horizontal	Bar	indicates	average	
percentage	expansion	as	measured	by	MRI,	N=	Control-11	NE	-/-	-9	Bottom-	differences	in	
aortic	expansion	between	groups	as	measured	by	US	(0.0112,	unpaired	t-test)	Horizontal	
Bar	indicates	average	percentage	expansion	as	measured	by	US.	N=	Control-	9	NE	-/-	-6	
7.2.5	Fine	Dissection	of	Mice	post-induction	of	AAA	models	confirm	findings	of	
Ultrasound	and	MRI	analysis 
             Within MRI and Ultrasound analysis, developed and outlined above, 
differences in aortic health were observed by both diagnostic imaging modalities. 
However, confirmation of this result by analysis of end-stage tissues was imperative to 
confirm the validity and reliability of the results. Following the termination of 
experiments at day 28, all mice were sacrificed by a CO2 Schedule 1 procedure prior to 
dislocation of the neck to confirm death. Immediately following this rough dissection 
to remove the aorta of each animal was performed, with images being taken to confirm 
aortic health. Upon removal of the aorta from the heart to iliac bifurcation, finer 
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dissection was carried out to remove as much connective tissue surrounding the aorta 
as possible without damaging the vessel itself. The following figures show 
representative images of the results, with confirmation of the MRI and Ultrasound 
imaging results. Identification of some vascular expansions in regions outside to region 
of interest was also identified within Control groups, however, no areas of localized 
aneurysmal expansion were identified within the NE knockout group.  
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Description 
of Aorta 
Percentage of 
Baseline 
Measurement 
as Measured 
by US 
Healthy <105% 
Dilated 105-149% 
Aneurysmal 
(AAA) 
150%+ 
 
 
NE-
/- 
Average 
Expansion 
WT 
Control 
Average 
Expansion 
Healthy 3 2.883% 0  
Dilated 3 32.033% 4 31.471% 
AAA 0  5 102.979% 
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Figure	 25-Typical	 findings	 at	 post-mortem.	 	 Rough-dissection	 images	 following	 Ang	 II	
treatment,	with	 large	 expansions	observed	within	WT	Control	mice	 in	5	 control	animals	
(Left),	diffuse	minor	dilation	within	WT	mice	in	four	control	mice	(Centre)	and	no	similar	
expansions	observed	in	NE	Knockout	mice	(Right)	
7.2.6	Pulsatility	of	the	Aorta	differs	in	control	and	NE	knockout	mice	with	Ang	II	
administration	
During the progression of the AAA pathology, the ECM and structural proteins of the 
vessel such as elastin and collagen are hugely degraded. This degradation interrupts the 
normal functions and characteristics of the vessel, for instance, its ability to expand and 
recoil in response to pulses in blood flow. With the utilization of Ultrasound 
monitoring, the vessels elastic recoil can be monitored and compared across different 
time points within the same mouse and aortic location. Subsequent monitoring of mice 
from each cohort, both prior and following Ang II treatment was carried out. Analysis 
of the vessel location and image quality was imperative to being able to pinpoint minor 
changes within vessel characteristics as vessel characteristics are dynamic and change 
along the length of the vessel.  
 Vessel pulsatility was not significantly different when comparing NE knockout 
and Control groups across the 4 weeks of Ang II treatment. Baseline measurement 
comparisons between the Control and NE knockout mice showed a minor difference in 
the basal pulsatility of the vessel, (Figure 26), with NE knockout mice appearing to 
have a minimally more pulsatile infrarenal aorta when compared to Control 
counterparts, this was not significantly an different. However, the levels of pulsatility 
in NE knockout mice would fall below that of the Control mice following the complete 
4-week treatment with Ang II. Overall the two datasets regarding vessel pulsatility were 
comparable.  
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Figure	26-	Comparison	of	change	in	pulsatility	of	the	aorta	between	each	group	following	
Ang	 II	 treatment,	 as	 measured	 by	 US	 techniques	 at	 week	 0	 and	 week	 4	 of	 treatment.	
(P=0.2854,	Unpaired	t-test,	mean	displayed	by	major	horizontal	bar+/-	1	S.D,	N=	Control-	9,	
NE-/-	-	6).	No	Change	is	indicated	by	a	dotted	line	
7.2.7	Histological	analysis	displays	the	changes	of	vessel	morphology,	with	Collagen	
and	 H&E	 staining	 displaying	 significant	 alterations	 between	 Control	 and	 NE	
knockouts	in	end-stage	tissues	
             From the end-stage dissection, tissues were preserved and mounted within 
OCT or Paraffin in order to compare the cellular and structural changes as a result of 
Ang II treatment within the Control and NE knockout groups. H&E staining is a widely 
used within diagnostic histology as it visualizes the basic structures and components of 
the cells and tissues, with DNA material staining a purple colour and cytoplasm or 
collagen in a pink to red colouration.  
 Collagen is a well-known structural protein that helps to form the scaffold of 
the aorta. Remodelling of collagen and elastin is a well-known step within the 
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progression of AAA and even minor evidence of these changes should be visible within 
vessels that have not yet started to expand. 
H&E staining displayed a clear deviation from normal structural arrangement within 
Control group animal tissues (Figure 27 A). These changes were visible within all three 
layers of the vessel, with dysregulation of the media and adventitia evident and the loss 
of the intimal landmarks such as the prominent elastic lamina. Furthermore, the 
adventitial layer of the aorta in control mice appears to have developed outwards in a 
regional-specific manner, as the coverage of this layer surrounding the vessel is not 
proportional around the entire vessel circumference. Whilst looking further into the 
medial portion of the vessel, you can see clear dysregulation of the extracellular 
structure. The elastic lamina is typically seen within a formation of defined continuous 
lines with consistent distances between the many layers, however, these have become 
broken and changeable in gaps between layers of elastin are highly inconsistent with 
loss of nuclear staining within the expanded regions (Figure 27 A).
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Figure	27-	H&E		images	of	histological	sections	from	both	WT	Control	(A)	and	NE	Knockout	
mice	(B)	following	the	completion	of	the	4-week	protocol.	Collagen	staining	by	Sirius	Red	
used	within	the	bottom	two	rows.	WT	Control	(C)		and	NE	Knockout	mice	(D)	are	displayed,	
showing	the	erratic	and	irregular	banding	of	proteins	in	C	when	compared	to	the	uniform	D	
image.	
In comparison to this phenotype observed with control mice, the NE knockout mice 
displayed minimal signs of remodelling, with all three distinct layers of the vessel intact 
and undisrupted (Figure 27 B). Clear elastic lamina folds are visible throughout the 
tissue sections, with consistent distances between the layers and no evidence of medial 
layer destruction. Intimal, medial and adventitial layers are consistent in form and depth 
throughout the sections prepared. No clear changes to adventitial layers can be seen. 
Intimal analysis shows some elastin folds have appeared to flatten slightly, however no 
breaks or loss of nuclei within the region can be seen. 
Collagen staining shows highly similar patterns of remodelling when compared to the 
H&E analysis (Figure 27 C&D). Both Control and NE knockout mice show the 
different densities and forms of collagen present within the aorta. Intimal and medial 
layers stain lighter in comparison to the adventitial layer that is much deeper in staining 
colour. This difference in staining colour is also due to the differential uptake by type I 
and III collagen fibres that are visualized within Sirius red collagen stains. In WT 
Control mice (Figure 27 C), all the aortas displayed higher levels of remodelling within 
the intimal portion of the vessel, whilst the outer adventitial layer was far more similar 
to that of NE knockout mice (Figure 27 D). High levels of breakdown of intima layers 
and even exposure of the deeper layers at times where the luminal layers of collagen 
had been stripped away were observed in WT control mice. Such changes were never 
seen in NE knockout mice, with consistent coverage of the medial and adventitial layers 
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with luminal layers of collagen. One major shortcoming is the lack of scale bars in both 
Figure 27 C & 27 D due to problems with microscope scale bar accuracy at the time 
of the experiments, therefore whilst patterns of expression can be assessed no 
quantification or references to scale can be drawn.  
7.2.8	Immunofluorescent	staining	confirmed	upregulation	of	MMPs	and	presence	
of	immune	cells	within	the	vessel	wall	
               Dissected sections of the aorta were taken and preserved prior to mounting 
and sectioning within OCT or Parafin. These end-stage samples were sectioned by 
microtome before adherence to polylysine coated slides took place. These prepared 
slides underwent chemical antigen retrieval and were then able to be stained and imaged 
using immunofluorescent techniques in order to visualize specific proteins of interest, 
as well as said proteins localization and structure.  
 Within this experiment, we identified MMPs and immune cell invasion as an 
area of interest, with both being regarded as a key influence within the AAA pathology. 
Staining on these peptides occurred successfully with the secondary antibodies 
identifying diffuse expression within the vessel wall of aneurysmal tissues. Immune 
cell markers and MMPs were located most strongly within the adventitial portion of the 
vessel wall (Figure 28), with MMPs appearing less regionalized but imaged at greatest 
intensities within the same portion. Immune cell markers such as ly-6g were used to 
identify cells of immune origin.  
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7.2.9	Fractional	Distillation	of	the	Aorta	was	achieved,	separating	vessels	into	
three	distinct	groups	of	protein	content	
 
Following the continuously emerging result of NE playing a role within the initiation 
and development of AAA, there was a need to understand the mechanism by how NE 
was having an effect. RNA analysis had shed some light on the changes within end-
stage tissues composition, in terms of differential expression of key enzymes such as 
MMP2. However, we suspect that this was the product of more subtle changes at an 
earlier stage of the pathological mechanism. In order to address this in detail, we wanted 
to decipher which area of the vessel NE was having its most potent effect, and what it 
was regulating or modifying at the same time. To do so fractionation of the aortic 
sample was needed. Following the protocol set out by Didangelos et al.(11), aortic 
tissue samples were processed in order to separate proteins from three differing origins. 
Figure	28-	Example	images	of	immunofluorescent	staining	of	MMP8	within	WT	aortas	that	had	
undergone	Ang	II	protocols.	This	experiment	was	repeated	5	times	across	a	selection	of	WT	aortic	
section	slides.	 	All	 sections	were	counterstained	with	Hoescht	nuclear	staining,	 	MMP8	(Pink),	
Left-	x20	objective.	Right-	IgG	Control	from	the	same	aorta	but	a	number	of	sections	along	from	
immunostained	region	x	20	Objective.	
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Proteins were separated into; loosely bound newly synthesized proteins, intracellular 
proteins and finally extracellular matrix proteins. This occurred by a novel protein 
extraction process that enabled the precipitation of the relevant proteins at each stage.  
 After a few modifications to the protocol and optimization of the procedure, a 
successful extraction of all three fractions from within the same tissue sample was 
completed. Following this, the successful running of a gel was completed in order to 
separate all proteins contained within each sample. This displayed the abundance 
present within each fraction and each sample. Completed in triplicate, this allowed for 
the possibility of analysis of Control and NE knockout tissues by proteomics. 
Abbreviated results are included below in Figures 29-31 and a more extensive 
summary is included within Appendix 1-3.  
 
7.2.10	Proteomics	analysis	of	the	three	generated	fractions	produced	promising	
insights	into	proteins	implicated	in	NEs	protective	role	against	AAA	
 
As outlined above, following fine dissection of the aorta from three mice within both 
Control and NE knockout groups, fractional separation of the tissues occurred. Loosely 
bound and newly synthesized proteins, intracellular and extracellular matrix proteins 
were extracted into a total of eighteen samples for comparison between relevant 
fractions and genotypes. Due to us being more interested in the causal mechanism of 
AAA and the implications of NE within this process, all Ang II treatments were halted 
at the 14-day stage, prior to widespread modifications of the vessels. This was in order 
to identify the proteins that change early within the process and are causal in bringing 
about the phenotypical changes that we see later on within the AAA model. Following 
the extraction, gel separation of proteins followed by trypsinisation and mass 
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spectrometry techniques were used to identify the proteins present, as well as 
modifications to proteins such as phosphorylation of such molecules. All readouts from 
mass spectrometry analysis were assigned a Mascot score, with a threshold of 50 being 
used as a threshold of validity. From this list, analysis of change across the relevant 
samples were carried out, with a heat map generated in order to visualize changes, with 
fold change and p-values produced to determine the significance of these changes. 
Following on from this Volcano plots were utilized to determine the most appropriate 
proteins to follow up.  
	 Resultantly,	 the	volcano	plot	generated	by	 the	 comparison	of	Extraction	
fraction	1	between	WT	and	NE	knockout	mice	undergoing	the	Ang	II	model	of	AAA	
yielded	many	 positive	 results.	 Thresholds	 of	 change	 in	 both	 p-values	 and	 fold	
change	 were	 applied	 with	 some	 of	 the	 most	 significant	 changes	 seen	 in	 the	
proteins	 highlighted	 within	 the	 heat	 map	 below.	 Proteins	 such	 as	 VASP-like	
protein	 and	 DDRGK	 protein	 1	 were	 some	 of	 the	 most	 significantly	 different.	
However,	when	looking	deeper	 into	the	data	set,	genes	such	as	F-Box-Like/WD	
Repeat-Containing	 Protein,	 Transducin	 Beta	 Like	 1	 X-Linked	 (TBL1x),	 were	
highlighted	as	they	had	sufficient	levels	of	significance	whilst	increased	levels	of	
fold	 change	simultaneously	 (P=<0.0005).	Thousands	of	proteins	were	analysed	
with	only	a	small	fraction	of	these	regarded	as	significant	when	comparing	the	two	
groups	extraction	fractions.	
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Figure	29-	Volcano	plot	analysis	of	fraction	1	comparison	between	WT	Control	(lane	1-3)	
and	NE	knockout	mice	(lane	4-6).	Top	protein	hits	as	ranked	by	mascot	score	and	p-value	
between	proteins	identified	within	fractions	from	the	aorta	of	the	two	genotypes		
	
	 The	secondary	extraction	fraction	provided	similar	results,	with	regards	to	
the	number	of	significant	hits	that	were	produced.		However,	the	concentration	of	
hits	along	the	y-axis	was	far	greater,	with	less	of	an	effect	size,	if	any,	suggesting	
that	changes	for	the	majority	of	the	intracellular	proteins	did	not	reach	statistical	
significance.	There	were	a	number	of	proteins	however	that	did	deviate	from	the	
clustered	 group,	 as	 a	 result	 of	 a	 clear	 increase	 in	 fold	 change	 of	 the	 relevant	
proteins.	This	 includes	 a	protein	of	 note	 in	Caveolin-2,	which	was	 significantly	
different	 between	 the	 groups	 (p=	 <0.05)	 whilst	 a	 significant	 fold	 change	 was	
concurrently	recorded.		
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Figure	30-	Volcano	plot	analysis	of	fraction	2	comparison	between	WT	Control	(lane	1-3)	
and	NE	knockout	mice	(lane	4-6).	Top	protein	hits	as	ranked	by	mascot	score	and	p-value	
between	proteins	identified	within	fractions	from	the	aorta	of	the	two	genotypes		
	 Finally,	 the	 third	 extraction	 fraction	 contained	 the	 proteins	 that	 were	
identified	to	be	within	the	extracellular	matrix	of	the	aortic	tissues.	Interestingly	
this	fraction	produced	the	most	significant	results	in	terms	of	p-value	recordings.	
Similarly,	the	spread	of	the	data	points	in	terms	of	fold	change	were	much	more	
disparate	 and	 less	 concentrated	 around	 the	 origin	 in	 comparison	 to	 other	
fractions.	 Skew	 of	 the	 fold	 change	 was	 towards	 the	 negative	 with	 the	 most	
significant	and	greatest	changes	being	found	within	this	portion.	Included	in	this	
was	the	protein	COP9	signalosome	complex	subunit	8	(COPS8),	a	protein	involved	
in	the	regulation	of	signaling	pathways	and	modulation	of	enzymes	 involved	 in	
protein	degradation.	
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Figure	31-	Volcano	plot	analysis	of	fraction	3	comparison	between	WT	Control	(lane	1-3)	
and	NE	knockout	mice	(lane	4-6).	Top	protein	hits	as	ranked	by	mascot	score	and	p-value	
between	proteins	identified	within	fractions	from	the	aorta	of	the	two	genotypes		
7.2.11	Staining	of	Proteins	identified	within	Proteomics	analysis	were	verified	as	
displaying	differential	expression	between	WT	Controls	and	NE	Knockout	groups	
Identification of proteins by proteomic analysis indicates various mechanisms by which 
NE could act. Volcano plots were used to narrow down the changes in aortic proteins 
to highlight the most significantly modulated proteins between the Control and NE 
knockout datasets. Following comparison of the fold change and p-value, identified 
proteins with marked differences were identified with greater detail, with research into 
each protein and their potential mechanism of involvement being assessed. Proteins 
that deviated from the group in the volcano plot were identified and researched for any 
past research, relevance to vascular function and similar proteins with known roles in 
pathology. One protein was chosen from each fraction to be verified, with the protein 
deemed to have most potential significance following evaluation chosen. TBL1x, 
Caveolin-2 and COPS8 were the respective proteins that were selected, before 
consequentially being stained for within histological sections from both WT and NE 
Knockout genotypes.  
163	
	
	
Initial staining resulted in TBL1x visualizing the differences in expression levels of the 
protein between WT and NE Knockout observed in proteomics data. Consistently, 
TBL1x displayed increased expression within NE Knockout aortas (Figure 32B) in 
comparison to the Control vessels (Figure 32A). This difference was seen across all 
layers of the vessel however most significantly within the medial and adventitial 
regions within NE Knockout samples. Low levels of expression were seen within 
Control mice, however, this appeared to be isolated to the adventitial portion and highly 
concentrated within small areas, appearing to be intracellular (Figure 32A) rather than 
the more disperse expression seen in NE Knockout scans (Figure 32B), although some 
erratic staining was seen elsewhere which was considered signal from poor washing 
rather than true expression. Furthermore, lack of scale bar in Figure 32A decreases our 
ability to draw comparative conclusions between the two sections. Consequentially, 
thanks to poor washing and scale availability this should be repeated prior to 
conclusions fully being drawn, even though proteomics and western blot data supports 
this result. Western blot protein analysis led to observations of higher levels of TBL1X 
within NE Knockout tissues when compared to WT controls (Figure 32C). 
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Figure	 32-Staining	 of	 TBL1x	 (Far-Red)	 in	WT	 Control	 (A)	 and	 NE	 Knockout	 (B)	 aortic	
sections	following	Ang	II	infusion	for	4	weeks,	counterstained	with	Hoescht	nuclear	staining	
(Blue)	and	SMC	(Green).	 	Western	Blot	data	for	TBL1x	within	Ang	II	treated	aortic	tissue	
lysates,	WT	Control	and	NE	Knockout	(C).	IgG	Control	(D)		
Caveolin-2 was another protein identified within proteomics analysis. Resultant 
staining saw Caveolin-2 visualized within both Control (Figure 33A) and NE 
Knockout sections (Figure 33B), with significantly higher expression observed within 
NE Knockout mouse sections. Caveolin-2 was visualized within intimal portions of 
Control vessels most strongly, similarly, this same pattern was observed with NE 
Knockout mice which displayed predominantly intimal expression of Caveolin-2 
however more intense expression and expression within intimal areas, with lower levels 
of medial expression also visualised. Increased staining intensities within the 
endothelial-intimal and adventitia layers was apparent in the vessels of NE Knockouts 
mice (Figure 33B). Expression of Caveolin-2 was not found to be dramatically 
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different within the medial portion of the vessels studied. The same outcomes were 
observed with utilisation of Western Blot techniques (Figure 33C). 
 
Figure	33-	Staining	of	Caveolin-2	(Far-Red)	in	WT	Control	(A)	and	NE	Knockout	(B)	aortic	
sections	following	Ang	II	infusion	for	4	weeks,	counterstained	with	Hoescht	nuclear	staining	
(Blue)	and	SMC	(Green).	(C)	Western	Blot	data	for	Caveolin-2	within	Ang	II	treated	aortic	
tissue	 lysates	with	respective	 loading	controls	 for	comparison	(D)	 IgG	control	 for	 images	
taken	above	of	the	Caveolin-2	stained	sections	
 Finally, COPS8 was the third protein investigated following identification of a 
significant difference in expression between Control (Figure 34A) and NE Knockout 
(Figure 34B) aortas after both have undergone Ang II treatment. Resultant staining was 
highly representative of the proteomics data with clear differences between Control and 
NE Knockout mice, similarly, western blot analysis (Figure 34C) further strengthened 
this observation. WT Control mice displayed very low levels of COPS8 within stained 
sections, with very low levels visualized within the adventitial portions of vessels 
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stained. Alternately, COPS8 were highly expressed within NE Knockout mice with 
significant expression within medial and adventitial portions of the vessel (Figure 34C) 
in all sections stained. Staining patterns of COPS8 in Control mice appears to show an 
intracellular pattern with expression localized surrounding nuclear stains and with cell-
like outlines visualized (Figure 34A). Alternately, NE Knockout mouse sections 
displayed a more nuclear pattern of staining with expression co-localizing with the 
nucleus predominantly (Figure 34B).  
 
 
Figure	34-	Staining	of	COPS8	(Pink)	in	WT	Control	(A)	and	NE	Knockout	(B)	aortic	sections	
following	Ang	II	infusion	for	4	weeks,	counterstained	with	Hoescht	nuclear	staining	(Blue)	
and	SMC	(Green).	(C)Western	Blot	data	for	COPS8	within	Ang	II	treated	aortic	tissue	lysates	
from	WT	Control	and	NE	Knockout.	IgG	control	images	for	COPS8	images	(D)	
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7.3	DISCUSSION	AND	LIMITATIONS	
           From the studies currently undertaken, the role NE plays within the development 
of AAA within animal models is becoming more clear. Relations between the enzyme 
and the pathology that were outlined in the previous chapter were further backed up 
and confirmed with the use of a secondary animal model,  namely the Ang II model. 
Furthermore, still, the model employed allowed for dynamic changes to be monitored 
such as blood flow patterns enabling us to understand in greater depths the differences 
between the two genotypes and likely where the changes lie. Continuing in this vein, 
following the completion of the model, further studies utilizing the tissues generated 
produced a greater insight into the molecular changes occurring within the model within 
both experimental genotypes, with the differences between each giving rise to new 
targets and molecules of interest for further study into the AAA pathology. Utilization 
of a proteomics approach enabled the possibility of identifying both known and novel 
peptides significant to the role of NE within the production of AAA. Confirmation of 
these peptides were necessary, and further work on these are still needed in order to 
fully understand the changes that are brought about as a result of the loss of NE within 
the AAA model.  
 Within early experiments, focusing on the changes in flow generated by the 
administration of Ang II, commonly observed readings for both Colour and PW 
Doppler were witnessed within all stages of the protocol within Control mice. However, 
the same was not seen within the NE knockout cohort in later stages of the study with 
later scans of NE knockout mice appearing highly similar to the week 0 and week 2 
scans within Control mice, with no progression or development of the AAA phenotype 
and associated alterations in either Doppler modalities. This is most likely due to the 
lack of aneurysmal development seen within the NE knockout mice. This in itself could 
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be related to NEs known function within reverse cholesterol transport. Inhibition of NE 
has previously been observed to decrease the levels of circulating cholesterol within 
animal studies, a known risk factor for AAA development (167). Consequently, 
reduced levels of circulating cholesterol, reduced inhibition of cholesterol efflux from 
macrophages and consequent decreased levels of atherosclerosis and inflammation may 
potentially have a beneficial impact on AAA incidence and could explain the outlined 
decrease in pathology incidence within the NE knockout cohort. Changes in Doppler 
readings are highly dependant upon vessel characteristics, with any change in the vessel 
diameter, wall thickness or elasticity impacting greater on the flow occurring within the 
lumen of each respective vessel. Within the Control mice, the greatest changes in PW 
and Colour Doppler readings were witnessed within the most remodelled vessels, 
notably, the production of a false lumen created huge changes in the Doppler profiles. 
This phenotype was never seen within NE knockout mice. Consequentially there was 
no large disruption of flow and creation of turbulence, all of which alter the Doppler 
signal created.  
 Moving onto the changes seen with regards to the expansion of the aorta within 
each experimental group, significant differences were seen with marked increases in 
both diameter and volume of the aorta in Control groups. NE knockout mice showed 
minimal increase and this as highly comparable to procedural control mice, with no 
significant difference seen. This finding backs up the result of the Calcium chloride 
study of similar finding, as well as supporting the work of Yan et al. (192) which shows 
an influence of serine proteases within AAA, however, the same study does contravene 
the result that NE alone is responsible for this difference. Yan et al. employed a third 
protocol, the elastase-induced model of AAA, with a reduction in expansion following 
the knockout of serine proteases, of which NE is one. This study highlights the role of 
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NETs and concludes their importance within the initiation of AAA. NE is required for 
NET formation, and therefore one finding of this study does seem to conflict with the 
other. As the loss of NE alone was considered a secondary preliminary study, and 
within an elastase-induced model where an elastase was removed by genetic knockout, 
I am confident that the previous finding of NETs influence on AAA and NEs role within 
NET formation is the primary finding of this study and it supports similar findings of 
my current work. This further strengthens the argument that NE plays an influential 
role within the AAA pathology although alternate pilot research may contradict this 
argument. Due to the AAA model Yan et al. are employing, I feel the experimental 
design was inappropriate for purpose with replacement of an endogenous elastase with 
an exogenous elastase to study elastase influence.  
 Developing this study further, analysis of the end-stage tissues ensued. With 
known contributing mechanisms of AAA development already outlined by numerous 
studies by such research groups as Alan Daugherty(1), Jonathon Golledge (79)(193) 
and Lisa Cassis(152), the role of inflammatory mediators, MMPs and ECM breakdown 
in the production of AAA are highly supported and well documented. Consequentially 
we looked to determine any significant differences within these areas that were 
produced as a result of the loss of NE. Firstly ECM and structural protein changes were 
looked into with the use of H&E as well as Sirus Red staining for collagen. Remodelling 
of the structural fibres of the aorta is a significant milestone in the progression of the 
AAA pathology. Collagen is degraded and distorted, morphing from the expected 
wave-like formations to linear weaker organizations of the micro infrastructure. This 
change in structural formation rather than the density of collagen itself is believed to be 
the reasoning for the weakening of the vessel, with these changes reported in both 
Marfan and non-Marfan AAA patients. With regards to this, our study lends support to 
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this argument, with little to no changes apparent within the structure of the vessel of 
NE knockout mice, however widespread alterations to this organization within the 
Control cohort. Within both Collagen as well as H&E staining, all vessels displayed 
signs of demarcation of the differing vessel layers, however, this was distorted within 
Control mice in comparison to NE knockouts, another sign of deteriorating vessel 
health.  
 Proteomics data gave rise to proteins and other novel targets that were 
implicated within the differences seen between the NE knockout and Control 
phenotype. During this chapter, the optimization of fractional extraction of proteins 
from different components of the aorta was successfully carried out. Within the three 
fractions of; novel synthesized and loosely bound proteins, intracellular proteins and 
extracellular matrix proteins, thousands of proteins were identified with a shortlist of a 
few hundred proteins being significantly different between the two experimental 
groups. The highlighting of one protein from each fraction within this study was to 
confirm the validity of the findings. Volcano plots were used in order to best identify 
which proteins measured were most like to play a significant role, this was based upon 
them concurrently having a highly significant p-value and a large fold change. This 
enabled the identification of a few highly appropriate candidates for further 
investigation from a very large dataset. Subsequent immunofluorescent staining 
validated TBL1x, Caveolin-2 and COPS8 as potential proteins of interest with 
differences in expression observed during staining. These differences were varied in 
terms of effect, with COPS8 expression differing in cellular localization, however, 
Caveolin-2 produced significant differences in expression levels largely within the 
adventitial portion, both intra- and extra-cellular. All three investigated proteins were 
much more highly expressed with knockout of NE, this suggests that NE could cleave 
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or breakdown the proteins TBL1x, Caveolin-2 and COPS8. These three proteins, as 
well as a number of other proteins, could be novel substrates for NE, with roles within 
the AAA process and warrant further investigation. In summary, this work has 
identified proteins that could have a possible influential role within the production of 
the AAA phenotype which has thus far not been studied.  
 As mentioned, the proteins raised are yet to be studied, however, they do have 
known function within other pathological or physiological pathways. In the case of 
Caveolin-2, related proteins already have a known role within the AAA disease, as 
Caveolin-1 genetic knockout has already been outlined as influential within Ang II and 
Thoracic Aortic Dissection (TAD) procedures, with inhibition of the ADAM17 as the 
underlying mechanism of aneurysm induction(194).  TBL1x has known roles within 
hormonal and transcription factor regulation but as yet no report to suggest its influence 
on related cardiovascular conditions(195). Whilst COPS8 has not had any significant 
link or study within the AAA or TAD pathology, unrelated work has elicited that 
COPS8, a G-protein coupled receptor mechanism, can indeed regulate NF-kB 
expression, which in turn has large ties to the AAA pathology(196). Similarly, work on 
TBL1x has yielded data suggesting an influential role of the protein on transcriptional 
activity, including modulations of NF-kB(197). 
 The use of NE inhibitors has recently been experimented with as a post-surgical 
option of pharmacological treatment within aortic dissection patients, with success 
within early phases of trials. However, these studies focused on the improvement of 
post-surgical coagulopathy rather than the initiating mechanism of the pathology, 
which is highly related to AAA(198). Positive results were obtained in terms of blood 
marker decreases seen and clinical outcomes, suggesting further study is warranted. 
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Furthermore, previous studies have shown similar degrees of positive benefit from NE 
inhibitors with respiratory symptoms following surgical interventions(199). 
 In summary, the findings outlined and discussed above are largely an 
observational dataset and require clarification, quantification and verification before 
they can be accepted as factually conclusive. Patterns identified within histological 
analysis require quantifiable comparison between the two groups, with statistical 
analysis to be performed on subsequent outcomes. This can be considered one of the 
greatest limitations of this dataset, with the observational nature limiting the 
conclusions able to be drawn. 
7.4	CONCLUSION	
Within this chapter, the role of NE in AAA has been investigated utilizing the Ang II 
model, with significant reduction in AAA arising as a result of genetic knockout of NE. 
Functional changes in vessel dynamics were observed and the pathway by which the 
effect was looked into. Expansion rates were significantly higher in Control animals 
when compared to NE Knockout mice, this occurred via a mechanism independent to 
AT1a-induced hypertension, as blood pressure changes were comparable. From this 
series of experiments, a difference in a MMPs -2 and -8  expressions, which have a 
known role in AAA induction, were found repeatedly. Furthermore, other possible 
mechanisms were looked into and novel pathways attempted to be identified via a 
proteomics approach. This work gave rise to the identification of a number of proteins, 
three of which were chosen for further investigation. All proteins highlighted by 
proteomics analysis were verified by immunofluorescent staining as well as Western 
blot analysis, with significant differences observed between genotypes. Further work is 
needed to elucidate the full influence these proteins have upon the AAA pathology.  
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8	THE	ROLE	OF	NE	IN	THORACIC	AORTIC	DISSECTION	
Aortic Dissection is the striping of the intimal layer of the aorta, most commonly within 
the ascending or proximal descending aorta, with tearing of elastic lamina resulting in 
the creation of a false lumen within the affected portion of the vessel. This pathology 
is associated with medial dysregulation, smooth muscle cell death and aortic rupture, 
with clinical outcomes ranging from chronic to acute, and survival rates currently poor 
if reparative surgery isn’t immediate. The AD pathology has many underlying 
similarities to AAA, with a large inflammatory component. Neutrophils and 
macrophages have been identified within the adventitial portion of AD affected sections 
of the aorta, with MMPs also known to influence the pathological outcome. 
Consequentially NE could play an influential role within the pathology, its initiation 
and progression. From previous chapters we have demonstrated NEs role within the 
AAA process, identifying new proteins that are regulated within NE Knockout mice, 
who do not exhibit the same level of vascular modification as WT Controls. This 
chapter will examine whether NE has a similar role within the AD pathology with the 
use of the BAPN model of TAAD using juvenile mice. 
 
8.1	MATERIALS	AND	METHODS		
For information regarding the methodologies utilized within this chapter please refer to 
the Materials and Methods chapter above.  
8.1.1 Aortic Dissection Model- BAPN 
Animal models are a commonly utilized tool used to study pathology and help identify 
the underlying mechanism by which the pathology occurs. Within this study, the BAPN 
Thoracic Aneurysm Aortic Dissection (TAAD) model was utilized to look into if or 
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how NE plays a role within the pathology. BAPN is a lysyl oxidase inhibitor that when 
administered to a mouse, usually via the drinking water, inhibits cross-linking of elastin 
and collagen. The inhibition of this process results in severely weakened vasculature 
and often produces an enlargement within the aorta, most commonly seen within the 
descending thoracic region of the vessel.  During further histological analysis dissection 
of the vessel can often be identified with significant medial degeneration and breaks 
within the elastin lamina visible. Aortic intramural hematoma can result from the 
intimal breaks seen, with this serving to strip the innermost portion of the vessel, again 
this can be seen within some histological sections.  
Aortic Dissection was induced by administration of b-Aminopropionitrile 
Monofumarate (BAPN) at 1g/kg/day for 28days within drinking water as described in 
the previous studies(200). Mice were monitored closely whilst under experimentation, 
with the study comparing Wild type (ApoE-/-/NE+/+) to NE Knockout (ApoE-/-/NE-/-) 
mice. Mice were administered BAPN for the 28 day period, or until death, with the 
aortic arch and heart dissected (Figure 35) and either preserved for staining or snap-
frozen for analysis of protein.  
Measurement of aortas was quantified following fine dissection using microscopy and 
Image J software to look at relative differences between groups. Alternately, 
differentiation between the two groups was carried out by the production of a Kaplan-
Meier curve. Differences in death rate were compared following cause of death being 
confirmed by a post-mortem dissection. Quantification of the Aorta occurs via the fine-
dissection of the aortic arch and ex vivo measurements of the dissected arch, as seen 
below.  
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Figure	35-	Video	still	images	of	BAPN	model	dissection	(Left),	with	isolation	of	the	aortic	
arch	following	fine	dissection	(Right)		
8.2	RESULTS	
8.2.1	 Death	 as	 a	 result	 of	 aortic	 dissection	 and	 consequential	 rupture	 is	
significantly	decreased	in	NE	knockout	mice	within	pilot	experimentation	
Within a pilot study comparing NE knockout mice (n=14) and Control mice (n=38), 
there was a significant difference seen between mortality rates of the two groups 
(p=0.0278) when compared by Log Rank statistical analysis. As seen within the Kaplan 
Meier graph (Figure 36) , all mice apart from one within the NE knockout contingent 
survived the full 28-day period, meaning a 92% survival rate under TAD conditions. In 
comparison, control mice had a much higher mortality, with only 60% of mice 
surviving under the same conditions. Deaths from the control group were all found to 
be of cardiovascular origin, namely Aortic Dissection (Figure 36 and Figure 37), 
identified by post-mortem dissection.  
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Figure	36-	(Top)-	Kaplan	Meier	survival	curve	of	BAPN-induced	TAD	mice,	
administered	for	4	weeks	to	3-week	old	mice.	(P=0.0278,	log-rank	test,	N=	
14	NE-/-	and	38	WT	Control)	(Bottom)-	Post-Mortem	dissection	image	for	
confirmation	 of	 cause	 of	 death.	 Black	 arrow	 demarcates	 the	 location	 of	
aortic	dissection.	No	expansion	within	the	thoracic	region	is	visible,	but	a	
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large	blood	volume	was	found	within	the	region,	followed	by	identification	
of	rupture.	
8.2.2	 Intimal	 tears	and	Elastic	Lamina	changes	were	seen	within	 the	descending	
aorta	and	aortic	arch	following	BAPN	administration	in	WT	but	not	in	NE	knockout	
mice	
 
Following dissection and preparation, staining of the elastic lamina took place, with 
elastin and H&E staining used to examine its arrangement and condition. Quantification 
of the distance between internal and external lamina of the vessel was measured by 
video micrometry and image analysis software. Distance between internal and external 
layers within healthy procedural control and experimental WT Control mice were 
significantly changed (p=<0.0001), with a drastic increase seen in the size of the medial 
portion within the aorta of experimental WT Control mice at the same region of the 
vessel. Similarly, there was a significant difference observed between experimental WT 
Control and NE knockout mice. Furthermore still, there was no difference quantified 
between procedural control measurements and NE knockout measurements (p=>0.05) 
for sections taken from within the same portion of the aorta at the same time period of 
the protocol. Statistical analysis was performed by ANOVA methods. 
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Figure	37-	Top-	Representative	images	of	H&E	plus	elastin	stained	aortic	sections	
following	4	weeks	of	BAPN	administration,	with	WT	Control	displaying	dissection	(A)	and	
NE	Knockout	mice	with	a	minimally	modified	vessel	wall	(B).	Bottom-	Quantification	of	the	
level	of	medial	dysregulation	by	measurement	of	distance	between	internal	and	external	
elastic	lamina.	(p	value=	<0.005,	Mean	+/-	1	S.D.	N=	3	per	group,	3	slides	per	animal,	
ANOVA)	
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8.2.3	Aortic	dissection	was	observed	in	the	majority	of	Experimental	WT	Control	
mice,	with	high	levels	of	rupture	also	observed	
 
 
Figure	38-	Left-	BAPN	treated	WT	Control	mice	analysis	and	categorized	based	upon	fine	
dissection	and	aortic	investigation,	with	categorization	of	each	dissected	aorta	into	Rupture,	
TAD,	Non-Significant	and	Not	affected.	Right-	Immunofluorescent	staining	of	aortic	sections	
within	WT	Control	(Top)	and	NE	Knockout	mice	(Bottom),	with	MMP2	(Left)	and	NE	with	
MPO	(Right)	
Within further rounds of experimentation, sections along the ascending, descending and 
aortic arch were cut, stained and studied in order to verify the elastin integrity, this was 
monitored throughout the vessel and across all genotypes. H&E with elastin staining 
was utilized to visualize these changes. Intimal tears were seen in 80% of aortas from 
the experimental WT Control animals (Figure 38), with more minor modifications to 
the elastin arrangement witnessed in a further 15% of aortic tissues in WT Control mice. 
In contrast, pilot NE knockout mice had no visible elastic lamina disruptions and 
minimal to no medial changes which were widely documented amongst the 
experimental WT Control mice. Only 5% of Experimental WT Control mice 
undergoing the BAPN model of Thoracic Aneurysm and Aortic Dissection were found 
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to not have undergone any noticeable level of vascular wall remodelling. On the other 
hand, the rate of rupture in the Experimental WT Control mice following the expansion 
of the pilot study was 35%. The NE experimental group was not expanded due to 
insufficient mouse litters.  
 
8.2.4	Decreased	expression	of	MMP-2,	MMP-8,	NE	and	Myeloperoxidase	was	
observed	in	NE	knockout	mice.		
	
Tissue	sections	from	the	ascending,	arch	and	descending	aorta	following	exposure	
to	 the	BAPN	TAAD	protocol	were	stained	 for	enzymes	and	proteins	of	 interest.	
This	was	in	order	to	gather	further	information	on	the	process	and	mechanism	by	
which	differences	in	phenotype	between	the	two	experimental	groups	are	being	
produced.	 Staining	 for	NE	 also	 served	 as	 a	 validation	 for	 the	 genetic	 knockout	
strain	being	utilized	within	the	study.	No	NE	significant	levels	of	NE	were	found	to	
be	expressed	within	any	NE	knockout	cohort	sections.	
Further	 staining	 for	 MMP-2,	 notable	 for	 its	 association	 with	 vascular	
remodelling	and	ECM	degrading	potential	was	 significantly	up-regulated	 in	 the	
medial	and	adventitial	portions	of	Experimental	Control	vessels	(Figure	40).	This	
staining	pattern	was	seen	most	strongly	in	the	more	highly	remodelled	areas	of	
the	 vessel,	 however	 it	 was	 still	 apparent	 in	 less	 modified	 areas	 although	
expression	 is	 seen	 at	 much	 lesser	 intensities.	 Whilst	 MMP-2	 was	 present	
throughout	the	regions	mentioned	there	were	distinct	portions	of	the	vessel	with	
raised	signal,	this	suggests	concentration	is	centred	on	and	surrounding	a	source	
cell.	
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Another	enzyme	of	interest	with	proteolytic	capabilities	was	MMP-8,	with	
staining	being	carried	out	on	similar	sections	to	that	of	the	NE	and	MMP-2	stained	
samples.	These	ascending	and	descending	aortic	 sections	of	both	Experimental	
Control	 and	 NE	 knockout	 groups	 were	 stained	 for	 MMP-8	 with	 signal	 being	
significantly	 decreased	within	 Experimental	 NE	 knockout	 group	 sections.	 Both	
groups	displayed	some	degrees	of	signal,	however,	 the	pattern	of	expression	 is	
much	more	diffuse	and	 intense	within	 the	 sections	of	WT	Control	mice.	MMP-8	
expression	appears	to	very	localized	to	single	cells	within	the	adventitial	portion	
of	the	vessel	in	NE	knockout	mice.	Similarly,	the	predominant	staining	for	MMP8	
in	WT	Control	arteries	was	also	within	the	adventitial	region,	however,	this	is	not	
highly	localized	and	instead	spreads	across	much	of	the	adventitia	and	as	well	as	
the	media	layers	of	the	vessel	(Figure	38).	The	most	intense	signal	produced	was	
located	at	the	innermost	portion	of	the	adventitia	where	the	elastic	lamina	ends.	
Unlike	 within	 NE	 knockout	 sections,	 the	 diffuse	 expression	 of	 MMP-8	 in	 WT	
Control	arteries	suggests	that	it	is	secreted	into	the	extracellular	space	as	opposed	
to	being	contained	within	a	cell	in	NE	knockout	arteries.		
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Figure	39-	 Immunofluorescent	staining	of	aortic	sections	within	WT	Control	(A)	and	NE	
Knockout	mice	 (B),	with	MMP8	 (pink)	 counterstained	with	Hoescht	 (Blue)-	 IgG	 Control-	
Hoescht	absent	(C)	
8.3	DISCUSSION 
In Summary, this study displays that TAAD can be modelled in vivo in a reproducible 
manner that mimics the human pathology, with localized aortic remodelling and 
cardiovascular events produced in a number of instances. After the establishment of 
this model within the group, the Pilot study utilizing WT Control and NE knockout 
mice alluded to protection from TAAD as a result of the NE gene inactivation. 
However, due to the low numbers associated with the NE knockout group, as a product 
of insufficient breeding, this is only an early forecast. Further work is needed to 
attribute the significant impact of NE upon these conditions, no matter how promising 
early data is. The TAAD model produced highly comparable results to peer-reviewed 
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published work, with rates of AD discovered within 80% of histological sections within 
the WT Control cohort in comparison to published rates of 80% and 81% in papers 
from Jia et al. and Kurihaha et al. respectively. Rates of death as a result of complete 
rupture were reported as 40% within both of these papers, as well as within our own 
study. This suggests that the TAAD model is working reproducibly and comparably to 
other groups. 
 In continuation, following the Pilot study, the TAAD model was continued with 
the aim of looking further into the mechanism behind the pathology. Several proteins 
were stained for and look to play a role within the development of AD. MMP-2, MMP-
8, and MPO were all stained with decreased intensity and frequency within end-stage 
of NE knockout arteries compared to that of WT mice. This suggests that all of these 
molecules are likely modulated by NE during TAAD formation and progression. The 
location of these molecules varies, with MPO appearing to remain intracellular in 
comparison to MMP-2, and MMP-8 which are a lot more diffusely stained for, 
suggesting secretion of these enzymes occurs into the extracellular space. These 
findings agree well with current literature, such as Atherosclerosis attributing Aortic 
Dissection to MMP-9 levels (177) Similarly, MMP-2 has been well documented as a 
major contributor to the aneurysmal phenotype in AAA research for a prolonged period 
with field-leading labs such as that of A. Daugherty and J. Golledge both highlighting 
its role within murine aneurysm models(46,79). Furthermore still, MPO is used as a 
marker for neutrophils, their role has been well documented within literature and the 
localization of this cell type and other immune cells, within the adventitial portion of 
the vessel as it is undergoing remodelling is to be expected. Building on this point, it 
has been reported within our own group that MMP-8 and NE aid in the process of 
macrophage polarization and foam cell formation, respectively(167,201). Building on 
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this point, knockout of NE interferes with reverse cholesterol transport which impacts 
upon circulating cholesterol. Levels of circulating cholesterol, macrophage polarisation 
and foam cell formation beyond this are all known to impact AAA formation and AD. 
Consequently, the implications on these processes may be the reason for decreased rates 
of AD and AAA, as discussed in section 7.3.  Both MMP-8 and NE are present within 
the region of MPO expression as well as more diffusely. Both enzymes are known to 
be secreted and exert effects upon the ECM, with roles in matrix protein remodelling 
including that of collagen and elastin.  
 
8.4	CONCLUSION	
 
In this experiment, a reproducible methodology for studying TAAD was set up. This 
model then allowed for the studying of the role NE and other associated proteins play 
within the TAAD pathology. NE, MPO, MMP-2 and MMP-8 were all shown to be up-
regulated in WT Control sections in comparison to NE knockout samples. Within a 
Pilot study of NE knockout mice, no remodelling was seen within the aorta, in contrast 
to the 80% AD rate and widespread medial remodelling reported within Control 
samples, more work is needed to develop this Pilot in order to draw definitive 
conclusions on the knockout of NE and its impact upon the AD.  
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9	CHARACTERIZING	BASIC	BLOOD	TEST	RESULTS	AND	AN	
INVESTIGATION	TO	IDENTIFY	A	NOVEL	BLOOD	MARKER	OF		
AAA	PROGRESSION	
Due to the large risk of rupture and apparent ever-growing incidence of AAA within 
western populations, AAA screening programs have been implemented across the UK 
in order to aid in the diagnosis and consequential early treatment of the pathology. 
Aimed at most at-risk groups, the AAA screening program monitors the aortic health 
of men above the age of 65. All men are invited to attend as they turn 65 and anyone 
who missed or have not previously been tested are able to opt-in at any point. 
Participants are then scanned using ultrasound to identify any abnormalities in aortic 
dimensions. The Ultrasound scanning process is a non-invasive procedure taking less 
than 30 minutes to carry out, this results in high compliance, as it is minimally 
disruptive. Repeat monitoring is offered every 3-6months for minor enlargements of 
the vessel, whereas larger expansions of the aorta are referred for further investigations, 
most commonly resulting in surgical intervention. Patients with rapidly growing AAA 
may also be flagged by the screening program for further investigations as these 
patients are also deemed to be of high rupture risk. As a result of the screening program, 
it has been suggested that patients scanned and identified by the program have half the 
risk when compared to unmonitored patients(202).  
  Following the implementation of the screening program 11 years ago, over 700 
000 men have been investigated as part of the nationwide program(202). Following this 
over 1000 men had their aneurysms surgically repaired after a large aneurysm was 
discovered as a direct result of the scanning, this was in the first 5 years alone. 
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Resultantly, there is a growing body of data that gives us information on the prevalence 
of the condition within the UK. Furthermore, we also manage to get more qualitative 
data on the condition of the aorta with the degree of expansion and rate of surgical 
intervention. For instance, of the 700 000 men in the above 65 group scanned, only 
1.34% of these had an aneurysm measuring above the 2.9cm expansion. Patients with 
aneurysms considered as larger than >5.4cm hit the threshold used to define a large 
aneurysm. Within the initial cohort of scans resulting in 1000 referrals of patients 
deemed to possess a large aneurysm, the false-positive identification within these 
patients was only 3.2%. Of the remaining group, 870 underwent successful surgical 
interventions for AAA repair. Intervention rate within this group was over 91% with 
post-operative death standing at less than 1%. Results suggest the screening program 
to be successful with studies undertaken by the National Institute for Health Research 
with a decrease in AAA rupture incidence from 7.1 per 100 000 to 2.6 per 100 000 
person-years within a study of 23,300 participants. Continuing on from this decrease, 
it is calculated that the screening program prevents over 10 ruptures per year within the 
same group and consequentially saves both lives as well as money.  
 During the investigations taken place as part of the AAA screening program, 
many other patients undergo other tests, as males aged 65 and over are at risk for a 
number of conditions not solely AAA. Resultantly, blood tests and similar diagnostic 
tests are often performed around the same time as initial scans. From there, we can get 
a basic overview of an individual’s inflammatory status and cardiovascular health. As 
part of this experiment, we were able to correlate blood markers and screening results. 
Blood markers have been used to monitor the progression of cardiovascular disease in 
a number of conditions, such as post-myocardial infarction where troponin levels are 
used as an indication of cardiac health as it is selectively released at times of cell 
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damage or death. Furthermore, other conditions such as Chronic Obstructive 
Pulmonary Disorder, a disorder where NE has a significant influence, have started to 
develop similar monitoring tests using blood markers. Neutrophil to Lymphocyte ratio 
(NLR) has increasingly been utilized as a monitoring tool and indicator of disease 
progression. Within numerous studies, NLR has gained support as a marker and 
diagnostic tool, as its high prognostic accuracy and lack of need for further testing 
makes it a cost-efficient, quick and accurate marker that can aid in the diagnosis of 
patients. Consequentially following these results, we were interested to see whether the 
same patterns were evident with AAA patients and therefore whether NLR could be 
used as an indication of AAA progression. At the same time, we wanted to investigate 
the possibility of other basic blood test results being used as a biomarker for disease 
progression. This includes the quantity of differing white blood cells, as well as their 
ratio to one another.  
 As it is well reported that AAA affects certain demographics more severely than 
others, we also utilized the clinical data gathered to test whether the same demographic 
was observed. As a result, we utilized clinical data to look into the demographics of 
people scanned at St. Georges Hospital London, largely as part of the nationwide AAA 
screening program, and following this aimed to investigate whether there were any 
diagnostic blood markers that could be implemented from basic blood test results, 
similar to that of NLR. Within the cohort of patients we were able to observe both stable 
and expansive aneurysms, beyond this we could track the change of expansive 
aneurysms across many years in some instances, tracking how the blood results altered 
across the same time period.  
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9.1 MATERIALS AND METHODS 
9.1.1 AAA- Patient Audit 
In order to elicit whether there is a group of patients that have a distinct blood profile 
that is able to predict the likelihood of their aneurysm expanding, work with St Georges 
Hospital Tooting was undertaken looking into basic blood marker profiles with 
progression of AAA overtime. This was retrospective data collected from the AAA 
screening program based at St Georges, with permissions and ethical approval given by 
St Georges University and Consultants. Patients who matched the criteria of having 
undergone ultrasound scanning and blood tests within two weeks preceding the scan 
were selected. From these patients, history was searched, tracking both blood and scan 
results over time. This was performed for as long as there was a scan history. Blood 
test results and size of aneurysm at each point, as well as the date, were recorded for 
analysis. All blood markers consistently measured were recorded and analysed against 
the same patients' results at the time of subsequent scans. Relationships between 
markers were then produced in relation to aneurysm size and progression. Analysis of 
individual cell types was also undertaken, and ratios between cell types were also 
investigated for any potential relationship between them and aneurysm progression. 
Patients were divided into both static and expansive groups, with this dependent on 
status at each scan.  
 Later Biobank resources and blood samples from Aneurysmal repair patients 
would be compared against such groups in order to determine if NE level deviation has 
an impact on which group a patient falls into. This work will now be outlined below. 
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9.2	RESULTS	
9.2.1	Age	and	gender	differences	seen	within	the	general	population	are	seen	
within	St.	Georges	AAA	Screening	program	data	
 
Age and gender differences are often reported within patient cohorts and population 
statistics when assessing the most at-risk groups for AAA. Population data and statistics 
have been used repeatedly throughout medical research to spot correlation between 
variables in an attempt to identify most at-risk patients or to personalize treatment to 
patients based upon their specific needs. As mentioned previously, basic blood tests can 
give a large insight into a patient’s inflammatory and general health status.  
  
  
Figure	40-	Graphical	comparison	of	demographic	data	of	patients	within	the	AAA	screening	
program	 whose	 data	 is	 being	 utilized.	 	 Left,	 Size	 of	 AAA	 divided	 by	 gender	 displaying	
maximum,	minimum	and	average	size	of	AAA	recorded	(p=0.6083,	unpaired	t-test).	Right,	
Age	separated	by	gender,	with	maximum,	minimum,	Q1,	average	and	Q3	shown	by	box	and	
whisker	plot		(p=0.2520,unpaired	t-test)		N=	78	Male,	17	Female	
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Results of basic demographic analysis followed expected patterns, with highly 
comparable age and gender values between the cohort and national population statistics. 
Resultantly, Males made up a larger proportion of the population, experiencing AAA 
at a higher frequency to females within the cohort studied. Furthermore still, an increase 
in age at final scan is associated with worsening phenotype at both initial and final 
ultrasound investigations.  Significant correlation was observed within both stable and 
expansive cohorts when compared with AAA size (Figure 41) 
 
 
Figure	41-	Comparison	of	aneurysm	size	and	age	of	the	patient.	Differentiation	of	patients	
by	 expansive	 (Red,	 p=0.0207,	 R2=0.1363)	 and	 After-Stabilization	 (Blue,	 p=<0.0001,	
R2=0.1034)	Pearsons	Correlation	Analysis)	N=95	Patients	(50	Expansive,	45	Stable)	
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9.2.2	 Expansive	 and	 Stable	 aneurysm	 blood	 profiles	 are	 markedly	 different	
between	groups,	with	most	significant	changes	witnessed	in	monocyte	populations	
from	initial	scans	
Aneurysms are not continually expansive and can go through periods of growth and 
times of latency. Resultantly, the population cohort can be divided into separate groups 
by tracking the scanning outcomes at the 6-month intervals. Patients who undergo 
periods of aneurysm growth and stability were excluded from either group, in order to 
not interfere or skew with any significant patterns that may be seen within blood profile 
statistics. However, the excluded patients were looked at individually to see patterns 
that lead to changes in growth and similarly instability also.  
Collated blood profiles consisted of the measurement of basic blood test parameters, 
with overall white blood cell (WBC) count and quantity of subpopulations of white 
blood cells measured, before averaging values across patients within each group. The 
white blood cell population that is implicated most strongly within inflammatory 
diseases, including AAA, is the macrophage/ monocyte. This variable was highly 
altered between Expansive and Stable groups; with Expansive patients displaying 
increasing monocyte levels per 6-month interval (+ 0.45 cells/	𝜇l) when compared to 
their initial scan. Contrastingly, the opposite was observed within stable aneurysm 
patients. A decrease of 0.2 cells/	𝜇l across the Stable group was measured when 
compared to their internal initial controls. Monocyte levels were the most dissimilar 
between the two groups, and the only WBC subpopulation to display the opposite result 
across the two groups. Alternately, leukocyte population measurements were highly 
similar across the two groups with differences between the two groups being as small 
as 0.05 cells/	𝜇l. Leukocyte changes were seen to increase at a greater rate within the 
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Stable population compared to the Expansive group. Although unexpected, the 
Leukocyte pattern of a greater increase within the Stable group was not the only WBC 
population to increase. Neutrophils also saw an increase, which was also much greater 
than the increase seen within the Leukocyte population. Neutrophils increased by an 
average of 0.22 thousand cells/	𝜇l  per 6 months within the Expansive group; to almost 
0.4 thousand cells/	𝜇l per 6 months within the Stable group. This increase of 1.7 
thousand cells/	𝜇l  per 6 months change was the most marked increase across the blood 
profile analysis when comparing Expansive to Stable aneurysm groups.  
 
Figure	42-Alteration	in	blood	profile	at	6-month	follow	up	following	diagnosis	of	AAA	
compared	between	Expansive	(Left)	and	Stable	groups	(right).	N=95	Patients	(50	
Expansive,	45	Stable)	values	represent	a	mean	+/-	1	S.D.	
Overall White blood cell measurements go up drastically within the Expansive group 
when compared to the Stable group. This is largely in part to the huge change seen 
within monocyte results across the two groups, as both neutrophils and leukocytes 
actually increase further within the Stable group. However, due to large variance 
between patients there is no significant differences observed within this dataset. Much 
smaller variance is observed within the lymphocyte readings, however the neutrophils 
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readings are highly different between patients. Monocytes are most dissimilar with 
smaller levels of variation seen.  
9.2.3	All	WBC	populations	are	altered	in	the	expansive	cohort	with	most	
significant	changes	seen	in	leukocyte	and	monocyte	groups,	however,	no	
significant	differences	are	seen	between	any	WBC	sub-population	and	Aneurysm	
growth 
As mentioned above, WBC levels can be an indication of inflammatory status of a 
patient. AAA is categorized as a chronic inflammatory disease that leads to the 
expansion of the aorta. We now know that certain sub-populations of WBCs expand in 
response to infection and we also have determined that certain cell types play highly 
influential roles within the AAA initiation and progression process. For instance, 
macrophages and the proteinases that they produce significantly contribute to the 
remodelling of the ECM. By inhibiting the invasion of macrophages into vascular 
tissues or production of MMPs once they have crossed into the vasculature, you could 
inhibit the pathology at least within animal models of AAA.  
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Figure	43-	Changes	in	size	of	aneurysm	correlated	with	change	in	blood	profile,	with	each	
white	blood	cell	population	illustrated	with	different	trend	lines.	White	blood	cells	(Black,	
p=0.9854),	 Neutrophils	 (pink,	 p=0.3718),	 Monocytes	 (blue,	 p=0.6020)	 and	 Lymphocyte	
(green,	p=0.1813).	Pearson	Correlation	analysis	was	performed	but	no	significant	relations	
were	 discovered.	 White	 Blood	 Cell-	 R2=0.000004445	 p=0.9854,	 Neutrophil-	 R2=0.01051	
p=0.3718,	 Lymphocyte-	 R2=0.02339	 p=0.1813,	 Monocyte-	 R2=0.003597	 p=0.6020.	 N=	 50	
patients	per	group	
All subpopulations of WBCs were modulated between the two AAA screening program 
groups of Stable and Expansive AAA, with monocytes significantly falling whereas 
neutrophils and leukocytes minimally increasing on average within the same patients. 
However, trends within the analysis of WBC populations and size elicit further 
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information on the relationship between specific cells and the relation to the expansion 
of AAA.  
The monocyte cell population displayed the largest difference between Stable and the 
Expansive population; this trend was carried over within regression analysis. 
Expanding patients’ data points produced a weak positive correlation (r2= 0.0489) 
between monocyte count and aneurysm size. This trend was repeated using both final 
and individual time-point measurements in comparison to monocyte count (r2= 0.0334 
and r2= 0.0489 respectively). Stable AAA patients produced a different trend; with 
negative or near flat correlation when comparing final aneurysm size against average 
monocyte count and aneurysm size and monocyte count at each time point, 
respectively.  
Contrastingly, the remaining two WBC cell types display the opposing trait, with cell 
count decreasing as aneurysm size increases in both neutrophils and leukocytes. This 
trend is remarkably more drastic within leukocyte populations in the Expansive 
population of the screening program. Interestingly, the Stable group within the same 
analysis displayed a similar pattern although to a much less drastic extent with expected 
aneurysm size decreasing at a much steeper rate within the Expanding group in 
comparison to Stable cohorts, with over a three-fold difference being observed. 
Differences in neutrophil cell population between groups were even starker, with a 
small average AAA size fall but increases in the neutrophil cell population within 
Expansive cohort patients, this is compared to an increase in AAA size with neutrophil 
count inflation within Stable Aneurysm patients. This is an unexpected finding within 
both groups. However, when taking the entire dataset into consideration using a one 
timepoint analysis the pattern is altered significantly. Within neutrophil analysis AAA 
size increases with rise in WBC sub-populations (r2= 0.018). Furthermore, Leukocyte 
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trends become far less angular, with correlation becoming almost flat (r2= 0.0012) with 
no apparent relation being seen at the one-time point analysis.  
9.2.4	NLR	shows	no	change	across	a	6	month	period	when	compared	across	
cohorts	and	at	both	6	month	and	longer-term	time-points	
 
NLR	has	been	increasingly	used	as	an	indicator	of	Chronic	Obstructive	Pulmonary	
Disease	(COPD),	with	great	success.	This	 low	cost	and	 low	skilled	 investigation	
using	blood	biomarkers	removes	the	need	for	further	invasive,	highly	skilled	and	
consequentially	costly	investigations	within	COPD	patients.	Neutrophil	is	highly	
implicated	within	the	COPD	phenotype	and	the	progression	of	the	disease.	As	a	
result,	verification	of	whether	the	same	observations	in	NLR	could	potentially	be	
seen	are	worthwhile,	as	they	have	a	high	potential	to	save	time	and	money	within	
the	NHS	and	further	healthcare	settings.		
All	 patients	 who	 underwent	 investigation	 within	 the	 AAA	 screening	 and	 had	
follow	up	of	6	months	or	 longer	were	used	within	this	analysis.	 Initially,	Stable	
cohorts	were	included	to	look	at	the	spread	in	NLR	value	within	this	group,	this	
enabled	us	to	see	whether	this	was	clustered	and	highly	similar.	NLR	values	within	
the	Stable	group	were	calculated	to	fall	within	the	0.16	and	17.64,	however,	this	is	
highly	skewed	by	the	upper-value	outlier,	which	is	markedly	higher	than	the	rest	
of	the	cohort.	Excluding	this	value	would	produce	a	more	representative	range	of	
0.16-3.52	for	the	Stable	population	measured.	However,	similarly,	the	Expansive	
cohort	had	a	value	range	of	between	1.18	and	6.17,	with	peaks	of	1.4	per	6	months	
expansion	 rate	 within	 this	 group	 as	 opposed	 to	 the	 0	 of	 Stable	 data	 points.	
Correlation	 for	 Expansive	 groups	 is	 very	 low,	 with	 r2	 values	 of	 0.001	 for	
comparison	between	NLR	and	long-term	expansion	rates	and	this	value	falls	even	
197	
	
	
further	when	comparing	the	expansion	rate	observed	within	the	first	6	months	of	
observation	and	NLR,	falling	to	an	r2	value	of	0.000001	(Figure	44).		
	
Figure	44-	Neutrophil	to	Lymphocyte	ratio	compared	to	change	in	AAA	size	at	the	6-month	
period	post-diagnosis.	(p-value=	0.3518,	R2=0.008851,	Pearsons	Correlation	analysis)	N=	95	
patients		
9.3	DISCUSSION,	LIMITATIONS	&	CONCLUSION	
Overall	the	results	from	Blood	Profile	analysis	in	relation	to	AAA	size	were	not	as	
expected	with	no	significant	correlation	found,	however	not	unexpected.	No	clear,	
strong	 and	 significant	 results	 were	 found	 within	 basic	 blood	 markers	 when	
compared	to	AAA	size	or	progression	of	aneurysm.	Some	changes	in	patterns	were	
seen	within	the	Stable	as	opposed	to	Expansive	groups,	however,	these	were	not	
significantly	different.	For	population	data,	this	audit	was	comparatively	low	in	n	
number,	power	and	true	results	may	become	more	clear	and	apparent	with	an	
increase	in	this,	however,	at	the	moment,	this	is	not	something	that	is	warranted	
based	on	current	results.		
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	 These	 results	when	 put	 into	 context	with	what	 is	 currently	 understood	
within	 the	 literature	 are	 surprising,	 as	 the	 pathology	 is	 accepted	 as	 a	 chronic	
inflammatory	 pathology	 with	 significant	 contribution	 from	 blood-derived	
cells(26,203).	 Furthermore,	 the	 manipulation	 of	 specific	 white	 blood	 cell	
populations	 in	previous	studies	has	highlighted	 the	significance	of	 their	 impact	
upon	the	initiation	and	progression	of	the	phenotype.	With	regards	to	the	previous	
data	presented	within	this	report,	there	are	also	some	surprising	contradictions,	
with	significance	reached	in	some	early	work	on	NE	knockout	mice	 in	terms	of	
preventing	the	incidence	of	AAA	within	animal	models.	For	there	to	be	no	relation	
to	WBC	subpopulation	levels,	Age	or	Gender,	the	results	appear	to	go	against	the	
majority	of	the	other	body	of	work	carried	out	within	this	study,	and	what	is	also	
accepted	within	the	literature	as	strong	risk	factors	for	AAA(1,65).		
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10	DEVELOPMENT-	BARTS	BIOBANK	RESOURCE	
Following the success of our In Vivo works, which suggests a role for NE within the 
production of the AAA phenotype, we endeavoured to verify that this result was 
translatable to the human pathology. It is already known that inhibition of NE within a 
clinical setting can lead to improved patient outcomes in COPD, and if high levels of 
NE were found within human AAA tissues it could identify NE as a potential target for 
AAA treatment. In order to carry out this round of experimentation, collaboration with 
the Barts BioBank Resource was developed. The Barts BioBank Resource enables 
collaboration between Clinicians and Researchers at QMUL and Barts in order to 
further research aims with the use of human tissues, pooling the skills or the Clinical 
and Academic staff within a singular project. In this instance, our Lab partnered with a 
group of Cardiovascular Surgeons in order to obtain tissues from AAA repair patients, 
giving us the ability to analyse and investigate the role of NE within the human AAA 
condition. This all occurred post-assessment of our research proposal by RedCap and 
attending meetings with the Barts BioResource panel to discuss the best way in which 
we could carry out experiments. This concluded in obtaining approval for our study 
along with ethics. 
 This study is the next step in determining whether NE has a role within AAA 
within the human and not just within the mouse models as determined earlier in our 
work. By carrying out investigations within the human we are able to conclusively 
determine whether NE is present and if there is a potential role for the enzyme with the 
production of the phenotype. Whilst In Vivo studies used are the gold standard for 
theoretical and academic purposes, information founded within murine models can be 
fallible and at times can fail to translate to the human equivalent pathology, this can be 
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due to a number of factors such as differences in immune systems or small variations 
between human and murine versions of the same proteins.  
	
10.1 MATERIALS AND METHODS 
10.1.1 Biobank Resource Analysis 
In order to look into the potential translational relevance of all In Vivo and previous 
works, collaboration with the Barts Biobank facility was organized. Barts Biobank 
work to provide contact between researchers and clinicians, this is so tissues can be 
made available for research purposes. In order to look into AAA and the association of 
the pathology with NE, contact with cardiothoracic surgeons at Barts hospital was 
made.  
In order to verify whether the effect seen within In Vivo works were translatable to the 
human pathology, human samples were obtained from AAA patients undergoing aortic 
repair surgery at Barts Hospital, London. Surgeons were consulted, and patients 
consented for the permission to taken samples during already planned procedures. 
Patients were made aware that the taking of samples would not change the procedure 
that they were undergoing and would mean tissues would be analysed for NE 
expression in order to better understand the pathology. Any patients that were deemed 
unsuited due to comorbidities were not consented, and therefore no samples were 
collected. Ethical approval and approval for all work was approved as part of REDCAP 
application process, with project code NEAAA being utilized and approved at first 
instance.  
 Resultantly, weekly surgical lists were looked at to identify appropriate patients 
who were undergoing aneurysmal surgical intervention. Following this, patients were 
approached and consent for both blood and aneurysm tissue discussed. If permission 
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was granted, blood was collected from patients via a central line, and tissues were taken 
upon the opening of the aorta. Tissues were then divided and preserved in liquid 
nitrogen or PFA immediately, to ensure sample quality. Blood was immediately taken 
to the laboratory upon exiting surgery. At this point, blood was spun down at 1300g for 
12minutes with supernatant removed in order to isolate the plasma, with cellular 
content discarded. This was then snap-frozen and stored at -80degrees until a cohort of 
patients had been collected for analysis. Following the collection of a patient cohort, 
plasma was analysed for NE expression and basic blood profiles. Tissues were 
processed alongside, with PFA submerged samples left overnight before rehydration 
and mounting in OCT prior to sectioning.  
 Once the tissues were taken, they were processed for analysis similarly to other 
tissues outlined above within alternate In Vivo experiments.  
10.1.2 Neutrophil Elastase Fluorometric Analysis 
In order to determine whether NE was elevated within human AAA repair patients, 
blood collected during work with the Barts Biobank were analyzed using an enzyme-
based fluorometric assay. Blood taken from patients during surgery were spun down at 
13000g for 12minutes in order to remove the cellular content from the sample. A 200µl 
aliquot of serum was taken before serial dilution was performed, with 9 final dilutions 
and final volume of 50µl per read sample. This was the performed for each patient 
within a 96-well plate and consequential steps were followed in accordance with 
Abcam kit instructions. Patient sample dilutions were then compared against a standard 
curve for NE. 96-well plates containing samples were read with output data analysed 
using GraphPad Prism statistical analysis software.  
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10.2	RESULTS	
10.2.1	Extra	Cellular	Matrix	proteins	are	deregulated	within	Human	AAA	tissue	
samples	similar	to	that	of	AAA	animal	models	
 
A part of investigations into verification of the translatability of our In Vivo findings, 
collaboration with the Barts BioBank resource led to the formation of collaborations 
with cardiovascular surgeons at Barts Hospital. Following agreement with these 
surgeons, patients upon their surgical lists were identified when determined appropriate 
and consented for inclusion within our study. Once patients had given consent and were 
undergoing AAA repair procedures, tissues were collected during the procedure. By 
taking both blood and aortic tissues we were able to identify both expression and 
localization of NE expression within relevant aspects of the AAA patients.  
 Patient aneurysm samples were collected and processed immediately following 
AAA repair surgeries, with tissues snap-frozen prior to being mounted within OCT and 
sectioned by cryo-sectioning methodologies. Sections were collected from the blade 
using poly-l-lysine slides before staining. Stains were applied to sections of aneurysmal 
and healthy internal control aorta in order to visualize the ECM proteins, namely 
collagen and elastin, before imagining using light microscopy techniques were 
employed utilizing the EVOS system.  
 Within staining for both Elastin and Collagen, AAA patient samples displayed 
high levels of medial dysregulation with diseased samples. Collagen patterns generated 
were non-uniform and disjointed wave-like structures with clear breaks and gaps in 
sections, dissimilar to continuous homogenous healthy regions. Collagen stained 
sections had clear areas of difference, with some regions of the vessel possessing more 
tightly arranged fibres compared to the areas of medial damage.  
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 Within Elastin staining, a similar pattern was observed with the loss of 
consistent elastic banding seen within healthy vessels being replaced by highly 
fragmented patchy staining of elastin. The areas in which most fragmentation has 
occurred was localized to the portions of the media with most disruption to both 
Collagen and Elastin fibres, with some regions of stained sections appearing relatively 
more structured and healthy compared to others. In continuous homogenous healthy 
regions, elastin fibres are arranged in continuous bands as opposed to the fragmented 
appearance seen within the aneurysmal aortic tissues. 
 
Figure	 45-	 Human	 aortic	 samples	 from	 different	 patients,	 stained	 for	 (A)	 collagen,	 (B)	
collagen	and	elastin	and	(C)	Collagen	
10.2.2	Healthy	and	aneurysmal	aortic	tissues	have	differential	expression	of	NE	
and	MMPs,	with	co-localization	of	the	two	enzymes	found	within	areas	of	
extracellular	matrix	breakdown	
 
Following the staining of ECM proteins, the identification of NE within Human tissue 
samples was carried out in order to elicit whether NE could have a role within the 
human pathology. From works carried out within the Ang II In Vivo models, the 
staining of NE, as well as MMP-2 and MMP-9 were present within AAA sections. 
Human sections were stained for NE, MMP-2 and MMP-9 using antibodies from 
Abcam, with both staining positive within human aneurysmal aortic tissues. Both NE 
and MMP are apparent within areas of high medial degeneration and remodelling. 
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Furthermore, the two enzymes were co-localised at the points of the most prominent 
changes to the vessels structure, although the majority of MMP2 staining is dispersed 
and not colocalised to NE expression. Similarly, MPO and NE majority of expression 
is within different areas. MPO staining is highly localised to the intimal portion of the 
vessel and areas of significant damage such as the regions of dissection. NE is seen 
within the same areas however also more diffusely, most commonly situated 
surrounding unclear staining (Figure 46). In both instances the visualisation of the 
elastic lamina seems to be autofluorescence although the negative control counters this. 
It is possible that an inappropriate part of the tissue was used for this instance. 
In comparison, this staining was not found within comparable staining of continuous 
homogenous healthy aortic tissues from the same patient. MMP2 staining also appeared 
more diffusely with areas of the enzyme scattered throughout the vessel wall, however, 
NE appeared far more localized within sections stained. Localisation of NE was 
contained to the cytoplasm in the majority of instances, however, there were exceptions 
to this with small regions of non-cellular NE staining (Figure 46).  
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Figure	46-	Identification	of	NE,	MPO	and	MMP-2	within	human	samples	obtained	during	
AAA	repair	surgery.	Top	Left-	MPO(Red)	and	NE	(Green)	Top	Right-	Health	Human	Aorta	
stained	for	NE	(Red)	and	MMP2(Green)	Bottom	Left-	indicates	area	of	MMP-2	staining	
with	small	portions	of	co-staining	for	NE(Red)	and	MMP2(Green).	Bottom	Right-	Negative	
IgG	Control	
 
10.2.3	Human	blood	samples	collected	from	AAA	repair	patients	displayed	higher	
levels	of	NE	activity	when	compared	to	Healthy	Control	blood	samples	
 
Fluorometric assay analysis of human blood samples collected from AAA repair 
patients and unaffected Control patients showed a higher level of NE activity in AAA 
surgical repair patients (n=5) than that of controls (n=3) (Figure 47). Samples 
fluorescence was measured in kinetic mode following the protocol set out in the Abcam 
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kit purchased. Reactions were measured in kinetic mode over the period of 30minutes 
to allow for the action of enzymes. On average, over double, the amount of activity was 
seen within AAA patients as opposed to Controls. Although dissimilar average values, 
significance was not reached, P=0.1699. AAA patient blood test values were largely 
within healthy ranges (Table 5), with little variability identified asides from within 
neutrophil and age variables.  
Table	5-	Demographic	and	Blood	profile	averages	of	AAA	patients	who	underwent	AAA	
repair	surgery	and	donated	tissue	and	/	or	serum	for	analysis.		
	
 
Figure	47-	Comparison	of	NE	activity	obtained	from	an	100microliter	aliquot	of	serum	from	
Control	patients	and	AAA-repair	patients	(p=0.1699,	t-test)		
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10.3	DISCUSSION	AND	LIMITATIONS	
Throughout the analysis of AAA patient repair tissues, NE was repeatedly found to be 
elevated on average within this group in comparison to the unaffected group used as a 
control, however significance was not reached within this study (Figure 47). ECM 
proteins were, as expected, highly remodelled within the diseased cohort with elastin 
fragmentation evidenced and H&E stains displaying the changes to vascular structures 
that occurred as a result of the AAA pathology (Figure 45 &46). These changes have 
been widely reported, suggesting our tissues are consistent and representative of AAA, 
consequentially we can assume further works to be indicative of the AAA phenotype, 
however, evidence of tissue damage as a result of the freezing process utilised may 
diminish the conclusions able to be drawn from this aspect of investigations (Figure 
45). Further staining of tissues isolated from the same region of the same aorta was 
performed in order to increase the understanding of proteins involved within AAA and 
answer one of our primary research questions of ‘Does NE play a role within the human 
AAA pathology’. Resultant staining suggests that NE is positively stained within areas 
of aortic remodelling, located predominantly within the medial and adventitial portions 
of the vessel. Staining of the enzyme was seen within areas of higher degrees of 
vascular change, although quantification is necessary to determine quantifiable 
differences, however comparatively no NE was stained for within healthy control 
portions of the same vessel (Figure 46). Furthermore, NE also co-stained with MMP2 
similarly to staining carried out within in vivo murine models. This suggests that 
pathways responsible for the AAA condition identified in animal model work could be 
transferred across to the human pathology. This pattern of co-localization has been 
identified within other pathologies, most thoroughly discussed has been the role of NE 
within COPD and respiratory conditions. NE has been proven to activate MMPs(164), 
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leading to worsening of respiratory conditions where remodelling breaks down the 
functional structures of tissues. Furthermore, still, NE has been reportedly responsible 
for further potentiating the pro-MMP and pro-inflammatory environment, not only 
activating MMPs but degrading their inhibitors(204). The cause of this phenomenon 
has also been investigated, with risk factors for AAA such as smoking being a reported 
trigger(170).  
 Resultantly, work within this chapter points towards NE having a negative 
impact on the AAA condition, aiding in potentiating the degrading enzymes responsible 
for a large part of vessel damage. Changes in NE was tested with the taking of blood 
from AAA repair patients, in order to identify whether it was up-regulated within the 
most severe instances of AAA. Activity of NE was not significantly different between 
the two groups tested within a relatively small pilot study (Figure 47). This suggests 
that with the expansion of the work a significant difference could be observed between 
healthy controls and AAA patients. Developing this further could lead to the 
identification of NE as a biomarker of AAA progression, however, work is still too 
early to indicate whether this will be at all possible.  
Limitations to this work however do exist, with the processing of the materials and 
tissues potentially influential in the outcomes produced. As seen within Figure 45 and 
Figure 46 there appears to be artefacts from the freezing process, damaging the tissue 
and leading to potential false conclusions. Beyond this, due to problems with the slide 
there are no scale bars for the same images contained within Figure 45 and therefore 
we are able to draw little from this resource which could have provided invaluable 
information. Subsequent tissues stained within Figure 46 come from a separate aorta 
and therefore were harvested at a different time, therefore it may be the case that this 
was unaffected, however as the protocol for processing remained consistent, it is 
209	
	
	
possible that this experiment result also has been skewed. Resultantly follow-up work 
to verify these results should be carried out, alongside quantification of any differences 
observed within IF staining. 
10.4	CONCLUSION	
Histological analysis of AAA-repair patient samples stained positive for NE and 
displayed patterns of a high level of remodelling, although quantification needs to be 
undertaken prior to conclusions being drawn. Minor areas of co-staining for NE with 
MMP2 was localized to the most damaged and remodelled regions of the stained 
vessels, however the majority of MMP expression was not adjacent to any NE signal. 
ECM proteins stained for displayed the highest level of remodelling within the medial 
portion of the vessel, the region where NE was most commonly stained. These patterns 
were not seen within healthy control sections, with ECM protein structure more 
consistent and regularly arranged, compared to AAA-repair patient samples. NE was 
not expressed within the healthy control samples stained, suggesting NE may play a 
role within the AAA phenotype in humans.  
Further work with the blood of the same patients displayed no significant 
difference in activity of NE within AAA-repair patients in comparison to healthy 
controls. This dampens the argument that NE has an influence within the AAA 
pathology, however further work is needed in order to fully elicit the role of NE within 
the human pathology following contradictory previous results within alternate avenues 
of investigation.  
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11	GENERAL	DISCUSSION	
During this project, there was a number of key hypothesise addressed in order to 
understand the role of NE within AAA. Development of imaging methodologies were 
imperative for monitoring of vessels in a time-course manner, allowing for the 
observation of how the AAA pathology develops over time and any differences that 
occur as a result of the genetic knockout of NE. Following on from this, the 
understanding of NEs impact on AAA was the primary focus, with secondary and 
tertiary aims of improving our knowledge of the mechanisms that contribute to the 
AAA pathology and whether findings of our main investigations were translatable to 
the human condition.  
 Imaging modalities used within this group of work were all learnt and developed 
during this PhD. Both contrast-MRI and US imaging were utilised as they were 
regarded as the most appropriate methods to visualise vasculature changes and the 
changes in flow patterns that are associated with these. This was determined following 
research into alternatives, as well as consultation with the Cancer Imaging group. 
Optimisation of protocols and procedures were carried out in collaboration with the 
same group, in order to achieve the most accurate and thorough process. MRI reached 
the point where semi-automation became possible, eliminating operator bias whilst 
gathering vast information in a 3D format. Volumetric measurement of the vessel 
consequentially became possible, with this being suggested within the literature to be a 
better indication of rupture risk following analysis of clinical outcomes(182). However, 
at the same time, clinical observations are most commonly carried out with the 
utilisation of US due to the modalities improved ease of use, lower levels of training 
required and ability to gather functional and flow information on the vessel. Therefore, 
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a dual scanning protocol was carried out, to gain a greater data bank on each vessel. 
This meant the benefits of both methods were gained, with one method verifying the 
results of the other, with no discrepancies observed between the two. 
 The primary focus of this work was the understanding of NEs role within AAA. 
This developed from AAA to TAAD. Multiple animal models were employed, 
comparing WT with NE Knockout mice, in order to see the difference genetic loss of 
NE had. Initial AAA models both resulted in the observation that loss of NE was 
protective against the induction of AAA within animal models. Later, the same was 
seen within TAD and rupture, with loss of NE being protective against the remodelling 
and rupture seen within Control mice. These findings were developed further, with 
histology, RNA analysis and proteomics carried out to develop the understanding of 
how this result was occurring. Modulation of MMP2 and MMP9 were one pathway 
investigated, due to its huge significance in the initiation process(205). Changes in 
levels of expression were observed, with a reduction in NE Knockout sections 
observed. Furthermore, structural organisation was hugely significantly different and 
this was seen across the three models, a phenomena already established within human 
and animal model tissue dissection (11,206). Most notably within TAD, this was 
significantly different with medial degradation and dysregulation apparent within 
Control animals. Distance between internal and external elastic lamina were 
comparable between procedural controls and NE Knockout mice however both were 
vastly different from treated WT mice. Following the identification of these changes, 
we aimed to identify novel pathways using a proteomics approach (11). Fractionation 
of the aortic proteins into there portions allowed for the focused identification of both 
proteins and compartments of significant interest within the disease, these consisted of; 
loosely bound proteins and novel peptides, intracellular proteins and extracellular 
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matrix proteins. This approach and consequential analysis produced a number of 
proteins of interest, some of which were looked into further. COPS 8, Caveolin 2 and 
TBL1x were verified as being different between WT and NE Knockout mice. This 
suggests that these proteins may warrant further investigation.  
11.1	SIMILAR	CONCLUSIONS	HAVE	BEEN	REACHED	WITHIN	CACL2	AND	ANG	II	
EXPERIMENTS,	WITH	NE	KNOCKOUT	MICE	SIGNIFICANTLY	LESS	IMPACTED	BY	
BOTH	MODELS	WHEN	COMPARED	TO	CONTROL	MICE	
 
The basis of this round of experimentation was to answer the research question of ‘Does 
NE play a role within AAA?’. Experiments were undertaken within both Control and 
NE Knockout mice so that observations could be made that display the difference loss 
of NE makes within the AAA process. The CaCl2 model and Ang II procedures were 
undertaken in order to verify the results of each respective model were physiological 
effects attributable to the AAA phenotype and not a consequence of NEs involvement 
solely within the models triggering mechanism. For instance, blood pressure 
measurements were carried out within Ang II experiments to ensure loss of the NE gene 
does not impede the rise in blood pressure that in turn results in the production of the 
AAA phenotype.  
The conclusions drawn within both Ang II and CaCl2 model experiments were highly 
similar. Induction of both models resulted in an aneurysmal phenotype being produced 
within the majority of Control mice, with significant expansions of the aorta observed 
by scanning and post-mortem dissection methods. However, within NE Knockout mice 
the occurrence of aneurysms was decreased with fewer expansions of the infrarenal 
aorta being produced or found within NE knockout experimental mice. Further 
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investigation as to the histological differences between groups resulted again in 
dissimilar results between genotypes, although quantification analysis is required prior 
to definitive conclusions being drawn. However, early indications suggest vessel 
structural proteins follow in the same pattern as seen within expansion results, with 
minimal alteration to collagen and elastin, both highly remodelled within the AAA 
phenotype (61,207). Histologically, NE Knockout mice that had undergone one of the 
AAA models appeared akin to procedural control mice. Changes in the elastic lamina 
that were seen within WT mice, with widespread elastin breakage and medial 
disruption, were absent within NE Knockout mice. Similar changes were also seen 
within collagen staining when comparing between the two groups, with collagen 
structure and arrangement preserved within NE Knockout mice while high levels of 
collagen dysregulation were evidenced in WT mice.  
Within Ultrasound and MRI scanning quantification of aortic expansion, the same 
patterns emerged, with WT aortas expanding further than those of sex and age-matched 
NE Knockout aortas. Ultrasound scanning provided both quantitative and qualitative 
data, with Colour Doppler results visualizing hemodynamic changes occurring in the 
vessels over time. Quantitatively, US observed a much higher level of expansion within 
WT mice cohort in comparison NE Knockout cohort mice, this occurred in both AAA 
models. Similarly, MRI reported the same phenomena. However, within MRI studies 
the increase in infrarenal volume within CaCl2 mice was lower than that seen within 
Ang II studies. This is most likely due to the higher localization of the CaCl2 model 
(84), with application occurring to a select portion of the vessel in comparison to the 
global Ang II model, which has implications on the entirety of the mouse (46), with 
systemic pressure increasing and consequentially systemic consequence. Furthermore, 
the Ang II model is known to produce a far more severe phenotype in comparison to 
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the CaCl2 model and therefore diametric expansion has the potential to be much greater 
generally between the two models. Qualitatively Colour Doppler US displayed the 
production of a false lumen in some instances within Control mice, with significant but 
less severe changes observed in other mice belonging to the Control cohort with Ang 
II infusion procedure, whereas minor to no Colour Doppler US changes were seen 
within NE Knockout vessels, matching the findings of Dissection investigations. 
Similarly, within CaCl2 model experiments more severe disturbances to laminar flow 
were recorded within Control cohort scans in comparison to NE Knockout mice, 
although the changes in vessel dynamics were less severe within this model when 
compared to the Ang II results(208). Again, this could be a result of the model being 
more severe and often producing large volatile aneurysms prone to rupture in 
comparison to the more minor changes seen within the CaCl2 model experimentation.  
Overall, there were a lot of comparable results and findings from both rounds of 
investigation into the effects loss of the NE gene has within Ang II and CaCl2 model 
procedures. The findings suggest loss of NE gene to be protective within AAA animal 
models. Loss of NE gene led to the abolishment of AAA within both Ang II and CaCl2 
models, this loss of aortic expansion was accompanied by the loss of hemodynamic 
changes when analyzed by US imaging modalities as well as the diminution of 
histological changes to the extracellular matrix proteins largely responsible for the 
development of the pathological phenotype. 
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11.2	COMPARISONS	CAN	BE	DRAWN	BETWEEN	TAAD	AND	AAA,	WITH	
SIMILAR	RESULTS	SEEN	WITHIN	PILOT	TAAD	WORK	AND	AAA	MODELS	WITH	
RELATION	TO	THE	IMPACT	OF	LOSS	OF	THE	NE	GENE	
 
Many of the observed contributors to changes seen within Control tissues and Control 
animal phenotypes have been highly similar between both the TAAD and AAA models. 
Involvement of MMPs, NE and immune cells has been visualized by histological and 
RNA analysis methodologies both within current studies and previous (209). On top of 
this, the results within some elements of study within NE Knockout mice have been of 
the same outcome, suggesting a common causal or at least contributory pathway that 
exists in both AAA and TAAD(111).  
NE Knockout mice undergoing animal models for both AAA and TAAD both showed 
decreases in incidence of the respective conditions, with decreases or abolishment of 
vessel remodelling and downregulation of key proteases such as MMP-2, MMP-8, and 
MMP-9, all previously identified as pivotal within the underlying pathological 
mechanism(9,103). Further work is required for full understanding of the pathways 
linking these three molecules to NE in the aneurysm pathology as a whole, as without 
a conclusive idea on the underlying disease mechanism the identification and 
development of a successful clinical treatment is far less likely. The use of a proteomics 
approach within one of the models has identified potential novel targets for the 
furthering of this research, with TBL1x, Cavanin-2 and COPs-8 all significantly 
highlighted within fractional analysis of the aortic tissues generated within the Ang II 
model. However, this work is in its infancy, and translation of work to the human 
pathology is necessary in order to boost chances of being able to conclusively state the 
pathological mechanism underlying aneurysm development in the human.  
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Consequentially, work on NE and its potential role within AAA was carried out in the 
human in an aim to further the project and our understanding of the disease as a whole.  
 
Final developments of the project allowed for the verification and translation of 
information developed within murine studies to the human pathology. An audit of blood 
profiles of an AAA screening program produced information on the complex nature of 
the disease. NLR and blood cell values were compared to expansion amongst other 
characteristics, with no significantly strong relationship identified, contrary to 
expectation. NLR is a highly accurate indicator of systemic inflammatory 
conditions(171)(210). The identification of a biomarker would greatly improve 
monitoring and diagnosis of AAA, with NE being a candidate for this. Consequentially, 
a pilot study looking at the expression of NE within human samples ensued. Tissues 
and blood were obtained from patients undergoing AAA repair surgery. The following 
analysis was focused on the expression on NE within both types of sample, with both 
staining positive for the enzyme, in contrast to healthy control tissues. NE and MMP2 
were identified in regions of high dysregulation, as expected for MMP levels when 
compared to published literature(205), as identified by histological analysis. However, 
NE activity within AAA patients was on average similar within repair patients when 
compared to healthy controls, this was unexpected from previous results from this body 
of work but predicted by previous studies on NE in AAA (142). Development of this 
Pilot study is needed in order to identify whether this is a representative result, as due 
to the small sample size we are unable to put NE forward as a definitive biomarker. If 
upon expansion of the study, significance was reached, there is a possibility that this 
could have great potential and hold benefit for clinical diagnostics. 
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In summary, NE appears to play a role within the AAA animal model pathology, 
although no clear link can be claimed within the human phenotype. Genetic loss of NE 
is protective against animal models of AAA, with no significant increases in vessel 
diameter observed by MRI or US when compared with the procedural controls. 
Development and optimisation of MRI and US analysis allowed the study of vessels 
over the entire time course of experiments, with this protocol translatable to any size or 
power of vessel or MRI respectively. Greater understanding to potential contributing 
mechanisms was reached, with identification of new investigative targets within the 
AAA pathology achieved and confirmed by proteomics and histological analysis. The 
work in vitro and in vivo was continued in human studies with surprising results within 
pilot experiments. Further work is needed before we are able to suggest that NE has an 
real significance within the human pathological phenotype as In Vivo results did not 
translate to similar Human Pilot results.  
11.3	STUDY	LIMITATIONS	
Throughout the experimental process, there are always investigations that are beyond 
the scope of the study that may yield beneficial information on the topic at hand. NE is 
implicated in a number of processes, many of which are discussed within this project. 
The primary focus of this work was to determine the role of NE within the AAA 
process, resulting experiments lead to the conclusion that genetic knockout of NE led 
to inhibition of AAA. This was followed up within preliminary Human works. The next 
step within this process would be to prove the human link further; as well as to ascertain 
whether the changes in phenotype seen within the 3 animal models studied were 
reproducible with pharmacological knockout of NE. By carrying out these two rounds 
of experimentation we would be able to determine the potential benefit that the 
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inhibition of NE could have on AAA treatment. One major limitation was the lack of 
significance within the AAA screening program data. Expansion of the human pilot 
study would enable the development of in depth analysis, helping to determine whether 
NE could be regarded as an indicative biomarker of AAA progression.  
Whilst we have extensively outlined the benefit that loss of NE has within AAA models 
we have not taken it any further, for instance with the pharmacological knockout of NE. 
Use of a pharmacological agent to inhibit NE, within animal models initially, would 
help determine whether targeting the enzyme for therapeutic benefit would be a 
possibility. Both administration of NE prior to induction of AAA, as well as a 
regression study where any inhibitor was administered post AAA induction would 
produce a comprehensive overview of where NE has its greatest impact. Furthermore, 
this would give an indication of whether any treatment would need to be administered 
as a prophylactic to most at-risk groups, or if once aneurysms are identified a NE 
inhibitor could still be effective as a form of treatment. Within the second instance, the 
stabilisation of aneurysms and the consequential reduction of surgeries or death due to 
rupture would both be regarded as a positive and significant result, improving the 
current therapeutic options.  
Furthermore, In Vitro results were inconclusive with no concrete significant differences 
observed, any hypothesis of a relation between AAA-markers and NE were not fully 
conclusive. Whilst these hypothesis were, in-part confirmed within AAA-models, 
continuation of this work looking into further markers could be of benefit to the 
understanding of the overall pathology. However,  results produced within cell culture 
in vitro work are not always representative of the action of cells within a tissue system, 
as cell to cell, interactions can have a large influence on expression and reactions 
occurring within the cell. Therefore, whilst indicative and informative, verification of 
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in vitro results with in vivo works should always be considered as stronger evidence for 
transferable insights, especially within conditions involving a multitude of cell types. 
Similarly, in vivo works have their own downfalls, with murine immune systems, 
specific protein constitution and other processes differing from the human and 
consequentially direct translation from animal models to the human condition are not 
guaranteed. Consequentially, the gold standard of research is always proof of concepts, 
first developed within both in vitro and in vivo studies, within human experimentation. 
Whilst the production of insight into the function of NE with the AAA phenotype has 
been successful, the assessment of NE activity has been limited to human work. 
Transferring this to mouse procedures could further emphasise the differences between 
WT Controls and NE Knockout mice within affected tissues. RNA analysis and 
histology work on these tissues were indicative of increased levels of NE within the 
affected areas, however, furthering this with functional analysis would strengthen the 
argument for NE making a causative difference to the AAA pathology. 
 
11.4	FUTURE	DIRECTIONS	
 
Within this work, NE has been put forward and illustrated as having a role within AAA 
and TAAD, the exact manner by which it takes its effect have been looked into with 
implications in the regulation of MMPs within the pathologies highlighted. However, 
further work to fully understand the mechanism behind AAA and TAAD, as well as 
NEs role within this, is still necessary. The highlighting of further implicated proteins, 
namely TBL1x, Cops 8 and Caveolin 2 are under investigation for their role within the 
NE associated mechanism and its relation to the aneurysm pathology at large. Whilst 
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NE has a high substrate promiscuity already established, it is highly possible cleavage 
of a novel protein or peptide sequence by the enzyme could be responsible for the 
physiological effects observed within animal models. Further analysis of proteomic 
results could potentially yield information regarding the modifications made by NE, 
and as a result, provide influential insights into aneurysm formation mechanisms.  
Beyond work already underway, the use of currently utilised medicines that influence 
NE could have huge potential. Following the influence of genetic NE knockout upon 
the models of aneurysm, a pharmacological antagonist for the same enzyme should be 
looked into. Pharmacological agents already exist and have been used in academic 
studies with beneficial physiological effects(167). Beyond this trials of already 
approved human medicines, used within COPD and previously discussed conditions 
could potentially lead to repurposing of drugs. An intervention study, firstly within 
rodent models, using NE inhibitors whilst undergoing AAA and/or TAAD induction 
should be of utmost importance. This will confirm whether NE could be considered as 
a target for the production of a pharmacologic treatment of AAA. Utilisation of novel 
technology may be able to yield further information, such as 4D ultrasound imaging 
technology that could provide a dynamic reconstruction of the vessel over time. This 
new technology could provide flow information and allow in-depth mapping of how 
genes and proteins are regulated by the changes in vessel dynamics, alongside the 
already studied alterations in vessel wall conformation and diameter. 
Following on from mouse studies, development of human translational work is 
imperative to understanding whether the results of obtained from animal investigations 
can be transferred to the human pathology and lead to eventual treatment. Patients 
suffering from COPD in severe instances were often found to have NE inhibitor 
deficiency, leading to worsening of the COPD condition. Studies within a similar cohort 
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of alpha-1 antitrypsin deficiency patients could provide a dynamic case study, with the 
potential to greatly increase our understanding of NE within the AAA pathology.   
At this point in time, the aneurysm field needs extensive molecular science-based 
studies to further understand causal mechanisms of AAA, and consequentially 
understand the pathologies initiation and development process. From there we will be 
able to identify further candidate genes or proteins that have an influence on AAA, 
leading to the possibility of being able to control them and resultantly improve 
treatment of AAA.  
Beyond clinical implications and translation to human therapeutic treatment, the 
identification of causal pathways would be a significant milestone in the study of AAA. 
Proteomics analysis produced novel therapeutic targets and potential mechanisms of 
the AAA process. Three of these proteins were verified to be implicated within 
differences seen between NE Knockout and Control tissues, however further study on 
TBL1x, Caveolin 2 and COPS8 could yet yield significant results with a large impact 
on the understanding of AAA as a pathology and the underlying mechanisms that 
induce and progress it. Undertaking of similar works done within this study but 
focusing on one of the alternate proteins would be appropriate for determining the 
impact of the protein upon the pathology. Production of genetic knockout mouse strains 
or initial work within cell lines could produce information on the impact of these 
proteins within specific cells involved within the AAA process.  
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12	CONCLUSION	
In conclusion, during this study, we were able to demonstrate the influence of NE 
within the AAA pathology with genetic abolishment of the enzyme limiting the effects 
of three separate models of aneurysm in vivo. Following analysis of generated tissues, 
the link between NE and MMPs has been strengthened and appears to play an 
influential role within the AAA phenotype, as evidenced within histology and RNA 
analysis from Ang II, CaCl2 and BAPN treated aortas. Furthermore, identification of 
novel target molecules within the AAA pathology was achieved via proteomic 
methodologies, before verification by western blot and immunostaining methods. NE 
appears to regulate an array of proteins, most noted within this study being TBL1x, 
Cops 8 and Caveolin 2, all with potential influence in the decrease of AAA incidence.  
 Translatability of the research into the human needs to be further developed and 
verified, currently, initial pilot human studies demonstrated NE staining with AAA 
patient tissues although no significant difference was determined between serum 
samples of healthy and AAA patients. Identification of NE co-localising with MMPs 
within human AAA samples were carried out suggesting the findings of in vivo studies 
could be applicable within the human condition.  
These studies were carried out after the successful development of AAA 
imaging protocols that give automated and reproducible results. This enabled a non-
biased analysis of the aorta within all mice over the time course of AAA models.  
 In conclusion, genetic knockout of NE inhibits AAA/TAAD production within 
animal models, occurring in part by regulation of MMPs, with the other potential 
mediators of the phenomena put forward.  
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